

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 October 2001 (18.10.2001)

PCT

(10) International Publication Number
WO 01/77155 A2

(51) International Patent Classification⁷: **C07K 14/00**

(21) International Application Number: PCT/US01/40469

(22) International Filing Date: 6 April 2001 (06.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/195,576 6 April 2000 (06.04.2000) US
09/826,734 5 April 2001 (05.04.2001) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US 60/195,576 (CIP)
Filed on 6 April 2000 (06.04.2000)
US 09/826,734 (CIP)
Filed on 5 April 2001 (05.04.2001)

(71) Applicant (for all designated States except US): **CURAGEN CORPORATION** [US/US]; 555 Long Wharf Drive, 11th floor, New Haven, CT 06511 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FERNANDES, Elma** [IN/US]; 77 Florence Road, #2, Branford, CT 06405 (US). **VERNET, Corine, A., M.** [FR/US]; 1739 Foxon Road, Box L, North Branford, CT 06471 (US). **MISHNU, Vishnu, S.** [IN/US]; 309 East Main Street #306, Branford, CT 06405 (US). **LEACH, Martin, D.** [GB/US]; 884

School Street, Webster, MA 01570 (US). **SHIMKETS, Richard, A.** [US/US]; 191 Leele Street, West Haven, CT 06516 (US). **ZERHUSEN, Bryan, D.** [US/US]; 485 Jefferson Road, Apt. 2-10, Branford, CT 06405 (US). **KEKUDA, Ramesha** [IN/US]; 1 Malthy Street, Branford, CT 06405 (US).

(74) Agent: **ELRIFI, Ivor, R.**; Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P. C., One Financial Center, Boston, MA 02111 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL POLYNUCLEOTIDES AND POLYPEPTIDES ENCODED THEREBY

(57) Abstract: The present invention provides ORFX, a novel isolated polypeptide, as well as a polynucleotide encoding ORFX and antibodies that immunospecifically bind to ORFX or any derivative, variant, mutant, or fragment of the ORFX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the ORFX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to others uses.

WO 01/77155 A2

NOVEL POLYNUCLEOTIDES AND POLYPEPTIDES ENCODED THEREBY

BACKGROUND OF THE INVENTION

The invention relates generally to nucleic acids and polypeptides encoded thereby, and methods of using these nucleic acids and polypeptides. The contents of this application are
5 incorporated herein by reference in their entirety.

SUMMARY OF THE INVENTION

The invention is based in part on the discovery of nucleic acids that include open reading frames encoding novel polypeptides, and on the polypeptides encoded thereby. The nucleic acids and polypeptides are collectively referred to herein as "ORFX".

10 Accordingly, in one aspect, the invention provides an isolated nucleic acid molecule that includes the sequence of any of SEQ ID NO:2*n*-1, wherein *n* is an integer between 1-132, that encodes a novel polypeptide, or a fragment, homolog, analog or derivative thereof. The nucleic acid can include, *e.g.*, a nucleic acid sequence encoding a polypeptide at least 85% identical to a polypeptide comprising the amino acid sequences of SEQ ID NO:2*n*, wherein *n*
15 is an integer between 1-132. The nucleic acid can be, *e.g.*, a genomic DNA fragment, or a cDNA molecule.

Also included in the invention is a vector containing one or more of the nucleic acids described herein, and a cell containing the vectors or nucleic acids described herein.

The invention is also directed to host cells transformed with a vector comprising any of
20 the nucleic acid molecules described above.

In another aspect, the invention includes a pharmaceutical composition that includes an ORFX nucleic acid and a pharmaceutically acceptable carrier or diluent.

In a further aspect, the invention includes a substantially purified ORF polypeptide, *e.g.*, any of the ORFX polypeptides encoded by an ORFX nucleic acid, and fragments,
25 homologs, analogs, and derivatives thereof. The invention also includes a pharmaceutical composition that includes a ORFX polypeptide and a pharmaceutically acceptable carrier or diluent.

In a still a further aspect, the invention provides an antibody that binds specifically to an ORFX polypeptide. The antibody can be, *e.g.*, a monoclonal or polyclonal antibody, and

fragments, homologs, analogs, and derivatives thereof. The invention also includes a pharmaceutical composition including ORFX antibody and a pharmaceutically acceptable carrier or diluent. The invention is also directed to isolated antibodies that bind to an epitope on a polypeptide encoded by any of the nucleic acid molecules described above.

5 The invention also includes kits comprising any of the pharmaceutical compositions described above.

 The invention further provides a method for producing an ORFX polypeptide by providing a cell containing a ORFX nucleic acid, *e.g.*, a vector that includes a ORFX nucleic acid, and culturing the cell under conditions sufficient to express the ORFX polypeptide
10 encoded by the nucleic acid. The expressed ORFX polypeptide is then recovered from the cell. Preferably, the cell produces little or no endogenous ORFX polypeptide. The cell can be, *e.g.*, a prokaryotic cell or eukaryotic cell.

 The invention is also directed to methods of identifying an ORFX polypeptide or nucleic acids in a sample by contacting the sample with a compound that specifically binds to
15 the polypeptide or nucleic acid, and detecting complex formation, if present.

 The invention further provides methods of identifying a compound that modulates the activity of a ORFX polypeptide by contacting ORFX polypeptide with a compound and determining whether the ORFX polypeptide activity is modified.

 The invention is also directed to compounds that modulate ORFX polypeptide activity
20 identified by contacting a ORFX polypeptide with the compound and determining whether the compound modifies activity of the ORFX polypeptide, binds to the ORFX polypeptide, or binds to a nucleic acid molecule encoding a ORFX polypeptide.

 In a another aspect, the invention provides a method of determining the presence of or predisposition of an ORFX-associated disorder in a subject. The method includes providing a
25 sample from the subject and measuring the amount of ORFX polypeptide in the subject sample. The amount of ORFX polypeptide in the subject sample is then compared to the amount of ORFX polypeptide in a control sample. An alteration in the amount of ORFX polypeptide in the subject protein sample relative to the amount of ORFX polypeptide in the control protein sample indicates the subject has a tissue proliferation-associated condition. A
30 control sample is preferably taken from a matched individual, *i.e.*, an individual of similar age, sex, or other general condition but who is not suspected of having a tissue proliferation-associated condition. Alternatively, the control sample may be taken from the subject at a

time when the subject is not suspected of having a tissue proliferation-associated disorder. In some embodiments, the ORFX is detected using a ORFX antibody.

In a further aspect, the invention provides a method of determining the presence of or predisposition of an ORFX-associated disorder in a subject. The method includes providing a
5 nucleic acid sample, *e.g.*, RNA or DNA, or both, from the subject and measuring the amount of the ORFX nucleic acid in the subject nucleic acid sample. The amount of ORFX nucleic acid sample in the subject nucleic acid is then compared to the amount of an ORFX nucleic acid in a control sample. An alteration in the amount of ORFX nucleic acid in the sample relative to the amount of ORFX in the control sample indicates the subject has a tissue
10 proliferation-associated disorder.

In a still further aspect, the invention provides method of treating or preventing or delaying a ORFX-associated disorder. The method includes administering to a subject in which such treatment or prevention or delay is desired a ORFX nucleic acid, a ORFX polypeptide, or an ORFX antibody in an amount sufficient to treat, prevent, or delay a tissue
15 proliferation-associated disorder in the subject.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are
20 described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following
25 detailed description and claims.

DETAILED DESCRIPTION OF THE INVENTION

The invention provides novel polypeptides and nucleotides encoded thereby. The polynucleotides and their encoded polypeptides can be grouped according to the functions played by their gene products. Such functions include, *e.g.* structural proteins, proteins associated with metabolic pathways such as fatty acid metabolism, glycolysis, intermediary metabolism, calcium metabolism, proteases, and amino acid metabolism.

Included in the invention are 132 novel nucleic acid sequences and their encoded polypeptides. The sequences are collectively referred to as "ORFX nucleic acids" or ORFX polynucleotides" and the corresponding encoded polypeptide is referred to as a "ORFX polypeptide" or "ORFX protein". For example, an ORFX nucleic acid according to the invention is a nucleic acid including an ORF1 nucleic acid, and an ORF polypeptide according to the invention is a polypeptide that includes the amino acid sequence of an ORF1 polypeptide. Unless indicated otherwise, "ORFX" is meant to refer to any of the ORF1-132 sequences disclosed herein.

In general, for an ORF n according to the invention (wherein n is any integer from 1 to 132), a nucleic acid corresponding to the ORF is SEQ ID NO:2 n -1, and an amino acid sequence encoded by the ORF is SEQ ID NO:2 n . For example, a nucleic acid sequence corresponding to an ORF1 nucleic acid is SEQ ID NO:1, and a polypeptide sequence corresponding to an ORF1 polypeptide is SEQ ID NO:2. Similarly, a nucleic acid sequence corresponding to an ORF4 nucleic acid is SEQ ID NO:7, and a polypeptide sequence corresponding to an ORF4 polypeptide is SEQ ID NO:8. Nucleic acid sequences and polypeptide sequences for ORFX nucleic acids according to the invention are provided in Table 1. Also shown in Table 1 are polypeptides related to the indicated ORFX sequence.

To determine similarity to previously described proteins, polypeptides encoded by ORFX DNA sequences were tested using the Framesearch Algorithm against a nonredundant version of the GenPept Database from NCBI/Genbank. DNA sequences that had a score of '90' or above (Framesearch algorithm score, Edelman et. al. GCG Genetics) to a known protein were selected. Percent sequence homology of ORFX polypeptides to known protein is provided in field 223 in section of the specification entitled "Disclosed Sequences of ORFX Nucleic Acid and Polypeptide Sequences." Open reading frames were extended beyond the region of the protein matched using standard DNA translation and codon tables. Novel

proteins that lacked a protein match were translated against the standard genetic codons and proteins with an ORF at least 80 amino acids.

ORFX nucleic acids, and their encoded polypeptides, according to the invention are useful in a variety of applications and contexts. For example, various ORFX nucleic acids and polypeptides according to the invention are useful, *inter alia*, as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins

ORFX nucleic acids and polypeptides according to the invention can also be used to identify cell types for an indicated ORFX according to the invention. Additional utilities for ORFX nucleic acids and polypeptides according to the invention are disclosed herein.

ORFX Nucleic Acids

The novel nucleic acids of the invention include those that encode an ORFX or ORFX-like protein, or biologically active portions thereof. The nucleic acids include nucleic acids encoding polypeptides that include the amino acid sequence of one or more of SEQ ID NO:2*n*, wherein $n = 1$ to 132. The encoded polypeptides can thus include, *e.g.*, the amino acid sequences of SEQ ID NO: 2, 4, 6, 8, 10, . . . 258, 260, 262, and/or 264.

In some embodiments, a nucleic acid encoding a polypeptide having the amino acid sequence of one or more of SEQ ID NO:2*n* (wherein $n = 1$ to 132) includes the nucleic acid sequence of any of SEQ ID NO:2*n*-1 (wherein $n = 1$ to 132), or a fragment thereof. Additionally, the invention includes mutant or variant nucleic acids of any of SEQ ID NO:2*n*-1 (wherein $n = 1$ to 132), or a fragment thereof, any of whose bases may be changed from the disclosed sequence while still encoding a protein that maintains its ORFX-like activities and physiological functions. The invention further includes the complement of the nucleic acid sequence of any of SEQ ID NO:2*n*-1 (wherein $n = 1$ to 132), including fragments, derivatives, analogs and homolog thereof. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications.

Also included are nucleic acid fragments sufficient for use as hybridization probes to identify ORFX-encoding nucleic acids (*e.g.*, ORFX mRNA) and fragments for use as polymerase chain reaction (PCR) primers for the amplification or mutation of ORFX nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (*e.g.*, cDNA or genomic DNA), RNA molecules (*e.g.*, mRNA), analogs of the DNA

or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.

"Probes" refer to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), 100 nt, or as many as about, *e.g.*, 6,000 nt, depending on use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are usually obtained from a natural or recombinant source, are highly specific and much slower to hybridize than oligomers. Probes may be single- or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies.

An "isolated" nucleic acid molecule is one that is separated from other nucleic acid molecules that are present in the natural source of the nucleic acid. Examples of isolated nucleic acid molecules include, but are not limited to, recombinant DNA molecules contained in a vector, recombinant DNA molecules maintained in a heterologous host cell, partially or substantially purified nucleic acid molecules, and synthetic DNA or RNA molecules. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated ORFX nucleic acid molecule can contain less than about 50 kb, 25 kb, 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material or culture medium when produced by recombinant techniques, or of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the present invention, *e.g.*, a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132), or a complement of any of this nucleotide sequence, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequence of any of SEQ ID NO:2*n*-1 (wherein *n*=1 to 132) as a hybridization probe, ORFX nucleic acid sequences can be isolated using standard hybridization and cloning techniques (*e.g.*, as described in Sambrook *et al.*, eds., MOLECULAR CLONING: A LABORATORY MANUAL 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; and Ausubel, *et al.*,

eds., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993.)

5 A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to ORFX nucleotide sequences can be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

10 As used herein, the term "oligonucleotide" refers to a series of linked nucleotide residues, which oligonucleotide has a sufficient number of nucleotide bases to be used in a PCR reaction. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise portions of a nucleic acid sequence having about 10 nt, 50 nt, or 15 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment, an oligonucleotide comprising a nucleic acid molecule less than 100 nt in length would further comprise at least 6 contiguous nucleotides of any of SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132), or a complement thereof. Oligonucleotides may be chemically synthesized and may be used as probes.

20 In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in any of SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132). In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in any of SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132), or a portion of this 25 nucleotide sequence. A nucleic acid molecule that is complementary to the nucleotide sequence shown in is one that is sufficiently complementary to the nucleotide sequence shown in of any of SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132) that it can hydrogen bond with little or no mismatches to the nucleotide sequence shown in of any of SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132), thereby forming a stable duplex.

30 As used herein, the term "complementary" refers to Watson-Crick or Hoogsteen base pairing between nucleotides units of a nucleic acid molecule, and the term "binding" means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, Von

der Waals, hydrophobic interactions, etc. A physical interaction can be either direct or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates.

Moreover, the nucleic acid molecule of the invention can comprise only a portion of the nucleic acid sequence of any of SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132), *e.g.*, a fragment that can be used as a probe or primer, or a fragment encoding a biologically active portion of ORFX. Fragments provided herein are defined as sequences of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids, respectively, and are at most some portion less than a full length sequence. Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice. Derivatives are nucleic acid sequences or amino acid sequences formed from the native compounds either directly or by modification or partial substitution. Analogs are nucleic acid sequences or amino acid sequences that have a structure similar to, but not identical to, the native compound but differs from it in respect to certain components or side chains. Analogs may be synthetic or from a different evolutionary origin and may have a similar or opposite metabolic activity compared to wild type.

Derivatives and analogs may be full length or other than full length, if the derivative or analog contains a modified nucleic acid or amino acid, as described below. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to, molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 70%, 80%, 85%, 90%, 95%, 98%, or even 99% identity (with a preferred identity of 80-99%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to the complement of a sequence encoding the aforementioned proteins under stringent, moderately stringent, or low stringent conditions.

See *e.g.* Ausubel, *et al.*, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993, and below. An exemplary program is the Gap program (Wisconsin Sequence Analysis Package, Version 8 for UNIX, Genetics Computer Group, University Research Park, Madison, WI) using the default settings, which uses the algorithm of Smith and

Waterman (Adv. Appl. Math., 1981, 2: 482-489, which is incorporated herein by reference in its entirety):

A "homologous nucleic acid sequence" or "homologous amino acid sequence," or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level as discussed above. Homologous nucleotide sequences encode those sequences coding for isoforms of ORFX polypeptide. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA.

Alternatively, isoforms can be encoded by different genes. In the present invention, homologous nucleotide sequences include nucleotide sequences encoding for a ORFX polypeptide of species other than humans, including, but not limited to, mammals, and thus can include, *e.g.*, mouse, rat, rabbit, dog, cat, cow, horse, and other organisms. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence does not, however, include the nucleotide sequence encoding human ORFX protein.

Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in any of SEQ ID NO:2*n* (wherein *n* = 1 to 132) as well as a polypeptide having ORFX activity. Biological activities of the ORFX proteins are described below. A homologous amino acid sequence does not encode the amino acid sequence of a human ORFX polypeptide.

The nucleotide sequence determined from the cloning of the human ORFX gene allows for the generation of probes and primers designed for use in identifying the cell types disclosed and/or cloning ORFX homologues in other cell types, *e.g.*, from other tissues, as well as ORFX homologues from other mammals. The probe/primer typically comprises a substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 200, 250, 300, 350 or 400 or more consecutive sense strand nucleotide sequence of SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132); or an anti-sense strand nucleotide sequence of SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132); or of a naturally occurring mutant of SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132).

Probes based on the human ORFX nucleotide sequence can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various embodiments, the probe further comprises a label group attached thereto, *e.g.*, the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such

probes can be used as a part of a diagnostic test kit for identifying cells or tissue which misexpress a ORFX protein, such as by measuring a level of a ORFX-encoding nucleic acid in a sample of cells from a subject *e.g.*, detecting ORFX mRNA levels or determining whether a genomic ORFX gene has been mutated or deleted.

5 “A polypeptide having a biologically active portion of ORFX” refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a “biologically active portion of ORFX” can be prepared by isolating a portion of SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132),
10 that encodes a polypeptide having a ORFX biological activity (biological activities of the ORFX proteins are summarized in Table 1), expressing the encoded portion of ORFX protein (*e.g.*, by recombinant expression *in vitro*) and assessing the activity of the encoded portion of ORFX. For example, a nucleic acid fragment encoding a biologically active portion of ORFX can optionally include a domain as shown in Table 1, column 4.

ORFX variants

The invention further encompasses nucleic acid molecules that differ from the disclosed ORFX nucleotide sequences due to degeneracy of the genetic code. These nucleic acids thus encode the same ORFX protein as that encoded by the nucleotide sequence shown
20 in SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132). In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in any of SEQ ID NO:2*n* (wherein *n* = 1 to 132).

In addition to the human ORFX nucleotide sequence shown in any of SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132), it will be appreciated by those skilled in the art that DNA sequence
25 polymorphisms that lead to changes in the amino acid sequences of ORFX may exist within a population (*e.g.*, the human population). Such genetic polymorphism in the ORFX gene may exist among individuals within a population due to natural allelic variation. As used herein, the terms “gene” and “recombinant gene” refer to nucleic acid molecules comprising an open reading frame encoding a ORFX protein, preferably a mammalian ORFX protein. Such
30 natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the ORFX gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in ORFX that are the result of natural allelic variation and that do not alter the functional activity of ORFX are intended to be within the scope of the invention.

Moreover, nucleic acid molecules encoding ORFX proteins from other species, and thus that have a nucleotide sequence that differs from the human sequence of any of SEQ ID NO:2*n*-1 (wherein $n = 1$ to 132), are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the ORFX cDNAs of the invention can be isolated based on their homology to the human ORFX nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.

In another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of any of SEQ ID NO:2*n*-1 (wherein $n = 1$ to 132). In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 500 or 750 nucleotides in length. In another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.

Homologs (*i.e.*, nucleic acids encoding ORFX proteins derived from species other than human) or other related sequences (*e.g.*, paralogs) can be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.

As used herein, the phrase "stringent hybridization conditions" refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at T_m , 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes, primers or oligonucleotides (*e.g.*, 10 nt to 50 nt) and at least about 60°C for longer

probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

Stringent conditions are known to those skilled in the art and can be found in CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6.

5 Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other.

A non-limiting example of stringent hybridization conditions is hybridization in a high salt buffer comprising 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65°C. This hybridization
10 is followed by one or more washes in 0.2X SSC, 0.01% BSA at 50°C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of any of SEQ ID NO:2n-1 (wherein n = 1 to 132) corresponds to a naturally occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (*e.g.*, encodes a
15 natural protein).

In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of any of SEQ ID NO:2n-1 (wherein n = 1 to 132), or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization conditions are
20 hybridization in 6X SSC, 5X Denhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55°C, followed by one or more washes in 1X SSC, 0.1% SDS at 37°C. Other conditions of moderate stringency that may be used are well known in the art. See, *e.g.*, Ausubel *et al.* (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL,
25 Stockton Press, NY.

In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of any of SEQ ID NO:2n-1 (wherein n = 1 to 132), or fragments, analogs or derivatives thereof, under conditions of low stringency, is provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35%
30 formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40°C, followed by one or more washes in 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50°C. Other conditions of low stringency that may be used are well known in

the art (*e.g.*, as employed for cross-species hybridizations). See, *e.g.*, Ausubel *et al.* (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY; Shilo and Weinberg, 1981, *Proc Natl Acad Sci USA* 78: 6789-6792.

5 **Conservative mutations**

In addition to naturally-occurring allelic variants of the ORFX sequence that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequence of any of SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132), thereby leading to changes in the amino acid sequence of the encoded ORFX protein, without
10 altering the functional ability of the ORFX protein. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence of any of SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132). A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of ORFX without altering the biological activity, whereas an "essential" amino acid residue is required for biological
15 activity. For example, amino acid residues that are conserved among the ORFX proteins of the present invention, are predicted to be particularly unamenable to alteration.

Amino acid residues that are conserved among members of an ORFX family members are predicted to be less amenable to alteration. For example, an ORFX protein according to the present invention can contain at least one domain (*e.g.*, as shown in Table 1) that is a
20 typically conserved region in an ORFX family member. As such, these conserved domains are not likely to be amenable to mutation. Other amino acid residues, however, (*e.g.*, those that are not conserved or only semi-conserved among members of the ORFX family) may not be as essential for activity and thus are more likely to be amenable to alteration.

Another aspect of the invention pertains to nucleic acid molecules encoding ORFX
25 proteins that contain changes in amino acid residues that are not essential for activity. Such ORFX proteins differ in amino acid sequence from any of any of SEQ ID NO:2*n* (wherein *n* = 1 to 132), yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 75% homologous to the amino acid sequence of any of SEQ ID
30 NO:2*n* (wherein *n* = 1 to 132). Preferably, the protein encoded by the nucleic acid is at least about 80% homologous to any of SEQ ID NO:2*n* (wherein *n* = 1 to 132), more preferably at least about 90%, 95%, 98%, and most preferably at least about 99% homologous to SEQ ID NO:2.

An isolated nucleic acid molecule encoding a ORFX protein homologous to the protein of any of SEQ ID NO:2*n* (wherein *n* = 1 to 132) can be created by introducing one or more nucleotide substitutions, additions or deletions into the corresponding nucleotide sequence, *i.e.* SEQ ID NO:2*n*-1 for the corresponding *n*, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.

Mutations can be introduced into SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132) by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in ORFX is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a ORFX coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for ORFX biological activity to identify mutants that retain activity. Following mutagenesis of SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132), the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined.

In one embodiment, a mutant ORFX protein can be assayed for (1) the ability to form protein:protein interactions with other ORFX proteins, other cell-surface proteins, or biologically active portions thereof, (2) complex formation between a mutant ORFX protein and a ORFX receptor; (3) the ability of a mutant ORFX protein to bind to an intracellular target protein or biologically active portion thereof; (*e.g.*, avidin proteins); (4) the ability to bind BRA protein; or (5) the ability to specifically bind an anti-ORFX protein antibody.

Antisense

Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132), or fragments, analogs or

derivatives thereof. An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein, *e.g.*, complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence
5 complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire ORFX coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of a ORFX protein of any of SEQ ID NO:2*n* (wherein *n* = 1 to 132) or antisense nucleic acids complementary to a ORFX nucleic acid sequence of SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132) are additionally provided.

10 In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding ORFX. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues (*e.g.*, the protein coding region of a human ORFX that corresponds to any of SEQ ID NO:2*n* (wherein *n* = 1 to 132)). In another embodiment, the antisense nucleic
15 acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding ORFX. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (*i.e.*, also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding ORFX disclosed herein (*e.g.*, SEQ ID
20 NO:2*n*-1 (wherein *n* = 1 to 132)), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of ORFX mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of ORFX mRNA. For example, the antisense oligonucleotide can be complementary to
25 the region surrounding the translation start site of ORFX mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally
30 occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, *e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used.

Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a ORFX protein to thereby inhibit expression of the protein, *e.g.*, by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, *e.g.*, by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an α -anomeric nucleic acid molecule. An α -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gaultier *et al.* (1987) *Nucleic Acids Res* 15: 6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue *et al.* (1987) *Nucleic Acids Res* 15: 6131-6148) or a chimeric RNA-DNA analogue (Inoue *et al.* (1987) *FEBS Lett* 215: 327-330).

Ribozymes and PNA moieties

Such modifications include, by way of nonlimiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.

In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (*e.g.*, hammerhead ribozymes (described in Haselhoff and Gerlach (1988) *Nature* 334:585-591)) can be used to catalytically cleave ORFX mRNA transcripts to thereby inhibit translation of ORFX mRNA. A ribozyme having specificity for a ORFX-encoding nucleic acid can be designed based upon the nucleotide sequence of a ORFX DNA disclosed herein (*i.e.*, SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132)). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a ORFX-encoding mRNA. See, *e.g.*, Cech *et al.* U.S. Pat. No. 4,987,071; and Cech *et al.* U.S. Pat. No. 5,116,742. Alternatively, ORFX mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, *e.g.*, Bartel *et al.*, (1993) *Science* 261:1411-1418.

Alternatively, ORFX gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the ORFX (*e.g.*, the ORFX promoter and/or enhancers) to form triple helical structures that prevent transcription of the ORFX gene in target cells. See generally, Helene. (1991) *Anticancer Drug Des.* 6: 569-84; Helene. *et al.* (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher (1992) *Bioassays* 14: 807-15.

In various embodiments, the nucleic acids of ORFX can be modified at the base moiety, sugar moiety or phosphate backbone to improve, *e.g.*, the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup *et al.* (1996) *Bioorg Med Chem* 4: 5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, *e.g.*, DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup *et al.* (1996) above; Perry-O'Keefe *et al.* (1996) *PNAS* 93: 14670-675.

PNAs of ORFX can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, *e.g.*, inducing transcription or translation arrest or inhibiting replication. PNAs of ORFX can also be used, *e.g.*, in the analysis of single base pair mutations in a gene by, *e.g.*, PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, *e.g.*, S1 nucleases (Hyrup B. (1996) above); or as probes or primers for DNA sequence and hybridization (Hyrup *et al.* (1996), above; Perry-O'Keefe (1996), above).

In another embodiment, PNAs of ORFX can be modified, *e.g.*, to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of ORFX can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, *e.g.*, RNase H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup (1996) above). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996) above and Finn *et al.* (1996) *Nucl Acids Res* 24: 3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, *e.g.*, 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5' end of DNA (Mag *et al.* (1989) *Nucl Acid Res* 17: 5973-88). PNA monomers are then coupled in a stepwise manner to produce a chimeric

molecule with a 5' PNA segment and a 3' DNA segment (Finn *et al.* (1996) above).

Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. See, Petersen *et al.* (1975) *Bioorg Med Chem Lett* 5: 1119-11124.

In other embodiments, the oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger *et al.*, 1989, *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556; Lemaitre *et al.*, 1987, *Proc. Natl. Acad. Sci.* 84:648-652; PCT Publication No. W088/09810) or the blood-brain barrier (see, *e.g.*, PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization triggered cleavage agents (See, *e.g.*, Krol *et al.*, 1988, *BioTechniques* 6:958-976) or intercalating agents. (See, *e.g.*, Zon, 1988, *Pharm. Res.* 5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, *e.g.*, a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, etc.

ORFX polypeptides

The novel protein of the invention includes the ORFX-like protein whose sequence is provided in any of SEQ ID NO:2*n* (wherein *n* = 1 to 132). The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in FIG. 1 while still encoding a protein that maintains its ORFX-like activities and physiological functions, or a functional fragment thereof. For example, the invention includes the polypeptides encoded by the variant ORFX nucleic acids described above. In the mutant or variant protein, up to 20% or more of the residues may be so changed.

In general, an ORFX-like variant that preserves ORFX-like function includes any variant in which residues at a particular position in the sequence have been substituted by other amino acids, and further include the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above. Furthermore, without limiting the scope of the invention, positions of any of SEQ ID NO:2*n* (wherein *n* = 1 to 132) may be substituted such that a mutant or variant protein may include one or more substitutions

The invention also includes isolated ORFX proteins, and biologically active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are

polypeptide fragments suitable for use as immunogens to raise anti-ORFX antibodies. In one embodiment, native ORFX proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, ORFX proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, a ORFX protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the ORFX protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of ORFX protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. In one embodiment, the language "substantially free of cellular material" includes preparations of ORFX protein having less than about 30% (by dry weight) of non-ORFX protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-ORFX protein, still more preferably less than about 10% of non-ORFX protein, and most preferably less than about 5% non-ORFX protein. When the ORFX protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, *i.e.*, culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of ORFX protein in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of ORFX protein having less than about 30% (by dry weight) of chemical precursors or non-ORFX chemicals, more preferably less than about 20% chemical precursors or non-ORFX chemicals, still more preferably less than about 10% chemical precursors or non-ORFX chemicals, and most preferably less than about 5% chemical precursors or non-ORFX chemicals.

Biologically active portions of a ORFX protein include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequence of the ORFX protein, *e.g.*, the amino acid sequence shown in SEQ ID NO:2 that include fewer amino acids than the full length ORFX proteins, and exhibit at least one activity of a ORFX protein.

Typically, biologically active portions comprise a domain or motif with at least one activity of the ORFX protein. A biologically active portion of a ORFX protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length.

5 A biologically active portion of a ORFX protein of the present invention may contain at least one of the above-identified domains conserved between the FGF family of proteins. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native ORFX protein.

10 In an embodiment, the ORFX protein has an amino acid sequence shown in any of SEQ ID NO:2*n* (wherein *n* = 1 to 132). In other embodiments, the ORFX protein is substantially homologous to any of SEQ ID NO:2*n* (wherein *n* = 1 to 132) and retains the functional activity of the protein of any of SEQ ID NO:2*n* (wherein *n* = 1 to 132), yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail below. Accordingly, in another embodiment, the ORFX protein is a protein that comprises an
15 amino acid sequence at least about 45% homologous, and more preferably about 55, 65, 70, 75, 80, 85, 90, 95, 98 or even 99% homologous to the amino acid sequence of any of SEQ ID NO:2*n* (wherein *n* = 1 to 132) and retains the functional activity of the ORFX proteins of the corresponding polypeptide having the sequence of SEQ ID NO:2*n* (wherein *n* = 1 to 132).

Determining homology between two or more sequences

20 To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in either of the sequences being compared for optimal alignment between the sequences). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same
25 amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (*i.e.*, as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity").

The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known
30 in the art, such as GAP software provided in the GCG program package. See, *Needleman and Wunsch* 1970 *J Mol Biol* 48: 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above

exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence shown in SEQ ID NO:2n-1 (wherein $n = 1$ to 132).

The term "sequence identity" refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (*e.g.*, A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (*i.e.*, the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term "substantial identity" as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region. The term "percentage of positive residues" is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical and conservative amino acid substitutions, as defined above, occur in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (*i.e.*, the window size), and multiplying the result by 100 to yield the percentage of positive residues.

Chimeric and fusion proteins

The invention also provides ORFX chimeric or fusion proteins. As used herein, a ORFX "chimeric protein" or "fusion protein" includes a ORFX polypeptide operatively linked to a non-ORFX polypeptide. A "ORFX polypeptide" refers to a polypeptide having an amino acid sequence corresponding to ORFX, whereas a "non-ORFX polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to the ORFX protein, *e.g.*, a protein that is different from the ORFX protein and that is derived from the same or a different organism. Within a ORFX fusion protein the ORFX polypeptide can correspond to all or a portion of a ORFX protein. In one embodiment, a ORFX fusion protein comprises at least one biologically active portion of a ORFX protein. In another embodiment, a ORFX fusion protein comprises at least two biologically active

portions of a ORFX protein. Within the fusion protein, the term "operatively linked" is intended to indicate that the ORFX polypeptide and the non-ORFX polypeptide are fused in-frame to each other. The non-ORFX polypeptide can be fused to the N-terminus or C-terminus of the ORFX polypeptide.

5 For example, in one embodiment a ORFX fusion protein comprises a ORFX polypeptide operably linked to the extracellular domain of a second protein. Such fusion proteins can be further utilized in screening assays for compounds that modulate ORFX activity (such assays are described in detail below).

10 In another embodiment, the fusion protein is a GST-ORFX fusion protein in which the ORFX sequences are fused to the C-terminus of the GST (i.e., glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant ORFX.

In yet another embodiment, the fusion protein is a ORFX protein containing a heterologous signal sequence at its N-terminus. For example, the native ORFX signal sequence can be removed and replaced with a signal sequence from another protein. In certain
15 host cells (*e.g.*, mammalian host cells), expression and/or secretion of ORFX can be increased through use of a heterologous signal sequence.

In another embodiment, the fusion protein is a ORFX-immunoglobulin fusion protein in which the ORFX sequences comprising one or more domains are fused to sequences derived from a member of the immunoglobulin protein family. The ORFX-immunoglobulin
20 fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a ORFX ligand and a ORFX protein on the surface of a cell, to thereby suppress ORFX-mediated signal transduction *in vivo*. In one nonlimiting example, a contemplated ORFX ligand of the invention is an ORFX receptor. The ORFX-immunoglobulin fusion proteins can be used to modulate the bioavailability of a
25 ORFX cognate ligand. Inhibition of the ORFX ligand/ORFX interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (*e.g.*, promoting or inhibiting) cell survival. Moreover, the ORFX-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-ORFX antibodies in a subject, to purify ORFX ligands, and in screening assays to identify
30 molecules that inhibit the interaction of ORFX with a ORFX ligand.

A ORFX chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional

techniques, *e.g.*, by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Ausubel et al. (eds.) *CURRENT PROTOCOLS IN MOLECULAR BIOLOGY*, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a GST polypeptide). A ORFX-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the ORFX protein.

ORFX agonists and antagonists

The present invention also pertains to variants of the ORFX proteins that function as either ORFX agonists (mimetics) or as ORFX antagonists. Variants of the ORFX protein can be generated by mutagenesis, *e.g.*, discrete point mutation or truncation of the ORFX protein. An agonist of the ORFX protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the ORFX protein. An antagonist of the ORFX protein can inhibit one or more of the activities of the naturally occurring form of the ORFX protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the ORFX protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the ORFX proteins.

Variants of the ORFX protein that function as either ORFX agonists (mimetics) or as ORFX antagonists can be identified by screening combinatorial libraries of mutants, *e.g.*, truncation mutants, of the ORFX protein for ORFX protein agonist or antagonist activity. In one embodiment, a variegated library of ORFX variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of ORFX variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential ORFX sequences is expressible as individual polypeptides, or alternatively, as a set

of larger fusion proteins (*e.g.*, for phage display) containing the set of ORFX sequences therein. There are a variety of methods which can be used to produce libraries of potential ORFX variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential ORFX sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, *e.g.*, Narang (1983) *Tetrahedron* 39:3; Itakura *et al.* (1984) *Annu Rev Biochem* 53:323; Itakura *et al.* (1984) *Science* 198:1056; Ike *et al.* (1983) *Nucl Acid Res* 11:477.

Polypeptide libraries

In addition, libraries of fragments of the ORFX protein coding sequence can be used to generate a variegated population of ORFX fragments for screening and subsequent selection of variants of a ORFX protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a ORFX coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal and internal fragments of various sizes of the ORFX protein.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of ORFX proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique that enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify ORFX variants

(Arkin and Yourvan (1992) PNAS 89:7811-7815; Delgrave *et al.* (1993) Protein Engineering 6:327-331).

Anti-ORFX Antibodies

The invention further encompasses antibodies and antibody fragments, such as F_{ab} or $(F_{ab})_2$, that bind immunospecifically to any of the proteins of the invention.

An isolated ORFX protein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind ORFX using standard techniques for polyclonal and monoclonal antibody preparation. Full-length ORFX protein can be used. Alternatively, the invention provides antigenic peptide fragments of ORFX for use as immunogens. The antigenic peptide of ORFX comprises at least 4 amino acid residues of the amino acid sequence shown in any of SEQ ID NO:2n (wherein $n = 1$ to 132). The antigenic peptide encompasses an epitope of ORFX such that an antibody raised against the peptide forms a specific immune complex with ORFX. The antigenic peptide may comprise at least 6 aa residues, at least 8 aa residues, at least 10 aa residues, at least 15 aa residues, at least 20 aa residues, or at least 30 aa residues. In one embodiment of the invention, the antigenic peptide comprises a polypeptide comprising at least 6 contiguous amino acids of any of SEQ ID NO:2n (wherein $n = 1$ to 132).

In an embodiment of the invention, epitopes encompassed by the antigenic peptide are regions of ORFX that are located on the surface of the protein, *e.g.*, hydrophilic regions. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, *e.g.*, Hopp and Woods, 1981, Proc. Nat. Acad. Sci. USA 78: 3824-3828; Kyte and Doolittle 1982, J. Mol. Biol. 157: 105-142, each incorporated herein by reference in their entirety.

As disclosed herein, an ORFX protein sequence of any of SEQ ID NO:2n (wherein $n = 1$ to 132), or derivatives, fragments, analogs or homologs thereof, may be utilized as immunogens in the generation of antibodies that immunospecifically-bind these protein components. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, *i.e.*, molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen, such as ORFX. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, F_{ab} and $(F_{ab})_2$ fragments, and an F_{ab} expression library. In a specific embodiment, antibodies to

human ORFX proteins are disclosed. Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies to a ORFX protein sequence of any of SEQ ID NO:2n (wherein n = 1 to 132) or derivative, fragment, analog or homolog thereof. Some of these proteins are discussed below.

5 For the production of polyclonal antibodies, various suitable host animals (*e.g.*, rabbit, goat, mouse or other mammal) may be immunized by injection with the native protein, or a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, recombinantly expressed ORFX protein or a chemically synthesized ORFX polypeptide. The preparation can further include an adjuvant. Various
10 adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (*e.g.*, aluminum hydroxide), surface active substances (*e.g.*, lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), human adjuvants such as *Bacille Calmette-Guerin* and *Corynebacterium parvum*, or similar immunostimulatory agents. If desired, the antibody molecules directed against ORFX can be
15 isolated from the mammal (*e.g.*, from the blood) and further purified by well known techniques, such as protein A chromatography to obtain the IgG fraction.

The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of ORFX. A monoclonal
20 antibody composition thus typically displays a single binding affinity for a particular ORFX protein with which it immunoreacts. For preparation of monoclonal antibodies directed towards a particular ORFX protein, or derivatives, fragments, analogs or homologs thereof, any technique that provides for the production of antibody molecules by continuous cell line culture may be utilized. Such techniques include, but are not limited to, the hybridoma
25 technique (see Kohler & Milstein, 1975 *Nature* 256: 495-497); the trioma technique; the human B-cell hybridoma technique (see Kozbor, *et al.*, 1983 *Immunol Today* 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, *et al.*, 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be
30 produced by using human hybridomas (see Cote, *et al.*, 1983. *Proc Natl Acad Sci USA* 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus *in vitro* (see Cole, *et al.*, 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Each of the above citations are incorporated herein by reference in their entirety

According to the invention, techniques can be adapted for the production of single-chain antibodies specific to a ORFX protein (see *e.g.*, U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of F_{ab} expression libraries (see *e.g.*, Huse, *et al.*, 1989 *Science* 246: 1275-1281) to allow rapid and effective identification of monoclonal F_{ab} fragments with the desired specificity for a ORFX protein or derivatives, fragments, analogs or homologs thereof. Non-human antibodies can be "humanized" by techniques well known in the art. See *e.g.*, U.S. Patent No. 5,225,539. Each of the above citations are incorporated herein by reference. Antibody fragments that contain the idiotypes to a ORFX protein may be produced by techniques known in the art including, but not limited to: (i) an F_{(ab)₂} fragment produced by pepsin digestion of an antibody molecule; (ii) an F_{ab} fragment generated by reducing the disulfide bridges of an F_{(ab)₂} fragment; (iii) an F_{ab} fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F_v fragments.

Additionally, recombinant anti-ORFX antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in PCT International Application No. PCT/US86/02269; European Patent Application No. 184,187; European Patent Application No. 171,496; European Patent Application No. 173,494; PCT International Publication No. WO 86/01533; U.S. Pat. No. 4,816,567; European Patent Application No. 125,023; Better *et al.* (1988) *Science* 240:1041-1043; Liu *et al.* (1987) *PNAS* 84:3439-3443; Liu *et al.* (1987) *J Immunol.* 139:3521-3526; Sun *et al.* (1987) *PNAS* 84:214-218; Nishimura *et al.* (1987) *Cancer Res* 47:999-1005; Wood *et al.* (1985) *Nature* 314:446-449; Shaw *et al.* (1988), *J. Natl Cancer Inst* 80:1553-1559; Morrison (1985) *Science* 229:1202-1207; Oi *et al.* (1986) *BioTechniques* 4:214; U.S. Pat. No. 5,225,539; Jones *et al.* (1986) *Nature* 321:552-525; Verhoevan *et al.* (1988) *Science* 239:1534; and Beidler *et al.* (1988) *J Immunol* 141:4053-4060. Each of the above citations are incorporated herein by reference.

In one embodiment, methods for the screening of antibodies that possess the desired specificity include, but are not limited to, enzyme-linked immunosorbent assay (ELISA) and other immunologically-mediated techniques known within the art. In a specific embodiment, selection of antibodies that are specific to a particular domain of a ORFX protein is facilitated by generation of hybridomas that bind to the fragment of a ORFX protein possessing such a

domain. Antibodies that are specific for one or more domains within a ORFX protein, *e.g.*, the domain spanning the first fifty amino-terminal residues specific to ORFX when compared to FGF-9, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

Anti-ORFX antibodies may be used in methods known within the art relating to the localization and/or quantitation of a ORFX protein (*e.g.*, for use in measuring levels of the ORFX protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies for ORFX proteins, or derivatives, fragments, analogs or homologs thereof, that contain the antibody derived binding domain, are utilized as pharmacologically-active compounds [hereinafter "Therapeutics"].

An anti-ORFX antibody (*e.g.*, monoclonal antibody) can be used to isolate ORFX by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-ORFX antibody can facilitate the purification of natural ORFX from cells and of recombinantly produced ORFX expressed in host cells. Moreover, an anti-ORFX antibody can be used to detect ORFX protein (*e.g.*, in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the ORFX protein. Anti-ORFX antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, *e.g.*, to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (*i.e.*, physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

ORFX Recombinant Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding ORFX protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable

of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (*e.g.*, in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (*e.g.*, tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including

fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., ORFX proteins, mutant forms of ORFX, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of ORFX in prokaryotic or eukaryotic cells. For example, ORFX can be expressed in bacterial
5 cells such as *E. coli*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

10 Expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (1) to increase expression of recombinant protein; (2) to increase the solubility
15 of the recombinant protein; and (3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor
20 Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc
25 (Amrann *et al.*, (1988) *Gene* 69:301-315) and pET 11d (Studier *et al.*, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant
30 protein. See, Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (Wada *et al.*, (1992)

Nucleic Acids Res. 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the ORFX expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1 (Baldari, *et al.*, (1987) *EMBO J* 6:229-234), pMFa (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz *et al.*, (1987) *Gene* 54:113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (Invitrogen Corp, San Diego, Calif.).

Alternatively, ORFX can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (*e.g.*, SF9 cells) include the pAc series (Smith *et al.* (1983) *Mol Cell Biol* 3:2156-2165) and the pVL series (Lucklow and Summers (1989) *Virology* 170:31-39).

In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed (1987) *Nature* 329:840) and pMT2PC (Kaufman *et al.* (1987) *EMBO J* 6: 187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells. See, *e.g.*, Chapters 16 and 17 of Sambrook *et al.*, *MOLECULAR CLONING: A LABORATORY MANUAL*. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (*e.g.*, tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert *et al.* (1987) *Genes Dev* 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) *Adv Immunol* 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) *EMBO J* 8:729-733) and immunoglobulins (Banerji *et al.* (1983) *Cell* 33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), neuron-specific promoters (*e.g.*, the neurofilament promoter; Byrne and Ruddle (1989) *PNAS* 86:5473-5477), pancreas-specific promoters (Edlund *et al.* (1985) *Science* 230:912-916), and mammary gland-specific promoters (*e.g.*, milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No.

264,166). Developmentally-regulated promoters are also encompassed, *e.g.*, the murine hox promoters (Kessel and Gruss (1990) *Science* 249:374-379) and the α -fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev* 3:537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to ORFX mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub *et al.*, "Antisense RNA as a molecular tool for genetic analysis," Reviews--Trends in Genetics, Vol. 1(1) 1986.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, ORFX protein can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (*e.g.*, DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or

electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.

5 For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (*e.g.*, resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer
10 resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding ORFX or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene will survive, while the other cells die).

15 A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (*i.e.*, express) ORFX protein. Accordingly, the invention further provides methods for producing ORFX protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding ORFX has been introduced) in a suitable medium
20 such that ORFX protein is produced. In another embodiment, the method further comprises isolating ORFX from the medium or the host cell.

Transgenic animals

The host cells of the invention can also be used to produce nonhuman transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or
25 an embryonic stem cell into which ORFX-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous ORFX sequences have been introduced into their genome or homologous recombinant animals in which endogenous ORFX sequences have been altered. Such animals are useful for studying the function and/or activity of ORFX and for identifying and/or evaluating modulators of
30 ORFX activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA

that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous ORFX gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, *e.g.*, an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing ORFX-encoding nucleic acid into the male pronuclei of a fertilized oocyte, *e.g.*, by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The human ORFX DNA sequence of SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132) can be introduced as a transgene into the genome of a non-human animal. Alternatively, a nonhuman homologue of the human ORFX gene, such as a mouse ORFX gene, can be isolated based on hybridization to the human ORFX cDNA (described further above) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to the ORFX transgene to direct expression of ORFX protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan 1986, In: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the ORFX transgene in its genome and/or expression of ORFX mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding ORFX can further be bred to other transgenic animals carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a ORFX gene into which a deletion, addition or substitution has been introduced to thereby alter, *e.g.*, functionally disrupt, the ORFX gene. The ORFX gene can be a human gene (*e.g.*, SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132)), but more preferably, is a non-human homologue of a human ORFX gene. For example, a mouse homologue of human

ORFX gene of SEQ ID NO:2n-1 (wherein $n = 1$ to 132) can be used to construct a homologous recombination vector suitable for altering an endogenous ORFX gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous ORFX gene is functionally disrupted (*i.e.*, no longer encodes a functional protein; also referred to as a "knock out" vector).

Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous ORFX gene is mutated or otherwise altered but still encodes functional protein (*e.g.*, the upstream regulatory region can be altered to thereby alter the expression of the endogenous ORFX protein). In the homologous recombination vector, the altered portion of the ORFX gene is flanked at its 5' and 3' ends by additional nucleic acid of the ORFX gene to allow for homologous recombination to occur between the exogenous ORFX gene carried by the vector and an endogenous ORFX gene in an embryonic stem cell. The additional flanking ORFX nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5' and 3' ends) are included in the vector. See *e.g.*, Thomas *et al.* (1987) *Cell* 51:503 for a description of homologous recombination vectors. The vector is introduced into an embryonic stem cell line (*e.g.*, by electroporation) and cells in which the introduced ORFX gene has homologously recombined with the endogenous ORFX gene are selected (see *e.g.*, Li *et al.* (1992) *Cell* 69:915).

The selected cells are then injected into a blastocyst of an animal (*e.g.*, a mouse) to form aggregation chimeras. See *e.g.*, Bradley 1987, In: TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley (1991) *Curr Opin Biotechnol* 2:823-829; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169.

In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, see, *e.g.*, Lakso *et al.* (1992) *PNAS* 89:6232-6236. Another

example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman *et al.* (1991) *Science* 251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided
5 through the construction of "double" transgenic animals, *e.g.*, by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmot *et al.* (1997) *Nature* 385:810-813. In brief, a
10 cell, *e.g.*, a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, *e.g.*, through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The
15 offspring borne of this female foster animal will be a clone of the animal from which the cell, *e.g.*, the somatic cell, is isolated.

Pharmaceutical Compositions

The ORFX nucleic acid molecules, ORFX proteins, and anti-ORFX antibodies (also referred to herein as "active compounds") of the invention, and derivatives, fragments, analogs
20 and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like,
25 compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be
30 used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, oral (*e.g.*, inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, 5 intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates, and agents 10 for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous 15 solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under 20 the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by 25 the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the 30 composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (*e.g.*, a ORFX protein or anti-ORFX antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, *e.g.*, a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (*e.g.*, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by any of a number of routes, *e.g.*, as described in U.S. Patent Nos. 5,703,055. Delivery can thus also include, *e.g.*, intravenous injection, local administration (see U.S. Pat. No. 5,328,470) or stereotactic injection (see *e.g.*, Chen *et al.* (1994) *PNAS* 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, *e.g.*, retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

Additional Uses and Methods of the Invention

The nucleic acid molecules, proteins, protein homologues, and antibodies described
5 herein can be used in one or more of the following methods: (a) screening assays; (b) detection assays (*e.g.*, chromosomal mapping, cell and tissue typing, forensic biology), (c) predictive medicine (*e.g.*, diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenomics); and (d) methods of treatment (*e.g.*, therapeutic and prophylactic).

The isolated nucleic acid molecules of the invention can be used to express ORFX
10 protein (*e.g.*, via a recombinant expression vector in a host cell in gene therapy applications), to detect ORFX mRNA (*e.g.*, in a biological sample) or a genetic lesion in a ORFX gene, and to modulate ORFX activity, as described further below. In addition, the ORFX proteins can be used to screen drugs or compounds that modulate the ORFX activity or expression as well as to treat disorders characterized by insufficient or excessive production of ORFX protein, for
15 example proliferative or differentiative disorders, or production of ORFX protein forms that have decreased or aberrant activity compared to ORFX wild type protein. In addition, the anti-ORFX antibodies of the invention can be used to detect and isolate ORFX proteins and modulate ORFX activity.

This invention further pertains to novel agents identified by the above described
20 screening assays and uses thereof for treatments as described herein.

Screening Assays

The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, *i.e.*, candidate or test compounds or agents (*e.g.*, peptides, peptidomimetics, small molecules or other drugs) that bind to ORFX proteins or have a
25 stimulatory or inhibitory effect on, for example, ORFX expression or ORFX activity.

In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of a ORFX protein or polypeptide or biologically active portion thereof. The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the
30 art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The

biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam (1997) *Anticancer Drug Des* 12:145).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt *et al.* (1993) *Proc Natl Acad Sci U.S.A.* 90:6909; Erb *et al.* (1994) *Proc Natl Acad Sci U.S.A.* 91:11422; Zuckermann *et al.* (1994) *J Med Chem* 37:2678; Cho *et al.* (1993) *Science* 261:1303; Carrell *et al.* (1994) *Angew Chem Int Ed Engl* 33:2059; Carell *et al.* (1994) *Angew Chem Int Ed Engl* 33:2061; and Gallop *et al.* (1994) *J Med Chem* 37:1233.

Libraries of compounds may be presented in solution (*e.g.*, Houghten (1992) *Biotechniques* 13:412-421), or on beads (Lam (1991) *Nature* 354:82-84), on chips (Fodor (1993) *Nature* 364:555-556), bacteria (Ladner U.S. Pat. No. 5,223,409), spores (Ladner USP '409), plasmids (Cull *et al.* (1992) *Proc Natl Acad Sci USA* 89:1865-1869) or on phage (Scott and Smith (1990) *Science* 249:386-390; Devlin (1990) *Science* 249:404-406; Cwirla *et al.* (1990) *Proc Natl Acad Sci U.S.A.* 87:6378-6382; Felici (1991) *J Mol Biol* 222:301-310; Ladner above.).

In one embodiment, an assay is a cell-based assay in which a cell which expresses a membrane-bound form of ORFX protein, or a biologically active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to a ORFX protein determined. The cell, for example, can of mammalian origin or a yeast cell.

Determining the ability of the test compound to bind to the ORFX protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the ORFX protein or biologically active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with ^{125}I , ^{35}S , ^{14}C , or ^3H , either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, test compounds can be enzymatically labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In one embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of ORFX protein, or a biologically active portion thereof, on the cell surface with a known compound which binds ORFX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a ORFX protein, wherein determining the ability of the test compound to interact with a ORFX protein comprises

determining the ability of the test compound to preferentially bind to ORFX or a biologically active portion thereof as compared to the known compound.

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of ORFX protein, or a biologically active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (*e.g.*, stimulate or inhibit) the activity of the ORFX protein or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of ORFX or a biologically active portion thereof can be accomplished, for example, by determining the ability of the ORFX protein to bind to or interact with a ORFX target molecule. As used herein, a "target molecule" is a molecule with which a ORFX protein binds or interacts in nature, for example, a molecule on the surface of a cell which expresses a ORFX interacting protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. A ORFX target molecule can be a non-ORFX molecule or a ORFX protein or polypeptide of the present invention. In one embodiment, a ORFX target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (*e.g.*, a signal generated by binding of a compound to a membrane-bound ORFX molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with ORFX.

Determining the ability of the ORFX protein to bind to or interact with a ORFX target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of the ORFX protein to bind to or interact with a ORFX target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (*i.e.* intracellular Ca^{2+} , diacylglycerol, IP_3 , etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising a ORFX-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, *e.g.*, luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.

In yet another embodiment, an assay of the present invention is a cell-free assay comprising contacting a ORFX protein or biologically active portion thereof with a test

compound and determining the ability of the test compound to bind to the ORFX protein or biologically active portion thereof. Binding of the test compound to the ORFX protein can be determined either directly or indirectly as described above. In one embodiment, the assay comprises contacting the ORFX protein or biologically active portion thereof with a known
5 compound which binds ORFX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a ORFX protein, wherein determining the ability of the test compound to interact with a ORFX protein comprises determining the ability of the test compound to preferentially bind to ORFX or biologically active portion thereof as compared to the known compound.

10 In another embodiment, an assay is a cell-free assay comprising contacting ORFX protein or biologically active portion thereof with a test compound and determining the ability of the test compound to modulate (*e.g.*, stimulate or inhibit) the activity of the ORFX protein or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of ORFX can be accomplished, for example, by determining the ability
15 of the ORFX protein to bind to a ORFX target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of ORFX can be accomplished by determining the ability of the ORFX protein further modulate a ORFX target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be
20 determined as previously described.

In yet another embodiment, the cell-free assay comprises contacting the ORFX protein or biologically active portion thereof with a known compound which binds ORFX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a ORFX protein, wherein determining the ability of the
25 test compound to interact with a ORFX protein comprises determining the ability of the ORFX protein to preferentially bind to or modulate the activity of a ORFX target molecule.

The cell-free assays of the present invention are amenable to use of both the soluble form or the membrane-bound form of ORFX. In the case of cell-free assays comprising the membrane-bound form of ORFX, it may be desirable to utilize a solubilizing agent such that
30 the membrane-bound form of ORFX is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton[®] X-100, Triton[®] X-114, Thesit[®], Isotridecypoly(ethylene glycol ether)_n, N-dodecyl--

N,N-dimethyl-3-ammonio-1-propane sulfonate, 3-(3-cholamidopropyl)dimethylamminiol-1-propane sulfonate (CHAPS), or 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-1-propane sulfonate (CHAPSO).

In more than one embodiment of the above assay methods of the present invention, it may be desirable to immobilize either ORFX or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to ORFX, or interaction of ORFX with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-ORFX fusion proteins or GST-target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or ORFX protein, and the mixture is incubated under conditions conducive to complex formation (*e.g.*, at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of ORFX binding or activity determined using standard techniques.

Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either ORFX or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated ORFX or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (*e.g.*, biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with ORFX or target molecules, but which do not interfere with binding of the ORFX protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or ORFX trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the ORFX or target molecule,

as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the ORFX or target molecule.

In another embodiment, modulators of ORFX expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of ORFX mRNA or protein in the cell is determined. The level of expression of ORFX mRNA or protein in the presence of the candidate compound is compared to the level of expression of ORFX mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of ORFX expression based on this comparison. For example, when expression of ORFX mRNA or protein is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of ORFX mRNA or protein expression. Alternatively, when expression of ORFX mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of ORFX mRNA or protein expression. The level of ORFX mRNA or protein expression in the cells can be determined by methods described herein for detecting ORFX mRNA or protein.

In yet another aspect of the invention, the ORFX proteins can be used as "bait proteins" in a two-hybrid assay or three hybrid assay (see, *e.g.*, U.S. Pat. No. 5,283,317; Zervos *et al.* (1993) Cell 72:223-232; Madura *et al.* (1993) J Biol Chem 268:12046-12054; Bartel *et al.* (1993) Biotechniques 14:920-924; Iwabuchi *et al.* (1993) Oncogene 8:1693-1696; and Brent WO94/10300), to identify other proteins that bind to or interact with ORFX ("ORFX-binding proteins" or "ORFX-bp") and modulate ORFX activity. Such ORFX-binding proteins are also likely to be involved in the propagation of signals by the ORFX proteins as, for example, upstream or downstream elements of the ORFX pathway.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for ORFX is fused to a gene encoding the DNA binding domain of a known transcription factor (*e.g.*, GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming a ORFX-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (*e.g.*, LacZ) that is operably linked to a transcriptional

regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with ORFX.

5 This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.

Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a
10 minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample.

The ORFX sequences of the present invention can also be used to identify individuals from minute biological samples. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for
15 identification. The sequences of the present invention are useful as additional DNA markers for RFLP ("restriction fragment length polymorphisms," described in U.S. Pat. No. 5,272,057).

Furthermore, the sequences of the present invention can be used to provide an
20 alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the ORFX sequences described herein can be used to prepare two PCR primers from the 5' and 3' ends of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner,
25 can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the present invention

Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences of SEQ ID NO:2*n*-1 (wherein
5 *n* = 1 to 132), as described above, can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

Predictive Medicine

10 The present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the present invention relates to diagnostic assays for determining ORFX protein and/or nucleic acid expression as well as ORFX activity, in the context of a
15 biological sample (*e.g.*, blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant ORFX expression or activity. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with ORFX protein, nucleic acid expression or activity. For example, mutations in
20 a ORFX gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with ORFX protein, nucleic acid expression or activity.

Another aspect of the invention provides methods for determining ORFX protein, nucleic acid expression or ORFX activity in an individual to thereby select appropriate
25 therapeutic or prophylactic agents for that individual (referred to herein as "pharmacogenomics"). Pharmacogenomics allows for the selection of agents (*e.g.*, drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (*e.g.*, the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)

30 Yet another aspect of the invention pertains to monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity of ORFX in clinical trials.

Use of Partial ORFX Sequences in Forensic Biology

DNA-based identification techniques can also be used in forensic biology. Forensic biology is a scientific field employing genetic typing of biological evidence found at a crime scene as a means for positively identifying, for example, a perpetrator of a crime. To make
5 such an identification, PCR technology can be used to amplify DNA sequences taken from very small biological samples such as tissues, *e.g.*, hair or skin, or body fluids, *e.g.*, blood, saliva, or semen found at a crime scene. The amplified sequence can then be compared to a standard, thereby allowing identification of the origin of the biological sample.

The sequences of the present invention can be used to provide polynucleotide reagents,
10 *e.g.*, PCR primers, targeted to specific loci in the human genome, that can enhance the reliability of DNA-based forensic identifications by, for example, providing another "identification marker" (*i.e.* another DNA sequence that is unique to a particular individual). As mentioned above, actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments. Sequences
15 targeted to noncoding regions of SEQ ID NO:2*n*-1 (where *n* = 1 to 132) are particularly appropriate for this use as greater numbers of polymorphisms occur in the noncoding regions, making it easier to differentiate individuals using this technique. Examples of polynucleotide reagents include the ORFX sequences or portions thereof, *e.g.*, fragments derived from the noncoding regions of one or more of SEQ ID NO:2*n*-1 (where *n* = 1 to 132), having a length
20 of at least 20 bases, preferably at least 30 bases.

The ORFX sequences described herein can further be used to provide polynucleotide reagents, *e.g.*, labeled or label-able probes that can be used, for example, in an *in situ* hybridization technique, to identify a specific tissue, *e.g.*, brain tissue, etc. This can be very useful in cases where a forensic pathologist is presented with a tissue of unknown origin.
25 Panels of such ORFX probes can be used to identify tissue by species and/or by organ type.

In a similar fashion, these reagents, *e.g.*, ORFX primers or probes can be used to screen tissue culture for contamination (*i.e.* screen for the presence of a mixture of different types of cells in a culture).

Predictive Medicine

30 The present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically.

Accordingly, one aspect of the present invention relates to diagnostic assays for determining ORFX protein and/or nucleic acid expression as well as ORFX activity, in the context of a biological sample (*e.g.*, blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant ORFX expression or activity. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with ORFX protein, nucleic acid expression or activity. For example, mutations in a ORFX gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with ORFX protein, nucleic acid expression or activity.

Another aspect of the invention provides methods for determining ORFX protein, nucleic acid expression or ORFX activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as "pharmacogenomics"). Pharmacogenomics allows for the selection of agents (*e.g.*, drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (*e.g.*, the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)

Yet another aspect of the invention pertains to monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity of ORFX in clinical trials.

These and other agents are described in further detail in the following sections.

Diagnostic Assays

Other conditions in which proliferation of cells plays a role include tumors, restenosis, psoriasis, Dupuytren's contracture, diabetic complications, Kaposi's sarcoma and rheumatoid arthritis.

An ORFX polypeptide may be used to identify an interacting polypeptide a sample or tissue. The method comprises contacting the sample or tissue with ORFX, allowing formation of a complex between the ORFX polypeptide and the interacting polypeptide, and detecting the complex, if present.

The proteins of the invention may be used to stimulate production of antibodies specifically binding the proteins. Such antibodies may be used in immunodiagnostic procedures to detect the occurrence of the protein in a sample. The proteins of the invention may be used to stimulate cell growth and cell proliferation in conditions in which such growth

would be favorable. An example would be to counteract toxic side effects of chemotherapeutic agents on, for example, hematopoiesis and platelet formation, linings of the gastrointestinal tract, and hair follicles. They may also be used to stimulate new cell growth in neurological disorders including, for example, Alzheimer's disease. Alternatively,

5 antagonistic treatments may be administered in which an antibody specifically binding the ORFX-like proteins of the invention would abrogate the specific growth-inducing effects of the proteins. Such antibodies may be useful, for example, in the treatment of proliferative disorders including various tumors and benign hyperplasias.

Polynucleotides or oligonucleotides corresponding to any one portion of the ORFX
10 nucleic acids of SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132) may be used to detect DNA containing a corresponding ORF gene, or detect the expression of a corresponding ORFX gene, or ORFX-like gene. For example, an ORFX nucleic acid expressed in a particular cell or tissue, as noted in Table 2, can be used to identify the presence of that particular cell type.

An exemplary method for detecting the presence or absence of ORFX in a biological
15 sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting ORFX protein or nucleic acid (*e.g.*, mRNA, genomic DNA) that encodes ORFX protein such that the presence of ORFX is detected in the biological sample. An agent for detecting ORFX mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to ORFX mRNA or genomic DNA. The
20 nucleic acid probe can be, for example, a full-length ORFX nucleic acid, such as the nucleic acid of SEQ ID NO:2*n*-1 (wherein *n* = 1 to 132), or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to ORFX mRNA or genomic DNA, as described above. Other suitable probes for use in the diagnostic assays of the invention are
25 described herein.

An agent for detecting ORFX protein is an antibody capable of binding to ORFX protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (*e.g.*, Fab or F(ab')₂) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass
30 direct labeling of the probe or antibody by coupling (*i.e.*, physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include

detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect ORFX mRNA, protein, or genomic DNA in a biological sample *in vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of ORFX mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of ORFX protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. *In vitro* techniques for detection of ORFX genomic DNA include Southern hybridizations. Furthermore, *in vivo* techniques for detection of ORFX protein include introducing into a subject a labeled anti-ORFX antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting ORFX protein, mRNA, or genomic DNA, such that the presence of ORFX protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of ORFX protein, mRNA or genomic DNA in the control sample with the presence of ORFX protein, mRNA or genomic DNA in the test sample.

The invention also encompasses kits for detecting the presence of ORFX in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting ORFX protein or mRNA in a biological sample; means for determining the amount of ORFX in the sample; and means for comparing the amount of ORFX in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect ORFX protein or nucleic acid.

Prognostic Assays

The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant ORFX

expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with ORFX protein, nucleic acid expression or activity in, *e.g.*, proliferative or differentiative disorders such as hyperplasias, tumors, restenosis, psoriasis, Dupuytren's contracture, diabetic complications, or rheumatoid arthritis, etc.; and glia-associated disorders such as cerebral lesions, diabetic neuropathies, cerebral edema, senile dementia, Alzheimer's disease, etc. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the present invention provides a method for identifying a disease or disorder associated with aberrant ORFX expression or activity in which a test sample is obtained from a subject and ORFX protein or nucleic acid (*e.g.*, mRNA, genomic DNA) is detected, wherein the presence of ORFX protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant ORFX expression or activity. As used herein, a "test sample" refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (*e.g.*, serum), cell sample, or tissue.

Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (*e.g.*, an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant ORFX expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder, such as a proliferative disorder, differentiative disorder, glia-associated disorders, etc. Thus, the present invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant ORFX expression or activity in which a test sample is obtained and ORFX protein or nucleic acid is detected (*e.g.*, wherein the presence of ORFX protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant ORFX expression or activity.)

The methods of the invention can also be used to detect genetic lesions in a ORFX gene, thereby determining if a subject with the lesioned gene is at risk for, or suffers from, a proliferative disorder, differentiative disorder, glia-associated disorder, etc. In various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding a ORFX-protein, or the mis-expression of the ORFX gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one

of (1) a deletion of one or more nucleotides from a ORFX gene; (2) an addition of one or more nucleotides to a ORFX gene; (3) a substitution of one or more nucleotides of a ORFX gene, (4) a chromosomal rearrangement of a ORFX gene; (5) an alteration in the level of a messenger RNA transcript of a ORFX gene, (6) aberrant modification of a ORFX gene, such as of the methylation pattern of the genomic DNA, (7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of a ORFX gene, (8) a non-wild type level of a ORFX-protein, (9) allelic loss of a ORFX gene, and (10) inappropriate post-translational modification of a ORFX-protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in a ORFX gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, *e.g.*, U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, *e.g.*, Landegran *et al.* (1988) *Science* 241:1077-1080; and Nakazawa *et al.* (1994) *PNAS* 91:360-364), the latter of which can be particularly useful for detecting point mutations in the ORFX-gene (see Abravaya *et al.* (1995) *Nucl Acids Res* 23:675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (*e.g.*, genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to a ORFX gene under conditions such that hybridization and amplification of the ORFX gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Alternative amplification methods include: self sustained sequence replication (Guatelli *et al.*, 1990, *Proc Natl Acad Sci USA* 87:1874-1878), transcriptional amplification system (Kwoh, *et al.*, 1989, *Proc Natl Acad Sci USA* 86:1173-1177), Q-Beta Replicase (Lizardi *et al.*, 1988, *BioTechnology* 6:1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

In an alternative embodiment, mutations in a ORFX gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared.

5 Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, for example, U.S. Pat. No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in ORFX can be identified by hybridizing a

10 sample and control nucleic acids, *e.g.*, DNA or RNA, to high density arrays containing hundreds or thousands of oligonucleotides probes (Cronin *et al.* (1996) *Human Mutation* 7: 244-255; Kozal *et al.* (1996) *Nature Medicine* 2: 753-759). For example, genetic mutations in ORFX can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin *et al.* above. Briefly, a first hybridization array of probes can be used to

15 scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This step is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of

20 parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the ORFX gene and detect mutations by comparing the sequence of the sample ORFX with the corresponding wild-type (control) sequence.

25 Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert (1977) *PNAS* 74:560 or Sanger (1977) *PNAS* 74:5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (Naeve *et al.*, (1995) *Biotechniques* 19:448), including sequencing by mass spectrometry (see, *e.g.*, PCT International Publ. No. WO 94/16101; Cohen *et al.* (1996) *Adv*

30 *Chromatogr* 36:127-162; and Griffin *et al.* (1993) *Appl Biochem Biotechnol* 38:147-159).

Other methods for detecting mutations in the ORFX gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes (Myers *et al.* (1985) *Science* 230:1242). In general, the art

technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type ORFX sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S1 nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, for example, Cotton *et al* (1988) *Proc Natl Acad Sci USA* 85:4397; Saleeba *et al* (1992) *Methods Enzymol* 217:286-295. In an embodiment, the control DNA or RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in ORFX cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches (Hsu *et al.* (1994) *Carcinogenesis* 15:1657-1662). According to an exemplary embodiment, a probe based on a ORFX sequence, *e.g.*, a wild-type ORFX sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, for example, U.S. Pat. No. 5,459,039.

In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in ORFX genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids (Orita *et al.* (1989) *Proc Natl Acad Sci USA*: 86:2766, see also Cotton (1993) *Mutat Res* 285:125-144; Hayashi (1992) *Genet Anal Tech Appl* 9:73-79). Single-stranded DNA fragments of sample and control ORFX nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA, rather than DNA, in which the

secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility. See, *e.g.*, Keen *et al.* (1991) *Trends Genet* 7:5.

5 In yet another embodiment the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE). See, *e.g.*, Myers *et al.* (1985) *Nature* 313:495. When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich
10 DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA. See, *e.g.*, Rosenbaum and Reissner (1987) *Biophys Chem* 265:12753.

Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer
15 extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found. See, *e.g.*, Saiki *et al.* (1986) *Nature* 324:163); Saiki *et al.* (1989) *Proc Natl Acad. Sci USA* 86:6230. Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the
20 oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the
25 molecule (so that amplification depends on differential hybridization) (Gibbs *et al.* (1989) *Nucleic Acids Res* 17:2437-2448) or at the extreme 3' end of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (Prossner (1993) *Tibtech* 11:238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection. See, *e.g.*, Gasparini *et al.* (1992)
30 *Mol Cell Probes* 6:1. It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification. See, *e.g.*, Barany (1991) *Proc Natl Acad Sci USA* 88:189. In such cases, ligation will occur only if there is a perfect match at the 3' end of

the 5' sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, *e.g.*, in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a ORFX gene.

Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which ORFX is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

Pharmacogenomics

Agents, or modulators that have a stimulatory or inhibitory effect on ORFX activity (*e.g.*, ORFX gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders (*e.g.*, neurological, cancer-related or gestational disorders) associated with aberrant ORFX activity. In conjunction with such treatment, the pharmacogenomics (*i.e.*, the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (*e.g.*, drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of ORFX protein, expression of ORFX nucleic acid, or mutation content of ORFX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See *e.g.*, Eichelbaum, 1996, *Clin Exp Pharmacol Physiol*, 23:983-985 and Linder, 1997, *Clin Chem*, 43:254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur

either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is haemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

5 As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (*e.g.*, N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and
10 serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of
15 CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of
20 ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

Thus, the activity of ORFX protein, expression of ORFX nucleic acid, or mutation content of ORFX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding
25 drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a ORFX modulator, such as a modulator identified by one of the exemplary screening assays described herein.

30 **Monitoring Clinical Efficacy**

Monitoring the influence of agents (*e.g.*, drugs, compounds) on the expression or activity of ORFX (*e.g.*, the ability to modulate aberrant cell proliferation and/or differentiation) can be applied in basic drug screening and in clinical trials. For example, the

effectiveness of an agent determined by a screening assay as described herein to increase ORFX gene expression, protein levels, or upregulate ORFX activity, can be monitored in clinical trials of subjects exhibiting decreased ORFX gene expression, protein levels, or downregulated ORFX activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease ORFX gene expression, protein levels, or downregulate ORFX activity, can be monitored in clinical trials of subjects exhibiting increased ORFX gene expression, protein levels, or upregulated ORFX activity. In such clinical trials, the expression or activity of ORFX and, preferably, other genes that have been implicated in, for example, a proliferative or neurological disorder, can be used as a "read out" or marker of the responsiveness of a particular cell.

For example, genes, including ORFX, that are modulated in cells by treatment with an agent (*e.g.*, compound, drug or small molecule) that modulates ORFX activity (*e.g.*, identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of ORFX and other genes implicated in the disorder. The levels of gene expression (*i.e.*, a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of ORFX or other genes. In this way, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

In one embodiment, the invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (*e.g.*, an agonist, antagonist, protein, peptide, nucleic acid, peptidomimetic, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of a ORFX protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the ORFX protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the ORFX protein, mRNA, or genomic DNA in the pre-administration sample with the ORFX protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the

subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of ORFX to higher levels than detected, *i.e.*, to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of ORFX to lower levels than detected, *i.e.*, to decrease the effectiveness of the agent.

Methods of Treatment

The present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant ORFX expression or activity.

Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that antagonize (*i.e.*, reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, (i) a ORFX polypeptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to a ORFX peptide; (iii) nucleic acids encoding a ORFX peptide; (iv) administration of antisense nucleic acid and nucleic acids that are "dysfunctional" (*i.e.*, due to a heterologous insertion within the coding sequences of coding sequences to a ORFX peptide) that are utilized to "knockout" endogenous function of a ORFX peptide by homologous recombination (see, *e.g.*, Capecchi, 1989, *Science* 244: 1288-1292); or (v) modulators (*i.e.*, inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction between a ORFX peptide and its binding partner.

Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that increase (*i.e.*, are agonists to) activity. Therapeutics that upregulate activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, a ORFX peptide, or analogs, derivatives, fragments or homologs thereof; or an agonist that increases bioavailability.

Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (*e.g.*, from biopsy tissue) and assaying it *in vitro* for RNA or peptide levels, structure and/or activity of the expressed peptides (or mRNAs of a ORFX peptide). Methods that are well-known within the art include, but are not limited to, immunoassays (*e.g.*, by Western blot analysis, immunoprecipitation followed by sodium

dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect expression of mRNAs (*e.g.*, Northern assays, dot blots, *in situ* hybridization, etc.).

In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant ORFX expression or activity, by administering to the subject an agent that modulates ORFX expression or at least one ORFX activity. Subjects at risk for a disease that is caused or contributed to by aberrant ORFX expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the ORFX aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending on the type of ORFX aberrancy, for example, a ORFX agonist or ORFX antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein.

Another aspect of the invention pertains to methods of modulating ORFX expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of ORFX protein activity associated with the cell. An agent that modulates ORFX protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of a ORFX protein, a peptide, a ORFX peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more ORFX protein activity. Examples of such stimulatory agents include active ORFX protein and a nucleic acid molecule encoding ORFX that has been introduced into the cell. In another embodiment, the agent inhibits one or more ORFX protein activity. Examples of such inhibitory agents include antisense ORFX nucleic acid molecules and anti-ORFX antibodies. These modulatory methods can be performed *in vitro* (*e.g.*, by culturing the cell with the agent) or, alternatively, *in vivo* (*e.g.*, by administering the agent to a subject). As such, the present invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of a ORFX protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (*e.g.*, an agent identified by a screening assay described herein), or combination of agents that modulates (*e.g.*, upregulates or downregulates) ORFX expression or activity. In another embodiment, the method involves administering a ORFX protein or

nucleic acid molecule as therapy to compensate for reduced or aberrant ORFX expression or activity.

Determination of the Biological Effect of a Therapeutic

In various embodiments of the present invention, suitable *in vitro* or *in vivo* assays are
5 utilized to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue.

In various specific embodiments, *in vitro* assays may be performed with representative cells of the type(s) involved in the patient's disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in
10 suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for *in vivo* testing, any of the animal model system known in the art may be used prior to administration to human subjects.

Malignancies

15 Some ORFX polypeptides are expressed in cancerous cells (*see, e.g.*, Tables 1 and 2). Accordingly, the corresponding ORF protein is involved in the regulation of cell proliferation. Accordingly, Therapeutics of the present invention may be useful in the therapeutic or prophylactic treatment of diseases or disorders that are associated with cell hyperproliferation and/or loss of control of cell proliferation (*e.g.*, cancers, malignancies and tumors). For a
20 review of such hyperproliferation disorders, *see e.g.*, Fishman, *et al.*, 1985. MEDICINE, 2nd ed., J.B. Lippincott Co., Philadelphia, PA.

Therapeutics of the present invention may be assayed by any method known within the art for efficacy in treating or preventing malignancies and related disorders. Such assays include, but are not limited to, *in vitro* assays utilizing transformed cells or cells derived from
25 the patient's tumor, as well as *in vivo* assays using animal models of cancer or malignancies. Potentially effective Therapeutics are those that, for example, inhibit the proliferation of tumor-derived or transformed cells in culture or cause a regression of tumors in animal models, in comparison to the controls.

In the practice of the present invention, once a malignancy or cancer has been shown to be amenable to treatment by modulating (*i.e.*, inhibiting, antagonizing or agonizing) activity, that cancer or malignancy may subsequently be treated or prevented by the administration of a Therapeutic that serves to modulate protein function.

5 **Premalignant conditions**

The Therapeutics of the present invention that are effective in the therapeutic or prophylactic treatment of cancer or malignancies may also be administered for the treatment of pre-malignant conditions and/or to prevent the progression of a pre-malignancy to a neoplastic or malignant state. Such prophylactic or therapeutic use is indicated in conditions known or
10 suspected of preceding progression to neoplasia or cancer, in particular, where non-neoplastic cell growth consisting of hyperplasia, metaplasia or, most particularly, dysplasia has occurred. For a review of such abnormal cell growth see *e.g.*, Robbins & Angell, 1976. BASIC PATHOLOGY, 2nd ed., W.B. Saunders Co., Philadelphia, PA.

Hyperplasia is a form of controlled cell proliferation involving an increase in cell
15 number in a tissue or organ, without significant alteration in its structure or function. For example, it has been demonstrated that endometrial hyperplasia often precedes endometrial cancer. Metaplasia is a form of controlled cell growth in which one type of mature or fully differentiated cell substitutes for another type of mature cell. Metaplasia may occur in epithelial or connective tissue cells. Dysplasia is generally considered a precursor of cancer,
20 and is found mainly in the epithelia. Dysplasia is the most disorderly form of non-neoplastic cell growth, and involves a loss in individual cell uniformity and in the architectural orientation of cells. Dysplasia characteristically occurs where there exists chronic irritation or inflammation, and is often found in the cervix, respiratory passages, oral cavity, and gall bladder.

25 Alternatively, or in addition to the presence of abnormal cell growth characterized as hyperplasia, metaplasia, or dysplasia, the presence of one or more characteristics of a transformed or malignant phenotype displayed either *in vivo* or *in vitro* within a cell sample derived from a patient, is indicative of the desirability of prophylactic/therapeutic administration of a Therapeutic that possesses the ability to modulate activity of An
30 aforementioned protein. Characteristics of a transformed phenotype include, but are not limited to: (i) morphological changes; (ii) looser substratum attachment; (iii) loss of

cell-to-cell contact inhibition; (iv) loss of anchorage dependence; (v) protease release; (vi) increased sugar transport; (vii) decreased serum requirement; (viii) expression of fetal antigens, (ix) disappearance of the 250 kDal cell-surface protein, and the like. See *e.g.*, Richards, *et al.*, 1986. MOLECULAR PATHOLOGY, W.B. Saunders Co., Philadelphia, PA.

5 In a specific embodiment of the present invention, a patient that exhibits one or more of the following predisposing factors for malignancy is treated by administration of an effective amount of a Therapeutic: (i) a chromosomal translocation associated with a malignancy (*e.g.*, the Philadelphia chromosome (*bcr/abl*) for chronic myelogenous leukemia and t(14;18) for follicular lymphoma, etc.); (ii) familial polyposis or Gardner's syndrome
10 (possible forerunners of colon cancer); (iii) monoclonal gammopathy of undetermined significance (a possible precursor of multiple myeloma) and (iv) a first degree kinship with persons having a cancer or pre-cancerous disease showing a Mendelian (genetic) inheritance pattern (*e.g.*, familial polyposis of the colon, Gardner's syndrome, hereditary exostosis, polyendocrine adenomatosis, Peutz-Jeghers syndrome, neurofibromatosis of Von
15 Recklinghausen, medullary thyroid carcinoma with amyloid production and pheochromocytoma, retinoblastoma, carotid body tumor, cutaneous melanocarcinoma, intraocular melanocarcinoma, xeroderma pigmentosum, ataxia telangiectasia, Chediak-Higashi syndrome, albinism, Fanconi's aplastic anemia and Bloom's syndrome).

 In another embodiment, a Therapeutic of the present invention is administered to a
20 human patient to prevent the progression to breast, colon, lung, pancreatic, or uterine cancer, or melanoma or sarcoma.

Hyperproliferative and dysproliferative disorders

 In one embodiment of the present invention, a Therapeutic is administered in the therapeutic or prophylactic treatment of hyperproliferative or benign dysproliferative
25 disorders. The efficacy in treating or preventing hyperproliferative diseases or disorders of a Therapeutic of the present invention may be assayed by any method known within the art. Such assays include *in vitro* cell proliferation assays, *in vitro* or *in vivo* assays using animal models of hyperproliferative diseases or disorders, or the like. Potentially effective
Therapeutics may, for example, promote cell proliferation in culture or cause growth or cell
30 proliferation in animal models in comparison to controls.

Specific embodiments of the present invention are directed to the treatment or prevention of cirrhosis of the liver (a condition in which scarring has overtaken normal liver regeneration processes); treatment of keloid (hypertrophic scar) formation causing disfiguring of the skin in which the scarring process interferes with normal renewal; psoriasis (a common skin condition characterized by excessive proliferation of the skin and delay in proper cell fate determination); benign tumors; fibrocystic conditions and tissue hypertrophy (e.g., benign prostatic hypertrophy).

Neurodegenerative disorders

Some ORFX proteins are found in cell types have been implicated in the deregulation of cellular maturation and apoptosis, which are both characteristic of neurodegenerative disease. Accordingly, Therapeutics of the invention, particularly but not limited to those that modulate (or supply) activity of an aforementioned protein, may be effective in treating or preventing neurodegenerative disease. Therapeutics of the present invention that modulate the activity of an aforementioned protein involved in neurodegenerative disorders can be assayed by any method known in the art for efficacy in treating or preventing such neurodegenerative diseases and disorders. Such assays include *in vitro* assays for regulated cell maturation or inhibition of apoptosis or *in vivo* assays using animal models of neurodegenerative diseases or disorders, or any of the assays described below. Potentially effective Therapeutics, for example but not by way of limitation, promote regulated cell maturation and prevent cell apoptosis in culture, or reduce neurodegeneration in animal models in comparison to controls.

Once a neurodegenerative disease or disorder has been shown to be amenable to treatment by modulation activity, that neurodegenerative disease or disorder can be treated or prevented by administration of a Therapeutic that modulates activity. Such diseases include all degenerative disorders involved with aging, especially osteoarthritis and neurodegenerative disorders.

Disorders related to organ transplantation

Some ORFX can be associated with disorders related to organ transplantation, in particular but not limited to organ rejection. Therapeutics of the invention, particularly those that modulate (or supply) activity, may be effective in treating or preventing diseases or disorders related to organ transplantation. Therapeutics of the invention (particularly

Therapeutics that modulate the levels or activity of an aforementioned protein) can be assayed by any method known in the art for efficacy in treating or preventing such diseases and disorders related to organ transplantation. Such assays include *in vitro* assays for using cell culture models as described below, or *in vivo* assays using animal models of diseases and disorders related to organ transplantation, see *e.g.*, below. Potentially effective Therapeutics, for example but not by way of limitation, reduce immune rejection responses in animal models in comparison to controls.

Accordingly, once diseases and disorders related to organ transplantation are shown to be amenable to treatment by modulation of activity, such diseases or disorders can be treated or prevented by administration of a Therapeutic that modulates activity.

Cardiovascular Disease

ORFX has been implicated in cardiovascular disorders, including in atherosclerotic plaque formation. Diseases such as cardiovascular disease, including cerebral thrombosis or hemorrhage, ischemic heart or renal disease, peripheral vascular disease, or thrombosis of other major vessel, and other diseases, including diabetes mellitus, hypertension, hypothyroidism, cholesterol ester storage disease, systemic lupus erythematosus, homocysteinemia, and familial protein or lipid processing diseases, and the like, are either directly or indirectly associated with atherosclerosis. Accordingly, Therapeutics of the invention, particularly those that modulate (or supply) activity or formation may be effective in treating or preventing atherosclerosis-associated diseases or disorders. Therapeutics of the invention (particularly Therapeutics that modulate the levels or activity) can be assayed by any method known in the art, including those described below, for efficacy in treating or preventing such diseases and disorders.

A vast array of animal and cell culture models exist for processes involved in atherosclerosis. A limited and non-exclusive list of animal models includes knockout mice for premature atherosclerosis (Kurabayashi and Yazaki, 1996, *Int. Angiol.* 15: 187-194), transgenic mouse models of atherosclerosis (Kappel *et al.*, 1994, *FASEB J.* 8: 583-592), antisense oligonucleotide treatment of animal models (Callow, 1995, *Curr. Opin. Cardiol.* 10: 569-576), transgenic rabbit models for atherosclerosis (Taylor, 1997, *Ann. N.Y. Acad. Sci.* 811: 146-152), hypercholesterolemic animal models (Rosenfeld, 1996, *Diabetes Res. Clin. Pract.* 30 Suppl.: 1-11), hyperlipidemic mice (Paigen *et al.*, 1994, *Curr. Opin. Lipidol.* 5:

258-264), and inhibition of lipoxygenase in animals (Sigal *et al.*, 1994, Ann. N.Y. Acad. Sci. 714: 211-224). In addition, *in vitro* cell models include but are not limited to monocytes exposed to low density lipoprotein (Frostedgard *et al.*, 1996, Atherosclerosis 121: 93-103), cloned vascular smooth muscle cells (Suttles *et al.*, 1995, Exp. Cell Res. 218: 331-338),
5 endothelial cell-derived chemoattractant exposed T cells (Katz *et al.*, 1994, J. Leukoc. Biol. 55: 567-573), cultured human aortic endothelial cells (Farber *et al.*, 1992, Am. J. Physiol. 262: H1088-1085), and foam cell cultures (Libby *et al.*, 1996, Curr Opin Lipidol 7: 330-335). Potentially effective Therapeutics, for example but not by way of limitation, reduce foam cell formation in cell culture models, or reduce atherosclerotic plaque formation in
10 hypercholesterolemic mouse models of atherosclerosis in comparison to controls.

Accordingly, once an atherosclerosis-associated disease or disorder has been shown to be amenable to treatment by modulation of activity or formation, that disease or disorder can be treated or prevented by administration of a Therapeutic that modulates activity.

Cytokine and Cell Proliferation/Differentiation Activity

15 A ORFX protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient
20 confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

The activity of a protein of the invention may, among other means, be measured by the
25 following methods: Assays for T-cell or thymocyte proliferation include without limitation those described in: CURRENT PROTOCOLS IN IMMUNOLOGY, Ed by Coligan *et al.*, Greene Publishing Associates and Wiley-Interscience (Chapter 3 and Chapter 7); Takai *et al.*, *J Immunol* 137:3494-3500, 1986; Bertagnoli *et al.*, *J Immunol* 145:1706-1712, 1990; Bertagnoli *et al.*, *Cell Immunol* 133:327-341, 1991; Bertagnoli, *et al.*, *J Immunol*
30 149:3778-3783, 1992; Bowman *et al.*, *J Immunol* 152:1756-1761, 1994.

Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described by Kruisbeek and Shevach, In: CURRENT PROTOCOLS IN IMMUNOLOGY. Coligan *et al.*, eds. Vol 1, pp. 3.12.1-14, John Wiley and Sons, Toronto 1994; and by Schreiber, In: CURRENT PROTOCOLS IN IMMUNOLOGY.

5 Coligan eds. Vol 1 pp. 6.8.1-8, John Wiley and Sons, Toronto 1994.

Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described by Bottomly *et al.*, In: CURRENT PROTOCOLS IN IMMUNOLOGY. Coligan *et al.*, eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto 1991; deVries *et al.*, *J Exp Med* 173:1205-1211, 1991; Moreau *et al.*, *Nature* 336:690-692, 1988;

10 Greenberger *et al.*, *Proc Natl Acad Sci U.S.A.* 80:2931-2938, 1983; Nordan, In: CURRENT PROTOCOLS IN IMMUNOLOGY. Coligan *et al.*, eds. Vol 1 pp. 6.6.1-5, John Wiley and Sons, Toronto 1991; Smith *et al.*, *Proc Natl Acad Sci U.S.A.* 83:1857-1861, 1986; Measurement of human Interleukin 11-Bennett, *et al.* In: CURRENT PROTOCOLS IN IMMUNOLOGY. Coligan *et al.*, eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto 1991; Ciarletta, *et al.*, In: CURRENT
15 PROTOCOLS IN IMMUNOLOGY. Coligan *et al.*, eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto 1991.

Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described In:

20 CURRENT PROTOCOLS IN IMMUNOLOGY. Coligan *et al.*, eds., Greene Publishing Associates and Wiley-Interscience (Chapter 3Chapter 6, Chapter 7); Weinberger *et al.*, *Proc Natl Acad Sci USA* 77:6091-6095, 1980; Weinberger *et al.*, *Eur J Immun* 11:405-411, 1981; Takai *et al.*, *J Immunol* 137:3494-3500, 1986; Takai *et al.*, *J Immunol* 140:508-512, 1988.

Immune Stimulating or Suppressing Activity

25 A ORFX protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), *e.g.*, in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic
30 activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by vital (*e.g.*, HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases caused by vital, bacterial, fungal or other infection may be treatable using a protein of the present invention, including

infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania species., malaria species. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, *i.e.*, in the treatment of cancer.

5 Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the
10 present invention may also to be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein of the present invention.

 Using the proteins of the invention it may also be possible to immune responses, in a
15 number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T
20 cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or energy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon re-exposure to specific antigen in the absence of the tolerizing agent.

25 Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as, for example, B7), *e.g.*, preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in
30 tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2

activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (*e.g.*, B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to energize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of B lymphocyte antigens.

The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins *in vivo* as described in Lenschow *et al.*, Science 257:789-792 (1992) and Turka *et al.*, Proc Natl Acad Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., FUNDAMENTAL IMMUNOLOGY, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function *in vivo* on the development of that disease.

Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and auto-antibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of auto-antibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythematosus in MRL/lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and

murine experimental myasthenia gravis (see Paul ed., FUNDAMENTAL IMMUNOLOGY, Raven Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic vital diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.

Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells *in vitro* with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the *in vitro* activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells *in vivo*.

In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected *ex vivo* with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection *in vivo*.

The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which

fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I α chain protein and β_2 microglobulin protein or an MHC class II α chain protein and an MHC class II β chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell.

Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

The activity of a protein of the invention may, among other means, be measured by the following methods: Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described In: CURRENT PROTOCOLS IN IMMUNOLOGY. Coligan *et al.*, eds. Greene Publishing Associates and Wiley-Interscience (Chapter 3, Chapter 7); Herrmann *et al.*, *Proc Natl Acad Sci USA* 78:2488-2492, 1981; Herrmann *et al.*, *J Immunol* 128:1968-1974, 1982; Handa *et al.*, *J Immunol* 135:1564-1572, 1985; Takai *et al.*, *J Immunol* 137:3494-3500, 1986; Takai *et al.*, *J Immunol* 140:508-512, 1988; Herrmann *et al.*, *Proc Natl Acad Sci USA* 78:2488-2492, 1981; Herrmann *et al.*, *J Immunol* 128:1968-1974, 1982; Handa *et al.*, *J Immunol* 135:1564-1572, 1985; Takai *et al.*, *J Immunol* 137:3494-3500, 1986; Bowman *et al.*, *J Virology* 61:1992-1998; Takai *et al.*, *J Immunol* 140:508-512, 1988; Bertagnolli *et al.*, *Cell Immunol* 133:327-341, 1991; Brown *et al.*, *J Immunol* 153:3079-3092, 1994.

Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, *J Immunol* 144:3028-3033, 1990; and Mond and Brunswick In: CURRENT PROTOCOLS IN IMMUNOLOGY. Coligan *et al.*, (eds.) Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto 1994.

Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described In: CURRENT PROTOCOLS IN IMMUNOLOGY. Coligan *et al.*, eds. Greene Publishing

Associates and Wiley-Interscience (Chapter 3, Chapter 7); Takai *et al.*, *J Immunol* 137:3494-3500, 1986; Takai *et al.*, *J Immunol* 140:508-512, 1988; Bertagnolli *et al.*, *J Immunol* 149:3778-3783, 1992.

Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery *et al.*, *J Immunol* 134:536-544, 1995; Inaba *et al.*, *J Exp Med* 173:549-559, 1991; Macatonia *et al.*, *J Immunol* 154:5071-5079, 1995; Porgador *et al.*, *J Exp Med* 182:255-260, 1995; Nair *et al.*, *J Virol* 67:4062-4069, 1993; Huang *et al.*, *Science* 264:961-965, 1994; Macatonia *et al.*, *J Exp Med* 169:1255-1264, 1989; Bhardwaj *et al.*, *J Clin Investig* 94:797-807, 1994; and Inaba *et al.*, *J Exp Med* 172:631-640, 1990.

Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz *et al.*, *Cytometry* 13:795-808, 1992; Gorczyca *et al.*, *Leukemia* 7:659-670, 1993; Gorczyca *et al.*, *Cancer Res* 53:1945-1951, 1993; Itoh *et al.*, *Cell* 66:233-243, 1991; Zacharchuk, *J Immunol* 145:4037-4045, 1990; Zamai *et al.*, *Cytometry* 14:891-897, 1993; Gorczyca *et al.*, *Internat J Oncol* 1:639-648, 1992.

Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica *et al.*, *Blood* 84:111-117, 1994; Fine *et al.*, *Cell Immunol* 155: 111-122, 1994; Galy *et al.*, *Blood* 85:2770-2778, 1995; Toki *et al.*, *Proc Nat Acad Sci USA* 88:7548-7551, 1991.

Hematopoiesis Regulating Activity

A ORFX protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, *e.g.* in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (*i.e.*, traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention

or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either in-vivo or ex-vivo (*i.e.*, in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson *et al.* *Cellular Biology* 15:141-151, 1995; Keller *et al.*, *Mol. Cell. Biol.* 13:473-486, 1993; McClanahan *et al.*, *Blood* 81:2903-2915, 1993.

Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, In: CULTURE OF HEMATOPOIETIC CELLS. Freshney, *et al.* (eds.) Vol pp. 265-268, Wiley-Liss, Inc., New York, N.Y. 1994; Hirayama *et al.*, *Proc Natl Acad Sci USA* 89:5907-5911, 1992; McNiece and Briddeli, In: CULTURE OF HEMATOPOIETIC CELLS. Freshney, *et al.* (eds.) Vol pp. 23-39, Wiley-Liss, Inc., New York, N.Y. 1994; Neben *et al.*, *Exp Hematol* 22:353-359, 1994; Ploemacher, In: CULTURE OF HEMATOPOIETIC CELLS. Freshney, *et al.* eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, N.Y. 1994; Spoonceret *et al.*, In: CULTURE OF HEMATOPOIETIC CELLS. Freshney, *et al.*, (eds.) Vol pp. 163-179, Wiley-Liss, Inc., New York, N.Y. 1994; Sutherland, In: CULTURE OF HEMATOPOIETIC CELLS. Freshney, *et al.*, (eds.) Vol pp. 139-162, Wiley-Liss, Inc., New York, N.Y. 1994.

Tissue Growth Activity

A ORFX protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for

wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.

A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors *ex vivo* for return *in vivo* to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendonitis, carpal

tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, *i.e.* for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.

Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.

A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium).

5 Assays for wound healing activity include, without limitation, those described in: Winter, EPIDERMAL WOUND HEALING, pp. 71-112 (Maibach and Rovee, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Menz, *J. Invest. Dermatol* 71:382-84 (1978).

Activin/Inhibin Activity

10 A ORFX protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin family, may be useful as a contraceptive based on
15 the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin-b group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release
20 from cells of the anterior pituitary. See, for example, U.S. Pat. No. 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

25 The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for activin/inhibin activity include, without limitation, those described in: Vale *et al.*, *Endocrinology* 91:562-572, 1972; Ling *et al.*, *Nature* 321:779-782, 1986; Vale *et al.*, *Nature* 321:776-779, 1986; Mason *et al.*, *Nature* 318:659-663, 1985; Forage *et al.*, *Proc Natl Acad Sci USA* 83:3091-3095, 1986.

Chemotactic/Chemokinetic Activity

30 A protein of the present invention may have chemotactic or chemokinetic activity (*e.g.*, act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts,

neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections.

5 For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.

A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of
10 cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

The activity of a protein of the invention may, among other means, be measured by following methods:

15 Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: CURRENT PROTOCOLS IN IMMUNOLOGY, Coligan *et al.*,
20 eds. (Chapter 6.12, MEASUREMENT OF ALPHA AND BETA CHEMOKINES 6.12.1-6.12.28); Taub *et al. J Clin Invest* 95:1370-1376, 1995; Lind *et al. APMIS* 103:140-146, 1995; Muller *et al., Eur J Immunol* 25: 1744-1748; Gruber *et al. J Immunol* 152:5860-5867, 1994; Johnston *et al., J Immunol* 153: 1762-1768, 1994.

Hemostatic and Thrombolytic Activity

25 A protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and
30 for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (*e.g.*, stroke).

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet *et al.*, *J. Clin. Pharmacol.* 26:131-140, 1986; Burdick *et al.*, *Thrombosis Res.* 45:413-419, 1987; Humphrey *et al.*, *Fibrinolysis* 5:71-79 (1991); Schaub, *Prostaglandins* 35:467-474, 1988.

5 **Receptor/Ligand Activity**

A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell—cell
10 interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present
15 invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for receptor-ligand activity include without limitation those described
20 in: CURRENT PROTOCOLS IN IMMUNOLOGY, Ed by Coligan, *et al.*, Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai *et al.*, *Proc Natl Acad Sci USA* 84:6864-6868, 1987; Bierer *et al.*, *J. Exp. Med.* 168:1145-1156, 1988; Rosenstein *et al.*, *J. Exp. Med.* 169:149-160 1989; Stoltenborg *et al.*, *J Immunol Methods* 175:59-68, 1994; Stitt *et al.*, *Cell* 80:661-670,
25 1995.

Anti-Inflammatory Activity

Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell—cell interactions (such as, for
30 example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an

inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.

Tumor Inhibition Activity

In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via ADCC). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.

Other Activities

A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or

endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.

Neural disorders in general include Parkinson's disease, Alzheimer's disease, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), peripheral neuropathy, tumors of the nervous system, exposure to neurotoxins, acute brain injury, peripheral nerve trauma or injury, and other neuropathies, epilepsy, and/or tremors.

Table 1

TABLE NO	ACCNO	NUCL. SEQUENCE	Prot SEQUENCE	HOMOLOGY
1.	11612531/11612531	ncctgattggaggggaattcttctgctgggtct catggcctatgaccgctatgtggctgtgtgcaa ccctctacggtaccctctcctcatgaaccgcag ggttgcttattcatggtgtgctgctcctgggtg gtggtccttgatgggttcatgctgactcctgtc actatgagtttcccttctgtagatcccgagaga tcaatcactttttgtgagatcccagcgtgctg aagttgtctgcacagacacgtcactctatgag accctgatgtatgctgctgctgctgat (SEQ ID NO:1)	LIGGEFFLLGLMAYDRYVA VCNPLRYPLLNNRRVCLF MVVGSWWGGSLDGFMLT PVTMSFPFCRSREINHFF CEIPAVLKLSCDTSLEYET LMYACCVL (SEQ ID NO:2)	similar to gi 3983382 olfactory receptor E3 [Mus musculus]
2.	16401346/16401346	aagccgtggtgcccagaggtagaagccgtg gttggccaggaggtagaagccgtggttggcc aggaggtagaagccgtggtgcccaggaggt agaagccgtggtgcccaggaggtagaagc cgtggtgcccaggaggtagaagccgtggtg caccggttaagacacagtgtgccaagctg aacctgtgcgggccgctggcgtggacctgac gaacactatttctggtgtccaggatctgtaca gttgat (SEQ ID NO:3)	CRIISCGELPIPPNGHRIGT LSVYGATAIFSCNSGYTLV GSRVRECMANGLWSGSE VRCLAGHCCTPEPIVNGHI NGENYSYRGSVVYQCNA GFRLIGMSVRICQQDHHW SGKTPFCVPITCGHPGNP VNGLTQGNQFNLDVW (SEQ ID NO:4)	similar to gi 1255889 T07H6.5 gene product [Caenorhabditis elegans]
3.	17939072/17939072	gcaggcaggagttgggtcgtaagtttgcca gccccatcagcagaggcaagagatcagtg agctgccaaatggagggtggtgggacggcg agaaggcagatgtgtactcaccggcccagg gagctcgtgtcaggatggccggccctcc ctactggagagtggttcgcccaggcacaggt gggtggagaacattcacgaagagtgaggt gggtgctgggtggtggcgacaggagaccag cagggccaaag (SEQ ID NO:5)	RPRDCLDVLLSGQQDDG VYSVFPTHYPAGFQVYCD MRTDGGGWTFQRRREDG SVNFFRGWDAYRDGFGR LTGEHWLGLKRIHALTTQA AYELHVDLEDFENGTA RYGSFVGVLFSVDPEEDG YPLTVADYSGTAGDSLK HS (SEQ ID NO:6)	similar to gi 2506403 MICROFIBRIL- ASSOCIATED GLYCOPROTEIN 4
4.	11709218/11709218	cggtgatgaaggcaggctccgtgctgggtg gaaggccacgggctgactctgtgtgtcagt tggcacaggcggccgacctgcccctctcgc acagagaccgcccgtcacactcatggccc cccgggtgacgtatcgaagacgagccaga aaaggtcggggaggtcaggtcagcctggc cacgatcctgggtggacagggtccatctgctg	KGPSCDRCKPGFWGLSP SNPEGCTRCSCDLRGTLG GVAECQAGTGQCFCCKPH VCGQACASCKDGGFFGLD QADYFGCRSCRDIGGAL GQSCEPRTGVCRCPNT QGPTCSEPARDHYLPDLH	similar to gi 2851576 LAMININ ALPHA-5 CHAIN

		cgtagccctccagctgaagttctgaactcg aggg (SEQ ID NO:7)	HLRLELEEAAATPEGHAVR FGFN (SEQ ID NO:8)	
5.	17893306/178 93306	aacctgcgggagcttggctctatgacaacca catctctctacccgacaatgtcttcagcaac ctccgccagttgcaggtcctgattcttagccgc aatcagatcagcttcatctccccgggtgccttc aacgg (SEQ ID NO:9)	NLRELWLYDNHISLDPN VFSNLRQLQVLILSRNQIS FISPG (SEQ ID NO:10)	similar to gi 3183012 PLATELET GLYCOPROTEIN V PRECURSOR (GPV) (CD42D)
6.	16305313/163 05313	accggggctgtgccaccagccatgccacca cggcgctctgtgtgtgcccaggggtccagatc ccaacggctccgctgctactgctgcccgggtt tccagggccacgctgcgagctggacatcga tgagtgtgatcccgccgtgccaccatgggg ccacctgccgaacctggccgatcgctacga gtgccattgcccccttgctatgcaggcgtgac ctgcgagacggagggtggacgagtgccctc agcgccctgcctgcacg (SEQ ID NO:11)	CATQPCHHGALCVPQGS RPNGFRCYCVPGFQGGPR CELDIDECASRPCHHGAT CRNLADRYECHCPLGYAG VTCETEVDECASAPC(SEQ ID NO:12)	similar to gi 499686 fibropellin la [Heliocidaris erythrogramma]
7.	21652877/216 52877	acatacaggtaccactcaaatgaatgagcac tccagcagatcacatgcaattttacaatcagc atttgcagttcataaaaatatggaggcagct gaagatggatcatggtattcccctcgcatatt gtctcaaatccactttgtgatttgcaggat cagaaagagtaacaaaaacggggaatactg gtgaacggttcaagaatccattcaaatcaat agtggattgctggcttaggaatgaataagc gctctg (SEQ ID NO:13)	HTGTTQMNEHSSRSHAIF TISICQVHKNMEEAEDGS WYSPRHIVSKFHFVDLAG (SEQ ID NO:14)	similar to gi 1703701 KRP5=kinesin- related protein [rats, testes, Peptide Partial, 167 aa]
8.	16305313/163 05313	accggggctgtgccaccagccatgccacca cggcgctctgtgtgtgcccaggggtccagatc ccaacggctccgctgctactgctgcccgggtt tccagggccacgctgcgagctggacatcga tgagtgtgatcccgccgtgccaccatgggg ccacctgccgaacctggccgatcgctacga gtgccattgcccccttgctatgcaggcgtgac ctgcgagacggagggtggacgagtgccctc agcgccctgcctgcacg (SEQ ID NO:15)	CATQPCHHGALCVPQGS RPNGFRCYCVPGFQGGPR CELDIDECASRPCHHGAT CRNLADRYECHCPLGYAG VTCETEVDECASAPC(SEQ ID NO:16)	similar to gi 499686 fibropellin la [Heliocidaris erythrogramma]
9.	16296826/162 96826	ggggccctccgaggctgcctccaggacctgc gactcgatggctgccacctcccctcttctctg ccactggataactcaagccagcccagcgag ctcggcgccaggcagctcctggaacctctcttg gggccttgcgtctccgaggacatgtgcagctc gacccctgttcaatggtgggactgcctctgca cctggaatgacttccactgtacctgcctgcca atttcacggggcctacatgtgccagcagctgt ggtgtcccgccagccctgtctcccacctgcc acgtgtgtggcggaggccagctccgcgagg gtccccccgcgcgttcagcgggcacaacgc gt (SEQ ID NO:17)	DMCSPDPCFNGGTCLVT WNDFHCTCPANFTGPTC AQLWCPGQPCLPATC V(SEQ ID NO:18)	similar to gi 2373395 cell surface protein [Mus musculus]
10.	27981100/279 81100	tcattgattggggcccaacaggaggctgagg aatggctttctcaaatccactgcgcgccgga tcttctaaagggttatttcaattagcaaaagca cagagaggcttccccctaatgaaagatc aagtctaataaattcaaaaagtcacagagtat cgatgagattgacattggtacatataagtgta taacataccattagaaaactatgctctgggag tgatcacttaggaagccacgaacgaccggat aagatgctgggaccagagcatggtatgtcca gtatgtctgaaaccagtcagtcccaatgtcgg ggcgggaga (SEQ ID NO:19)	HDWGNRRLRNFGSQIH CRPESSKGVISISKSTERL SPLMKDIKSNKFKSQSID EIDIGTYKVYNIPLNYASG SDHLGSHERPDKMLGPE HGMSSMSRNQSVPMGR E(SEQ ID NO:20)	similar to gi 1657758 densin-180 [Rattus norvegicus]
11.	21648376/216 48376	gtcgacatgacgatcgaggagatgcggggc gcgtcggtgtcaccgcctgcacggggacgc cgagacgcaatcctagccaggctgccagca gcatcgccggcgcatcaccggcggtgactct	KDKLDAEVHAGEGTPGDV IVLRFSGAMAKRPASVILP LLSDSPVIAWWPFSQPD NLASDPICALADRRITDSA	similar to gi 3334791 hypothetical protein SC5A7.10c

		acccgagcgaaactgacggctcgtggatgttg atccaaagctgctgcagctagggctctcagc tgggtggtgcgagcccaacacaggctcggagtc accctcggttaggtgagccgacggcgatga gggcttgcacggatcttgcagctgcccagtc ggtgatgcggcggtccgcaagggtccgatg gggccgaggcgagggtgacgggcccggag aagggccaccacgcaatgacgggggagtc gacagtagcagcggaaggataactgaggca ggacgcttcgcatggctccggaaaaccgca gcacgatgacatccccgggggtgcttcacc ggcatgcacctcggcgtcaagctgtccttacg agaacgcgt (SEQ ID NO:21)	ADKDPCKALIRRAAHLTEG DSDLCWARTTSWRALAA AALDQHPATVKFARVESA AGNAPAMLLAAWLGLR(S EQ ID NO:22)	[Streptomyces coelicolor]
12.	10286716/10286716	acgctgacaggcttcagggtgggacggtagc tgtgggcggccctgtctcaccatggagtaagt ctgctcactctgacctctcgtatgtagtcggtc c (SEQ ID NO:23)	IRYYEKGQSEQTYSMVKT GAPTIVTVNLKP(SEQ ID NO:24)	similar to gi 2462302 Eph-like receptor tyrosine kinase [Gallus gallus]
13.	29200253/29200253	gccggctgtgcgtggatgtgagattggaacca tgtttcctcgatgggatgaggaagtggtggg gtaccctgcctggcaagtaccggatggacgt ctgctgctgctccatcgggcggtgtggggagt cgagtgcgaggcctgcccggatcccagtc ctggagttcgccagcctgtgcccggggggt gggcttcgcccagccgggactctctgtcggcc gaccattctataaagatgtgaatgaatgaag gtgtccctggcctcgcacgcacggtagctgc agaaacacgggtgggcagctccactgcgcct gtgcggggggctcggccggatgccagga acggaactgcacagatatgcagagtgctgc atctcctgacctctgcggccagggcacctgt gtcaacacgcccggcagcttgatgagtgag gtttcccggtacgagagtggtcctcatgctgat gaagaactgcag (SEQ ID NO:25)	RLCVDVRLEPCFLRWDED ECGVTLPGKYRMDVCCC SIGAVWGVECEACPDPES LEFASLCPRGLGFASRDF LSGRPFYKDVNECKVFP LCTHGTCTCRNTVGSFHCAC AGGFALDAQERNCTDIDE CRISPDLCGGQGTVCNTPG S(SEQ ID NO:26)	similar to gi 627438 fibrillin-2 precursor - human
14.	3885620/3885620	tgggtgcgggttctcgtgcgtcgtctcttnt tttccgtgggttcagcgcnccctgtcttgga ttgttccgggtccagggggggggccacgt gtactgggtgctgtagctgtaggggggtgct caggcgttctggcttctnaaaatnggtcctgt gccagggacgggtcttgggggtcggggcatc ttccgggggtggttttcttcttgggtgggg gtccactagttctgggggtctcttttaagtgtg ggggtatcttcccgctcgcncgggtggtgatn catcatcattgtagtggtattaaanaaaaaa aaaaaaaaaaaaaaaaaanaanaann nnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn naattaatttttatttaaaaaacaannnnnnnn (SEQ ID NO:27)	HQRKTKPPREDAPNPKNR PWAQGNFKPETPEHPSIK HTAPVTRGPPPLEPETIPE DRAETPRKKDETP(SEQ ID NO:28)	similar to gi 1519394 leptin receptor [Homo sapiens]
15.	19540620/19540620	agtacagcattatccagtaactcagtgtaactc gctgtattctatctaagtaacctaggagacttc cagtttctctcattgatctggcaatcatttgga gtggtatttacaatgagtttaaatctgcctgga aagaactgtggcacaagaccacctcggg tctatctgggggccctctctctcgttttgc agattatcatctcattggattcaatcttgggtt t (SEQ ID NO:29)	YSIIQYFSVTLLYSILSNLG DFQFLFIDLAILVVVFTMS LNPWKELVAQRPPSGLI SGALLFSVLSQIII(SEQ ID NO:30)	similar to gi 3451312 membrane atpase [Schizosaccharomyc es pombe]
16.	3223926/acc:3223926	nagctnnatgggctcagcaactctgtattac actgtctcatgtagtctcgcagctgttggcc tcttctcaagtgcggcatcagcaaggtaggt ggtatccctgggtgcctggtatcaacaattcc atcaagttatgggtagcatgaagtcttgaagt gaatcagttttagtttcttgggttctccgag gagcgcaacacttctctgacaattctgctgcc aaggcatactcaccttaataatgaatgcct gctaagccattgagagcacaactagctgtc	YSFIKILWRS AKKDVIDQ QIPPQTEEIHWHLFSPVER HFYHRQHEVCCQDVVVKL RKISDWALKLSSLDRTVT SILYPLRLRQACCHPQAV RGEFLPLQKSTMTMEELL TSLQKKGCTECEEHRLQ VCALNGLAGIHIIK(SEQ ID NO:32)	similar to gi 4895216 putative serine/threonine protein kinase [Arabidopsis thaliana]

		gatgtgcttctcacattcagttccacatttctctg caaagatgtcagcagctcttccattgtcatggt gctttttggagtggaagaactctccacgaac agcctgtgggtgacagcaggcctgtctgagcc tcagcaatggatacaggatagaggtgacagt ccttctgtctaggctgctgagcttcagagccca gtcagaaatcttctgagtttaccaccacatcc tggcagcacacctcatgctgacgggtataga aatgaccttccactggagaaaagtggagcca gtgtatttctcggttgggtgatttgnattgg tcaatcacatcttcttgcagacctccacagtat ctggcaataaagctgta (SEQ ID NO:31)		
17.	55777901/557 77901	cctagcacgtgaactggtaggtgtgggg ctgcagccctggcactaggaggtgagcagcc cccacaggcactgccaaggacacccagtc tgggtcattcggtcaggacgttggccagtgg gggtgaccagacactgaatctctgcagataac caccatcaaagccaggctcccaggagacatt ggcacccctgggcaagccaccacgggacac attgggtgacaacatgagggtagtgccagc acgtagacgttctggagggtggccactcggg ccacagcattgctggcactgattcccagtc ccgtgggctccttgggtcaatggtcgaggatg aggctgctgttgcctccactgggctggcctt gcagccccggcccacttgggtccaagagac aacaggaggagggtcccttggcgaggagca gggga (SEQ ID NO:33)	CSAQGDPPPVSWSWKVG RGLQGQAQVDSNSSLILR PLTKEAHGHWECSASNAV ARVATSTNVVVLGTSPHV VTNVSVVALPKGANVSWE (SEQ ID NO:34)	similar to gi 103105 cell adhesion protein Gp160-Dtrk - fruit fly (<i>Drosophila</i> <i>melanogaster</i>)
18.	15025413/150 25413	gcgatcaatgacccactaataaaaaggtag agggtccagtaccactgaacacccctcccaa ccagttggtgacctgaaaacccgtctgtatgat gtcaggattcagaacaatccttttgaatccag attcaacgcaaaaactccagcactgtgattg ggattctcaactccctggcttcatctcaatgac atgtttctctccatttctacgc (SEQ ID NO:35)	INDPTNKRYEVPVPLNTPP QPVGDPENRLYDVRIQNN PFGIQRKNSSTVIWDSQ LPGFIFNDMFLSIST (SEQ ID NO:36)	similar to gi 90144 sucrose alpha- glucosidase (EC 3.2.1.48) / oligo- 1, 6-glucosidase (EC 3.2.1.10) - rabbit
19.	29694725/296 94725	ggccggggctgcatatctcaaggtgtccccag ggccacttggcccggtgtgagcagctgtg ccaggtcagcatggagcagcctgtgaccac gtcagcggggcctgcacctgcccggccggt (SEQ ID NO:37)	CPQGHFGPGCEQLCQCQ HGAACDHVSGACTCPAG (SEQ ID NO:38)	similar to gi 3449294 MEGF6 [<i>Rattus</i> <i>norvegicus</i>]
20.	<221> misc_feature <222> (0)...(0) <223> Internal ID: FLC:2378 <221> misc_feature <222> (0)...(0)	gtgcaccaagccggccatcatcttgtcagca agaaggggaccttggctgtgccaacccagc gatctgagagtcagaagtgattaaagatt ggagcaaaactcacaaccacagatct (SEQ ID NO:39)	CTKPAIIFVSKKGTLCAN PSDLRVQKCIKRLEQNSQ PQ (SEQ ID NO:40)	similar to gi 1709026 MACROPHAGE INFLAMMATORY PROTEIN 1- GAMMA PRECURSOR (MIP- 1-GAMMA) (MACROPHAGE INFLAMMATORY PROTEIN-RELATED PROTEIN-2) (MRP-2) (CCF18)
21.	35056380/350 56380	tgccagcaacccctgctgggtgatttctgtg cattaatcagtggtatgctacaggtgttccct cctggggactgtgctccacccgtgccaga atggtggcagctgtgagccaggcctgcactcc ggcttccctgtagctgccagactgcacac gggaaggacctgtgagatgggtgggtgctgtc ttggcgtcctctgtcctcaggga (SEQ ID NO:41)	CVPPGDCASHPCQNGGS CEPGLHSGFTCSCPDSHT GRTCEM (SEQ ID NO:42)	similar to gi 3449286 MEGF1 [<i>Rattus</i> <i>norvegicus</i>]

22.	38905521/38905521	ccctggaggagccgatggtggacctggacg gcgagctgcttctgctggccccctgccccac attgcccgtgctccaggacgagctgcccgaact cttcaggatgacgacgctcggggcccgatgag gaagaggcagagttgctggggcgaaacacac gctcacagagaagtgtctgcttgatgactc cttggccatgactgagcttgacctgtgatgac tgaggaaacggaggacgtgctcctgggccc tggatggctgtgattgccccgagggggtgact gggggtattgcaatgagattgtctccg (SEQ ID NO:43)	LEPMVDLDGELPFVRPL PHIAVLQDELPLQFQDDD VGADEEEAEALRGEHTL KFVCLDDSGFHDCSLTCD DCRNGGTCLLGLDGCDC PEGWTGVICNEICPP(SEQ ID NO:44)	similar to gi 3449294 MEGF6 [Rattus norvegicus]
23.	5721829/5721829	ccgatcaggggcgccatctcacgcaggaa gtggtccacctgctggtgccacagcgggta agcgcagggtcacaggagacatggccaag gagttggccacccacagcccaggtcactg acaccaagccccggcagagctgggtcatg a (SEQ ID NO:45)	PQLCRGLVSVTWGCGVA NSLAMSPVTLRLPRCGHH EVDHFLREMPALIR(SEQ ID NO:46)	similar to gi 3983360 olfactory receptor A3 [Mus musculus]
24.	29447258/29447258	aglacagcctgatcagagctgctctgtttact gtcagtgaggttaagctggcattttctggccac caggtcagctaccactcctggacggccatgg gcacacgcaaaagtagagcagctctgttct ctgtccctgtctcaagtcattcagcctgagc aagatgctctccatcacctgttcacatcacctg cgatggcagcttggatcatgccagatcctt ctgccggactcggtacccggg (SEQ ID NO:47)	PGYRVRQKDLGMIHKA AGDVNKVMESILLRLNDLN DRDKKNRTALLACAHGR PGVVADLVARKCQLNLTD SENRTALIKAV(SEQ ID NO:48)	similar to gi 5689485 KIAA1074 protein [Homo sapiens]
25.	10131798/10131798	aggccaagcagcaaaaaccacagatcattg ctatgggaaatgtgctattttctgacaaacca caatctatgcccgtgactttctgagctccagga gttttttagcactgcccagacttctgagagga ggagggttctgcccatttcaatttcgaactgga ataaggcagggtctctgctgtcagtgaaactc agctgattcagggggtatcctcctcttctgagt gatggaaaacttaagtcgaatctctaccagcc a (SEQ ID NO:49)	AKQQKPQIIAMGNVSFSC SQPQSMPVTFLSSRSFLA LPDFSGEEVVSATFQFRT WNKAGLLLFSELQLISGGI LLFLSDGKLKSNLYQ(SEQ ID NO:50)	similar to gi 1857710 contactin associated protein [Rattus norvegicus]
26.	15028498/15028498	tggaaatacctctgtgtgggggtgtggaag ggacctgaggctcctctcactgccccaccca tgacagagtggcccaggaaacagcccattggt gctgctgctctccccagcagcatctcgccaa gggcccagcaggccacgtccacggccctc accctgacaaactcaccgccacttcacag aactggccggagaatctggcattgcagatac attcagacacccctccagctgcccggcagg gccccattcaagcagggttggcttcacagg ggagagtggggacctgacacctctggccagc aagacctccaggcagctgagttggcagcg ggagagccaccctcacatgggctgcatcga ggcagggtgacattcaggctgactccttgat gggacaggcaacctgcagcgcgggccccc gaagccaggcgggcagcggtcactgaagc g (SEQ ID NO:51)	RFECRCPPGFGGPRCRL PVPIKECSLNVTCLDGSPC EGGSPAANCSCLEGLAG QRCQVPTLPCEANPCLNG GTCRAAGGVSEICNARF SGQFCEVaV(SEQ ID NO:52)	similar to gi 3108187 Notch 3 [Homo sapiens]
27.	30676688/30676688	tgcataatgaaaattgctgcatgtataatgtcc aattttgaacatggagtaacagcacaaccaa ctttgaagaatgtgcccacaagctgaatat aattagaacagctccagagcaactgccaattt caaaattgtacattttctctgcatgccaacttc tgatagcaatactgcagtaaatcattttcagg gccgaccacataatttcaccaataaccataaa atttaggatggaccattgtacatctgtaaataa atattatgcgtaaacaaaca (SEQ ID NO:53)	CLFTHNIYLQDVQMVHPK FYGIGENMWVGPENEFTA SIAIRSWHAEKKMYNFEN GSCSGDCSNYIQLVWDHS YKVGCAVTPCSKI(SEQ ID NO:54)	similar to glioma pathogenesis-related protein - human
28.	2911016/2911016	cgattcacatgccaggggccccgtggcgaa ggagacagccgacgtggccaggaggaga agacgtagctgctggttcgaatcagggccttc atatctcgaggccatgaggtccgggccttgag	RTLMLSVFYFAIPLGSLG YITGSSVKQAAGDWHWAL RVSPVLGMITGTLLILVPA TKRGHADQLGDQLKARTS	similar to gi 3874275 Yeast low-affinity glucose transporter HXT4

		ctggccccgagctggcggcatgacctttt agtggctgggaccagaatgaggatgagtgc ctgtgatcatgcccaggacagggacaccg caatgcccagtgccagtctcgggtgcctgct cacgtggagccagtaatgtagccaggcca ctgcccagtgggatggcgaagtagaagacg gacagcatgagcgtacgcgt (SEQ ID NO:55)	WLRDMKALIRNRSYVFSS LATSAVSFATGAL (SEQ ID NO:56)	(PS:32467); cDNA EST EMBL:C12555 com
29.	16530243/165 30243	acgcgtcctgcctcagggcctcgggagcttc cgctgcctctgttggcaggctacagcggcga gctgtgcgaggtggacgaggacgagtgtgca tcgagcccctgcccagcatggggcggatgcc tgacgcgtctgacccggccctctacgggggt gtccaggccgctccctggcgccttcagcttc cgccatgctgcgggttctctgtgacctgcctc ctggcttgaggagccgactgcgggtgtggag gtggacgagtgtgcctcacggccatgcctcaa cggaggccactgccaggacctgccaatgg cttcagtgctactgccagatggctacgcag ggccgacatgtgaggaagatgtggaatgaatg cctgtcggatccctgcctgcacggcggaacct gcagtgcactgtggcaggctatatctgcagg tgcccagagacctgggtggcgcgactgttc tgtgcagctcactggctgcaggggccacact gcccgtcggctgccacctgcacctatcttcg agtctgggtccacagttacgtctgcactgcc cacctggtacccatggaccgtctgtggcag aataccacctctctgtgatggctgggagcccc attcaggcatcagtgccagctgtggccccct gggtctggcactgaggttgcaccacactgc ccgtcgggacctggccactcgcaatgacac caaggaaagctggagctggcattgtgtgga gccacactcaggccacactctggagctaca gcaccactgtgtctgtgactgcgggac ctggccc (SEQ ID NO:57)	ASCLEGLGSFRCLCWPGY SGELCEVEDEDECASSPCQ HGGRLQRSDPALYGGV QAAFPGAFSFRHAAGFLC HCPPGFEGADCGVEVDE CASRPCLNNGGHCQDLPN GFQCHCPDGYAGPTCEE DVDECLSDPCLHGGTCS TVAG (SEQ ID NO:58)	similar to gi 117422 CRUMBS PROTEIN PRECURSOR (95F)
30.	21646822/216 46822	taccaggtgggcagtgccagacgtaactgtg gacccagactcgaagataggatgcaggt ggcagccagcgggcaggtgtgcccctggca gccagtgcagctgcacagaacagtcgcgcc acccaggtctcgggcacctgcagatatagc ctgccacagtgctcaggttccgcccgtgc aggcagggatccgacaggcattcatccacat cttcctcacatgtcggccctgcgtagccatctg ggcagtgacactggaagccattgggcaggctc ctggcagtgccctccgttgaggcatggccgtg aggcacactcgtccacctccacaccgcagtc ggctccctcaaagccaggaggggcagtgga caggaaaccgcagcatggcggaagctga aggcgccagggaaggcgccctggacacc ccgtagaggggccgggtcagagcgctgcagg catcggccccatgtcggcaggggctcgtatg cacactcgtcctcgtccacctgcacagctcg ccgtgtagcctggccaacagaggcagcgg aagctcccaggccctcgaggcaggacggc t (SEQ ID NO:59)	GFLCHCPPGFEGADCGV EVDECASRPCLNNGGHCQ DLPNGFQCHCPDGYAGP TCEEDVDECLSDPCLHGG TCSDTVAGYICRCPETWG GRDCSVQLTGCQGHCTP LAATCI (SEQ ID NO:60)	similar to fibropellin la [Heliocidaris erythrogramma]
31.	20720154/207 20154	tgcacgtgtgcatatgtgtcgtgtgcgcactc aggagggtggcagccaaaggcaggccgg gactcacgctgtcgcacccggggccacgt agccagcctcacacagacacaggccgctga tggcatcacagctccgtggccagcgctgtatg ttgcagggtgtgctgcagtcaggtcccagtg cccagtatcacaggctcaacagaactcagg gtcacccggcgag (SEQ ID NO:61)	LSSVAACDTGHWGPDCS HPCNYSAGHGSCDAISGL CLCEAGYVGPRCEQ (SEQ ID NO:62)	similar to gi 3449294 MEGF6 [Rattus norvegicus]

32.	19506719/19506719	acatgacagaggaataatgtagtgatatttlaag gtaattttataactgtcatcatctgtcttttctaaact gtcaatgaaatcatcaggaagagcaccaagt tcagccttggaataatcaaggaaggtatcatc ctcattgaggtttttgttaaaatcaatacatagct cactcatcttttctcattgatttgatttcattctgta ctgttcagaagatg (SEQ ID NO:63)	EQVQNEIKSMKKRMSELC IDFNKLNEDDTFLVFSKA ELGALPDDFIDSLEKTD KYKITLKYPHYFPVM(SEQ ID NO:64)	similar to gi 1783127 endopeptidase 24.16 type M2 [Sus scrofa]
33.	16314987/16314987	cgcggtgccaatgtagtgatgtagtgatgtagt gcgtatgtgtgtgcatgtgtacgtgtgtatgca tgtgtgtatgtgcatgtacgtgtgtgcatatgcgt gtgcatgcatgcgtgtgcgtatgtgtacacat gtgcacacatgtacacacgtgtacatgttcattg catgtgcgcacgtgcatatgtgtacacgtgtat gcgtgtacatgtatgagcatatgtacacgtgtg gatgtgtgtatgcatgtgtgtgtgcacagata tgcccttttcttcatacaggctgtttgagattgc tgttaggcagtgacaacttccgtttctcagtc gaaaatgggtagctcatcattaataaagat (SEQ ID NO:65)	CACVYACMCVCVCMCVCI CMCVCACTCVCICVCMHA CAYVCIMCTHVHTCTCSC MCTCICVHVYACTCMSICT RVDVVCVCMVCV(SEQ ID NO:66)	similar to gi 854065 U88 [Human herpesvirus 6]
34.	11116197/11116197	gtgcactggcccaggtagcgctccacaccag cgcaactggaggtgtgccaggaagatgtctct gagccggggccaaagtgggctttccaagg gcagacatggctcgaccacaccaagctgc cggcacacaacctcagcttgcgtcaggtccca caggtcatcacacacgtgtgcccagggcgccc tgggtggagaatctccacgcgtctgagcacccg gccagagccacccaccagctgcagctccgg ccagtcctctgctctgtgtactgtctgggtg ttgtgtcgggatggtgattagatgtgggtctg caacactgcctcttgggtgcagagtaataata agcaatgaagtttttctcaggtgtgtgaagcttc ggaaatacacgagggtcattgagctggagga ggagatgtaggtgtgttgggaagccagagcag gtcctcccaatgactttactgaggatggtgga ccgtccaggatttcaaaatattcattgtgcagt caaggtcaagatgtggaaatgccagcagtat atgatcagatgcattgtcctgatttccacaca caagtgatgtgtcatgcatttcattctctggggg attcctaactcgctccagatgagttgtaataatg ccaccacaccgagattttctggtggtgcagaa gacgggtgggtgttgagccactgatalcacca (SEQ ID NO:67)	TARAGDWPELQLVGGSG RCSGRVEILHQGAWGTV DDLWDLNEAEVVCRLG CGRAMSALGKAHFGPGS GDIFLDNLQCAGVERYLG QC(SEQ ID NO:68)	similar to gi 1480359 scavenger-receptor protein [Sus scrofa]
35.	3072856/3072856	atcgacatgacgatcgcgagatgcggggc gcgtcggtgtgacccgcgtgacccggagcgc cgagacgcaatcctagccaggctgcccagca gcatcgccggcgcatcaccggcggtgactct accggagcgaactgacggctgcgtgagttg atccaaagctgctgcagctagggtcttcagc tgggtggtgcgagcccaacacaggtcgagtc accctcggttaggtgagccgacggcgtatga gggcttgcacggatcttgcagctgcggagtc ggtgatgcggcggtccgcaagggtccgatg gagtcaggcgaggtcgtcaggggccggag aaggggccaccacgcaatgacgggggaatcc gacagtagcagcggaagataaccggaggc agg (SEQ ID NO:69)	SVILPLLLSDSPVIAWWPF SGPDDLASDSIGALADRR TDSAADKDPCKALIRRAA HLEGGSDSLCWARTTSW RALAAAALDQHPATVKFA RVESAAGNAPAMLLAAWL GLRLGVPVERVTTDAPGIS AI(SEQ ID NO:70)	similar to gi 3334791 hypothetical protein SC5A7.10c. [Streptomyces coelicolor]
36.	21425621/21425621	gtacaccaaccggcgctgacggacttcagt ttgtgctcacctgtcccttctggggtggagaa cgctctgacttcaaatggcccttcggcaaggc catgtgtaagatcgtgtccatggtgacgtccat gaacatgtacgccagcgtgttcttctcactgc catgagtgtagcgctaccattcggtggcctc ggctctgaagagccaccggaccggaggaca cggccggggcgactgctgcggccggagcct gggggacagctgctgcttctcgcacaaqccg	NRALTDQFVLTLPLFWAV ENALDFKWPFGKAMCKIV SMVTSNMNYASVFFLTAM SVTRYHSVASALKSHRTR (SEQ ID NO:72)	similar to gi 5566386 angiotensin type 1 receptor [Cavia porcellus]

		ctgtgtgtgtgatcc (SEQ ID NO:71)		
37.	25177551/25177551	caactgcacttctggtaagttgttccctcagatgctctgagtgaggcagggccctggcttcccggtatagttgggtcagctgtggctcctgggcgtggccgtggcaggccaacgtggccctgggcttccggcacacgtgtggggctctgtgctagcgccacgtgggtgggtgactctgcacattgtatgcacagttcaggctggccgcctgtccagctggcgggttca (SEQ ID NO:73)	ECGARPLASRIVGGQSVAPGRWPWQANVALGFRHTCGGSVLAPRWVVTAAHCMHSFRLARLSSWRV(SEQ ID NO:74)	similar to gi 4210355 dJ1170K4.2 (novel Trypsin family protein with class A LDL receptor domains) [Homo sapiens]
38.	16783914/16783914	tgtacaggctagtgcaattctgaactgtaggtgatggatttcagggaactctgtgtccggg (SEQ ID NO:75)	RTKKSLKSIHLQFKNCTSLY(SEQ ID NO:76)	similar to gi 2497254 NOV PROTEIN HOMOLOG PRECURSOR (NOVH)
39.	20571460/20571460	gatcctgccaccagcccgcgggccccgtggcgaaccacgggctaggcggtgactgtccggcgaggaggcgccccggggcaactggaagaacaacttgggggtctgggttccaaggagaagtttgggaacagtcggcggtatgcggactttgcaggctgggatgggttccgggcagggttgggggaaaaaggaaggggctaagaccgcgcgggaaagatgccgtatttgg (SEQ ID NO:77)	PPNLPGNPIPACKSPHNA DCSQTSPPWNPRPPKLFSSCPGAPPPPGQSTPSARGSPAGP(SEQ ID NO:78)	similar to gi 81286 etensin - Volvox carteri (fragment)
40.	10093872/10093872	taacacaagttgttcctgcagctgcctccatagctgggtgggcactcagagcaggccggccattctgtagggggcttccaatccagttccctttggagaataatgcagacaaagtagaacgc (SEQ ID NO:79)	AFYFVCNYSPPKGNWIGEA PYKNGRPCSECPPSYGGSCRNNLC(SEQ ID NO:80)	similar to late gestation lung protein 1 [Rattus norvegicus]
41.	11755212/11755212	actcttgactcggcgccggcgggggcgcttgggcagcgcatgaaggatgtgagtcgggccccgggcagggtgctgtaactcggcagccccaggggcgacggcctgactgctgggcacccgcgcggccacgctcgggtggcgggcggtggcctgagggagagccgcggggcaagcaggggggccggatgagcctgctggggaagcgcctcttacacgagtagccagagctgccggcgcaacgtcaagtaccggcggtgcagaactacctgtacaacgtgctggagagacccgcggctggcggttcatctaccagcttctgttttctctgtcttgggtgctgatttgcagtgctctccccaaccctgagcacacgaattggcctcaagttgcctctggatcctggagttcgtgatgtgtgcttgggtcggagttcatctgaatttggtctgggtgtgtgtcgacatagaggatggcaaggaggtctgaggtgtgctcggaagcccttccccg (SEQ ID NO:81)	SYTSSQSCRNVKYRRVQNYLYNVLERPRGWAFIYHAFVFLVFGCLISSVFSP TPEHTKLASSCLWILEFVMIVVLGSEFIIRIWSAGCCCRHRGWQGSRLCARKPF(SEQ ID NO:82)	similar to gi 4758632 potassium voltage-gated channel, KQT-like subfamily, member 4
42.	20421338/20421338	cccacaacctcacatgccgggccttcaatgcgaagcctgctgccaccatcatctgttccgggacgggacgcagcaggaggcgctgtggcagcaaggaaatgctgaaggatgggaagaggagaccaccgtgagccaactgcttattaaccccacggacctggacatagggcggtgtcttacttgcgaagcatgaacgaagccatccctagtggcaaggagactccatcgagctggatgtgcaccacctctacagtgaacctgtccattgagccacagcggggcaggagggtgagcgtgtgtgttaccttccctgagccacagccaaccccgagatc (SEQ ID NO:83)	LTCRAFNAKPAATIIWFRDGTQQEGAVASTEIAEDGKRETTVSQLLINPTDLIGRVFTCRSMNEAIPSGKETSIELDVHHPPTVTLSIEPQTGQEGERVVFTCQATANP(SEQ ID NO:84)	similar to gi 3451335 F22162_1 [Homo sapiens]

43.	17684363/17684363	agatctgggctgtggaaatctgagacacag aagtgcacaccttgatgaaaagcccttagtg tctggggacacaggcaaaatccttggggttag gaaag (SEQ ID NO:85)	LSYPKDFACVHQTLKAFFS SKGVTSVSQIFHSPD(SEQ ID NO:86)	ncodes a protein in sequence listing 230 that is gi 3236326 C1 inhibitor [Mus musculus]
44.	17584851/17584851	cgatccttggcagagtatactgggtgttctaa gaaatggtaggagtgccgcggtcaaaaagtt ggattctaacaagcagccagaccaagagttc ttggcccaggtgtctatgggtcaaggctgaag catgaaaagtgtgcaggtgctgtgtactgtgc tgatgggacactccgcgtcctgttatgagttc gctacaatgggtccctcatgagatgct (SEQ ID NO:87)	SFGRVYLGVLNRNGRSAAV KKLDSNKQPDQEFLLAQVS MVSRLKHENNVVELLYCA DGTLRVLAYEFATMGSLH EM(SEQ ID NO:88)	similar to gi 3668069 Pto kinase interactor 1 [Lycopersicon esculentum]
45.	17134322/17134322	ccgcttggggagacgagcggtagccttccca gcaagctcatcgaggatgaacaatccgcy ccagcgttaagaccttctcggggtgtcacc gccgatctggagaagtgtggaccgatcaggt gacactcgcggtagaatgaatagatgcctga gtctgaagacactgtgtggtgacccaagag gccttcgataagctcactcaggagctggagta cctcaaaggcgaaggccgacccgtcattgcc aacaagattgccgacgcccgttcggaaggcg acctttctgagaacggcggtaccatgcggcc cgtgaggagcaggggcagccgaggcccg catccgtcaactcga (SEQ ID NO:89)	WLTQEAFDKLTQELEYLK GRGRTVIANKIADARSEG DLSENGGYHAAREEQGQ AEARIRQL(SEQ ID NO:90)	similar to gi 2896717 greA [Mycobacterium tuberculosis]
46.	46872089/46872089	agcaactacaggaaatggcttgggagttcca atatcagctctatctttattcaacgcaatgacag cactgaccgaagaggcagccgtgactgaac acctcaatcacagcccagcaaggtaactgg acagtaacaaaacagaagctgacaacata gaaggacccatagcctgaagttctcacacctt tgctggaagatcataacagttactgcatcaa cgggtgctgtgcattcccatgagctagaga aagccatctgcaggtgtttactggtatactgg agaaaggtgtgagcacttgacttaactcatat gctgtggattcttatgaaaatacattgcaatt (SEQ ID NO:91)	CLEDHNSYCINGACAFHH ELEKAICRCFTGYTGERC EHLTLT(SEQ ID NO:92)	similar to gi 4557567 epiregulin precursor
47.	16530243/16530243	acgcgtcctgcctcagggccctcgggagcttc cgctgcctctgttggccagggtacagcggcga gctgtgcgaggtggacgaggacgagtggtga tcgagcccctgcagcatggggcccgatgcc tgacgcgtctgacccggccctctacgggggt gtccaggccgcctccctggcgccctcagcttc cgcatgctgcgggttctgtgacctgcccctc ctggcttgaggggagccgactcgggtgtgg (SEQ ID NO:93)	ASCLEGLGSFRCLCWPGY SGELCEVDEDECASSPCQ HGGRCQLQRSDPALYGGV QAAFPGAFFSFRHAAGFLC HCPPGFEGADCGVEVDE CASRPCLNGGHCQDLPN GFQCHCPDGYAGPTCEE DVDECLSDPCLHGGTCS TVAG(SEQ ID NO:94)	similar to gi 117422 CRUMBS PROTEIN PRECURSOR (95F)
48.	30370359/30370359	gagtcaggaggcatgtaccactgccacagtg gctccaagcccacagaaaaggggcgaaat gagtagccctatgccagtggaactctgttct gcttcagcaatatgctcattttcatgattgcaga ggctgtgggtgggcacattgctgggagcttgc tgtgtcacagatgctgccacctcttaattgac ctgaccagtttctgctcagctcttctccctgtg gtgtcatcgaagcctccctctaag (SEQ ID NO:95)	YHCHSGSKPTEKGANEYA YAKWKLCASAIKFIFMIA EVVGGHIAGSLAVTDAA HLLIDLTSFLLSLFSLWLSS KPPSKRLTFGWHRAEILG ALLSILCIWVVTGVLVYLAC ERLLYPDYQIQATVMIIVSS CAVAANIVLTV(SEQ ID NO:96)	similar to gi 2144024 zinc transporter ZnT- 2 - rat
49.	32557285/32557285	caagtgatggcgtgctcctactactcttcc tgagtgccttcgcatggatgctgtggagggg ctgcacctctacaacatggtgatcaaggcttctg ggtcggaggacagcaagcaccgttactacta tgggatgggatgggttttctctctgatctgca tcatttcactgtcatttgccatggacagttacgg aacaag (SEQ ID NO:97)	VMAVLLHYFFLSAFAWML VEGLHLYNMVIVKVGSED SKHRYYYGMGWGFLLIC IISLSFAMDSYGT(SEQ ID NO:98)	similar to gi 4164075 latrophilin 3 splice variant bbbh [Bos taurus]

50.	30664188/30664188	aagcttgcgcaacgccagcctcaggcgaga tgagagcaatcacctcacagactgtaccgaa gagatgagacaatccaggtgaaaggaaacg gctacgtgcagagtcctagattccgaacagc taccacaggaacctgctcctgacatggcggt tactctcaggagaatacacggatacagcta gtgtttgacaatcagtttgattagaggaagca gaaaatgatatctgtaggtatgatttgggaag tgaagatatatccgaaccagtagcattatta gaggacgatgggtgtggacacaagggaagttcc tccaaggataaaatcaagaacgaaccaaatt aaaatcacattcaagtcgatgactacttgtg gctaaacctggattcaagatttatttcttctg gaagattccaaccgcagcagctcagaga ccaactgggaatctgtcacaagctctattcag (SEQ ID NO:99)	KNGYVQSPRFPNSYPR NLLLTWRLHSQENTRIQLV FDNSVWLEEAENDICRYD FVEVEDISETSTIIRGRWC GTKEVPPRIKSRTNQKITF KSDD(SEQ ID NO:100)	similar to gil209014 tld protein [Xenopus laevis]
51.	21648124/21648124	gacagggggccctgtccacagggcgctgccc ccctggctccggagggcgactctgtggcca gcaagcacgcccctacgcccgtccaggtgat cgctgacccctctggggccggggagg (SEQ ID NO:101)	ALSTGLPPLAPEGDSVAS KHAIYAVQVIADPPGPGE(SEQ ID NO:102)	similar to gil2047300 latent transforming growth factor-beta binding protein [Mus musculus]
52.	25334288/25334288	ctgcagaagttgaagccttcgctaggcacgt gagcgagcaggccctcacgccccctcccg tacgtttccactgtagaattccacggaaag ggatgctgtcaaatcagaacactgcactctct gaagtcctgggagccagggggacagtcac cgtgttcaggagcggtgccgctctctcacc cagacagtacttgcctccgatggttgccctgg ggctgtcgcaatgacggctagaaggagaca cgccgcccacaggtccggctgcagtcgcc ccatggagtcacggccccaggtccgctcc acacccctggggcgcgacccaaaggggaca cagacccgtttgtagcaccacccctgtcgatg gtgtgcgtctggcacagcgtgccctcgccggc cgggatgctgttgatgcaccg (SEQ ID NO:103)	VDGAWGPWTPWGDCSR TCGGGVSSSSSRHCDSPR PTIGGKYCLGERRRHRSC NTDDCPPGSQDFREVQC SEFDS(SEQ ID NO:104)	similar to gil5725508 METH2 protein [Homo sapiens]
53.	29674552/29674552	aatccctgactccagaacgcactcagctcct atctcctgtgtgtgtgtcatcattctgtttat attctgtgggggaatcatggcaaaacgaaa gcgtaagcatggctctctctggtcgtcgaagt (SEQ ID NO:105)	SLTPERTQLLYLLAVAVVII LFIILLGVIMAKRKRKHGSL WLPE(SEQ ID NO:106)	similar to Notch2 gene product [Feline leukemia virus]
54.	37446645/37446645	atgcatgttctggcttccacaccatgttcta ccttgccagccaggagcacacaagcaagtat aactctcaaaatttggtactcttgcaaacag cagcatctcacaaggggttgggaacagg agccaatactgtctgacaattctgcctagaaa (SEQ ID NO:107)	FLGKNCQTVLAPCSPNPC ENAAVCKESPINFESYTCL CAPGWQGKNMGVE(SEQ ID NO:108)	similar to gil2373395 cell surface protein [Mus musculus], notch2
55.	37004299/37004299	agggtgctggcgggtagagtcggcgccg ccaggaacctgcccgcgtgccagttccc acagagcggaccggtccaagcccggtctca caggcacgcacccgtgaacacgacgggtg acttcggggggaccacgtccttcagtgcaag gtgcgcagcagctgaagccgggtgatccagt ggctgaagcgcgtggagtacggcgccgagg gccgccacaactccaccatcgatgtggcg ccagaagtgtgtgtgtgcccacgggtgatg agcagcttattgaggtaggag (SEQ ID NO:109)	ERTRSKPVLGTGHPVNTT VDFGGTTSFQCKVRSDVK PVIQWLKRVE(SEQ ID NO:110)	similar to gil104045 fibroblast growth factor receptor A1 precursor - African clawed frog
56.	11751803/11751803	ccacagggggccggcgccagccacttgt ccagcgccatgggtgccgtgtatccgtccgg aggccctcgaaacagcagctggtactggcat gggagccaggctgtgggaagggtggccc nagcctcgtgccagcgggtgccctgggtgct ga (SEQ ID NO:111)	SGTQGNRWHEAATLSHQ PGSHAQYQLLFEGLRDGY HGTMALDKVAVRPGPC(S EQ ID NO:112)	similar to gil2498110 APICAL ENDOSOMAL GLYCOPROTEIN PRECURSOR

57.	25338668/25338668	ccaaaggcctccgaggttcaagccacogc atttctcaacgatcaggccttctccactacaac aacaacagtgggaaggcagagcccggtga accctggagccatgtggaaggaatggagga ctgggagaaggaaagccagctt (SEQ ID NO:113)	KGLPRFQATAFLNDQAFF HYNNNSGKAEPVEPWSH VEGMEDWEKESQL (SEQ ID NO:114)	similar to gi 2497917 ZINC-ALPHA-2- GLYCOPROTEIN PRECURSOR (ZN-ALPHA-2- GLYCOPROTEIN) (ZN-ALPHA-2-GP)
58.	5644863/5644863	cctagccaacacaaagttcacatctcagcctg gctacattggaaggctctatgggccctccctac caggaaactgcagttattgtctgctttcattat gccatctatggattttaaaaatgagtacacc ctagcagttacatcttgaagagaacctatgtg gttcaagagaagatct (SEQ ID NO:115)	LANTKFTSQPGYIGRLYGP SLPGNLQYCLRFHYAIYGF LKMSDTLAVYIFEENHVQ EKI (SEQ ID NO:116)	similar to gi 2498998 THYROID HORMONE- INDUCED PROTEIN B PRECURSOR
59.	20131408/20131408	gcgcgccaggaggagcgccaggggactggt actcagggggaaggaggactcaggacatggg ggcttgggatgctatctctctgggaaggacat gctgagggataggacagtgggccacagtg tgaaagtcctgttagggagcatttgtgggactg aatggattgggatatgacctggagccctaaa gcctgggctccttgccttgagggtgggtgaga gcacagctcggaccagagcagatggggg gacaggctcaccgatcgaggagcagccgatc catggccacagctcacaaggcccgccgcatc atggggaactcctcaagcacagcattgaaat ggtccacgctgagtgagtaaaaggcggcagta ggtgtcagccgaacactggctgtgcgcccgg cccctagttagcaggcagatctcccaaagta ggatcc (SEQ ID NO:117)	GSYFGEICLLTRGRRTASV RADTYCRLYSLSVDHFNA VLEEFPMRRRAFETVAMD RLLRIGE (SEQ ID NO:118)	similar to gi 3242244 hyperpolarization- activated cation channel, HAC3 [Mus musculus]
60.	30674971/30674971	ctggagcccagcattaccttctcatggaat ttgagatcacatttcggccagactcaggagat ggtgtcctcctgtacagctatgacacaggcag caaagactcctgtccatcaacttggcagggg gccacgtggagttccgttgcctgtggtctg gaccggtgtcctcaggagtgagatcccctca ccctgggcaactggcagcagcttctgtatctc gcacagcaaagaatggaatctacagggtgga taagcagaagatagtgagggaatggcaga gggaggctcacacagattaagtgaacaca gacatttcatggcgagtcacca (SEQ ID NO:119)	MEFEITFRPDSGDGVLLYS YDTGSKDFLSINLAGGHV EFRFDCSGSGTVLRSED P LTGNGWHELVRSTAKNG ILQVDKQKIVEGMAEGGFT QIKCNTDIFIGESP (SEQ ID NO:120)	similar to gi 2988422 agrin precursor [Homo sapiens]
61.	3928094/3928094	ctgatgcccgtacacagaaccagggtcgga ccgctgtagttctcctgatctgtgctgtatctg cccgtctcggcccactgagcctgtacaacac ctgtgctcgttggcgacctggcaacagga gcaccgataccggcaccgcatcagtgcat cagggcgagcatcgagagatgacgaacat catcgtcaggacgcccaggacggtgagcac cgacgtcaggagcgagggtcaacgtcgacga cagcgtc (SEQ ID NO:121)	TLSSLTSLTSLVTLVGLV TMMFVISPMLALIALIAPV SVLLVARVaKRAQVLYKA QWAETGKINAQIEENYS RDLVRVYGHQ (SEQ ID NO:122)	similar to gi 1723082 HYPOTHETICAL ABC TRANSPORTER ATP-BINDING PROTEIN CY50.10
62.	20940659/20940659.0.38	ccagggtccagatcccaacggcttcgctgct actgcgtgccgggtttcaggggcccacgctgc gagctggacatcgatgagtgatcccgcc gtgccacatggggccacctggcgaacctg gccgatcgctacgagtgccattgccccttg ctatgcaggcgtagctgcgagacggagggtg gacgagtgccctcagcgccctgcctgcacg gggcctcgtgcttgacggcggtgggtccttc cgctgtgtgtgcgcccagggtacggggga cccgttgccagctggacctgcagagtgcca gagccagccgtgcgcacatgggggcacgtg ccacgacctgtcaacgggttccggtgcgact gcgcgggcaccggctacgagggcacgcact gcgagcgggaggtgctggagtgcgatcgg	DPNGFRFCYVPGFQGPR CELDIDEASRPCHHGAT CRNLADRYECHCPLGYAG VTCETEVEDECASAPCLHG ASCLDGVGSFRCVCAPGY GGTRCQLDLDECQSPQC AHGGTCHDLVNGFRDCD AGTGYEGTHCEREVLECA S (SEQ ID NO:124)	similar to gi 117422 CRUMBS PROTEIN PRECURSOR (95F)

		c (SEQ ID NO:123)		
63.	2535440/2535440	cgatcatggtggcagccgcccctggggsagcc gtcgtgctgctcatcgtcatgctggcaggacga ttcatccactcctcgacgatccgtgctgctcg gcgtcatgatcgggtacttctgctgctggtggt caccgtactgctgctcgcgggcgagcccagag ctcattgccagtacaccgctggcagttcgg cagctaccaoggtgtgacgtggcagaacctg cgagtcattggtccgatcattgtggccatgac ctcgccagcctgctgctcgccaagccgctaa cgcttgtgctgggggaacgttacgctcagac gatgggaggaacctcaaggtggtgcgcacc ctgctggtggcgagcacagccatc (SEQ ID NO:125)	LLLLGVMIGYFVSSGVTVL LSRASPELIAQYTRWQFG SYHGVTWQNLRMVPIIV AMILASLLAKPLNALLGE RYAQTMGMNKVVRTLIV ASTAI(SEQ ID NO:126)	similar to gi 5006425 HmuU [Corynebacterium diphtheriae]
64.	21433117/21433117	ccgcagattcggaggagtccgatggccga gttcatctacaccatgcacaacgtccgaagg cgggtgggtgacaaagtatccttgacaatgtca cgctgctgcttcccggcgccaagattggtgt tgtcggaccgaatggcgctggcgaatcgacg atgtcaagctcatggctgctcgataagccc aataacggcgatgccaactggcctaaggcg ccaccgtcggaatcttgcctcaggagccccc ctcaccgaggacaaaactgttcgcgagaacg tcgaagaggccgtcgccgacatcaaagcca agctggcacgggtcagggaagtctccgcga gatggccaaccctgacgcccacttgacgcc ctgatggcgagatgggtgagctgcagaccg agctcgataacgccaacgcgc (SEQ ID NO:127)	MAEFIYTMHNVRKAVGDK VILDNVTLSPFPKAGIGVV GPNGAGKSTMLKLMAGL DKPNNGDANLAKGATVGI LLQEPPLTEDKTVRENVE EAVGDIKAKLARFEEVSAAE MANPDARLDALMAEMGE LQTELDNANA(SEQ ID NO:128)	similar to gi 2791517 hypothetical protein Rv2477c [Mycobacterium tuberculosis]
65.	8485858/8485858	acgcgtgatcgtaccatgcgcgtactgcttcgc atcgagctgtagtgtgccgagcgcgttcgtc agaccgcatactccacgggtgcggtgctcgt cattgcggttctcgcgcaatgtcgtcgccgtctt gttgcaccgtagcggctgttcacccccgtcgt attcagattgccgacactgaggctgtccgcatt caaaaccgcctgttca (SEQ ID NO:129)	LCRARSSDPHTPRCGCLH CGSRRMSSPSCCHRSWG SP(SEQ ID NO:130)	similar to gi 1419019 smaphorin F [Mus musculus]
66.	17705528/17705528	gccatcgttcagagtgtcaagaacaagcctct cttcttctgataaactgcacaagtccatgaa gggtgctggcacagatgagaagacctcacc aggggatggtgtctcggagtgcagatagatct gctcaacatccgga (SEQ ID NO:131)	AIVQSVKNKPLFFADKLHK SMKGAGTDEKTLTRVMVS RSEIDLLNIR(SEQ ID NO:132)	similar to gi 1351943 ANNEIN VI (LIPOCORTIN VI) (P68) (P70) (PROTEIN III) (CHROMOBINDIN 20) (67 KD CALELECTRIN) (CALPHOBINDIN-II) (CPB-II)
67.	2959314/2959314	cgcggtgccctggatactgtcggaggtggag cgaggccagaaagaagctctagcgagctta tctcggccatctgtactgctcgtgatctcctcag tccgatctcagcgcattgtcagtgacaagatg ctcaagaacgaagacgccccggaacatcgc atcactgttcggcttgaaacgtaccaagctgtc agggtcccgtcccggggggccgggaacgtct acatttagacaagacagcggatagttagcgc cctagcgggtggctgagggggccgtcagtcga taggcgcgtggacgattcgaatcgcgatacc aagcgcgcgcagccgggctagttctcgggggt cagcagagtcgtctgtaatgaggaggtcga (SEQ ID NO:133)	RVSLGYLSEVERGQKEAS SELISAICTALDLPQSDLM RIVSDKM(SEQ ID NO:134)	similar to gi 3294243 hypothetical protein SC7C7.10 [Streptomyces coelicolor]

68.	20615755/20615755	cgcgtggtcgatcgccatgggtgctgctatcac ctgtgcccctcagcatcattggccccttatttc cgctgactcgaccgctggtcgctcagcgca tcctgctataccgatggtcgcgctgcctcatt gcggtcggtggtggatctagctggaatgg cgcgcgatgataaacctcccactggccttgc tcatcggttactcatcgcatgagcctcaacc ggcttctgctcaccgcttggctgctgggttga ataccatcgacaagcgctgactacgtgacg gcgtcgatcatgccgacgattggccact cggtctcatgattggtgctggttctgctggc agtgcgcatgattgccggacgcatatccctgt gca (SEQ ID NO:135)	SIAMVLAITLLPFSIIGPFIS VVLDRWSRQRILVYTDGL RCLIAVGLGILVWNGARDT LPLALLIGLLIAMSLNRLL TALVAGLEYTIDKRDYLT SSIMPTIGPLGLMIGAVVA AAVRMI(SEQ ID NO:136)	similar to gi 4808394) putative membrane protein [Streptomyces coelicolor]
69.	10090583/10090583	caagacttttggtattggtggacttccgattacg actaatatttcttggccaacaactcaatatgg atgaaattctgatatgtcttccgtgcaatgata ccagttgacaccaactgtggaccagaatta gctagaaaattgaccgaaattgctgcttcag caaggggagatcaggtgicagatgcgactg cagcctccaagaagtgcaacaattgttcggct ttataactacgattattagtgccattgcaggatt tcccttttggaggagctggttgaacat catgctggttgcggtgacggagcgtagcg (SEQ ID NO:137)	LANNFNMDEISDIVFRVND TSLTPTVGPELARsLTEIA GLQQREYQVSDATAAFQE VQQLFGFITTIIAIGISLF VGGTGVMNIMLVSVTERT R(SEQ ID NO:138)	similar to gi 2633808
70.	10186453/10186453.0.1	acgcgtgtgccgggttctggtgtctgcagg catgaggatatacattcggtctgctatccactcca tgtaaatggcaaggcagggtcgagtcgtgg aacctgaatatgtagcctttctgcacctgaa aaaaaccgtgctccaactagagaggaaat ccaatactagctcagaggccaagggaatat acgaagtgtcaactagtatacctgaagtag acgcccagtagaaaagtagcagcaacttttc aggtaattgtcaagccactgtctaagtcaacat gtacatttaactgctgctacagtgtaacac aatgtagattgctcaatgaataatgaagatctt ctcgaatttgaaaatttagacggctgttgggta aagaaattatgctttctgttttagagttcttctt ttgtttgtaataattatttcttttcattttctg ccactcacattgaacaactggtattattaga aaattactttgttagcattccaagggtggtgc aactcctactcatagagtcacccaaaactc tacct (SEQ ID NO:139)	IPLEASESIGFPLVGSTVFF RCKRGYHIQGSTTRTCLA NLTWSGIQTECIPHACRQ PETPAHA(SEQ ID NO:140)	similar to gi 1685117 furrowed
71.	21643678/21643678	tggcttagcgcggtgggtgctcgtattcgtca aggggttgcagtcggtaggcgcggcggttgg gtcgtgcaactcaatgacctggcgacgaatcc gttcggagaattggtggcgatctcggggaa cagggtccataggggtccaatagccacgtg gaccaatggcgctccttttgtaacctggcttgc tcggacggcatagccgcatgctcctactaa agcaatcgggataaccggaacccacgtga aatagccaatgcggcagcccagggttgaag gtgcccattgcgcccgtgcgagaccgggtgc cctccggaagatcagcagggggacgc (SEQ ID NO:141)	LLIFPEGTRSRGTAMGTFK PGAAALAI SRGVPVPIALV GAWAA(SEQ ID NO:142)	similar to gi 2983494 long-chain-fatty-acid CoA ligase [Aquifex aeolicus]
72.	10344740/10344740	cggcagacgcaacatggcgtggcgacgag gggagcagagagcgccggcagcaggtagt gggtcagcggtcgccatcgccgacgccc ataccggcaacatcggtatagggctcgt gcgggttccgccaacaacgaagcacaatg ggcggccagcgagcccaact (SEQ ID NO:143)	SWAPLAHHCASLLAEART QPYIRMLPVLGVGRWRTL THYLLPALSAPLLRHAMLR LP(SEQ ID NO:144)	similar to gi 3483045 putative transport system permease protein [Streptomyces coelicolor]
73.	11395897/11395897	ccgcgttgaccagttctgcccacggcgtaatc gccacgccaacggcgacagaatcgatag gtgacggaggtctggaagaattgtaaaccac ctgcgagcctcgagcaggcggggaagc	GLPAPVGMLFVAVLVKLC NGASPRLEGSQVYKFF QTSVTYPILFAVGVAITPW QELVNA(SEQ ID NO:146)	similar to gi 1783249 (D83026) homologous to citrate-sodium

		gccgttgacaglttgaccagcaccgccaca aacaacatgccaaaccggagcaggcaggcc aatca (SEQ ID NO:145)		symport (citrate transporters); hypothetical [Bacillus subtilis]
74.	17937351/179 37351	cgatcttctggtcggcggtgatcacgctggtga ccatcgccctgctgttgcgggcaacttogaag ccatgcaaaccatggtcgtgctggcgggctg ccgttctcgggtggtgctgatttctcatgttcggtt tgacacaaggcgaatgcggaggacgtggccat ggagcaggagcaggcacaattggctgaacg tggtcgccgtggttcagcgagcgctgaccg cgctggacctgaaccgagccaggggcacccg tgcaacgcttatggacaaacatgtgacgccg gcgttgaacaagcggcgactgcgttgcgtg atcaag (SEQ ID NO:147)	IFWSAVITLVITIGLLFAGNF EAMQTMVVLGLPFSVLI FFMFGHLHKAMR(SEQ ID NO:148)	similar to gi 114921 HIGH-AFFINITY CHOLINE TRANSPORT PROTEIN
75.	19895736/198 95736	cgctgcgctcctgctggtcgggatttctgct gtagttaaccaaaccacggcgtaataccgt catgtattacgcgccaagggtgttgaggtcgc aggaatgagcaccagggcgtcgattattcag aggtggctaattggatcatgtctgtattggtgc cgctgcaggctgtggtcatcgaacggttga tcgtcgtcacctgcttacttcgatgtcacggcg gtcgggtgtgtctcctgtgattgogctacttcc gggctggcaattgctcctcatgtgggtcaagg ggtaaccgaagtggggcgcttctcgtgctcgt cctgatgagtatctcatgcttatcgtgca (SEQ ID NO:149)	RRLLLVGIFLAVVNQTTGV NTVMYYAPKVFLEFAGMST QASIISEVANGVMSVIGAA AGLWLIERFDRRHLLIFDV TAVGVCLLGIA(SEQ ID NO:150)	similar to gi 1750127 YncC [Bacillus subtilis]
76.	20370351/203 70351	tccgcactgtggcgaccatccttgcaccatta ccattgccgccctagtgtcacgggctgaata cggcggtgcgccaaacgggtgaagacgaggt ttcccgaagctcatcacggtgtgggtgctga gccacaaaaccactcctgcagccgacac caatgaaacggcgggcagaaagtcacac cgcttgttcggcgccgtgtgattacgacgc cgacggcaaaaccataatgatgtggccaa atccattgactcgatggcgaccgcacctaca cggtgacgctgcggaaccagattcgccg (SEQ ID NO:151)	GEDEVSRKLITVWGAEPQ NPLLADTNETGGTKVITA LFLAGLVYDADGKTHNDV AKSIDFDGDRITYTVTLR(S EQ ID NO:152)	similar to gi 2960090 dppA [Mycobacterium tuberculosis]
77.	20438222/204 38222	aatttaataaccatagccttctctgttgatcctct aggcatgagttatggcattaaaacgggcatcc atcttggtgtcgatctgacttaacggcgct aaacgagatcaagagcctgtcttggcggtg cctttgccgtattatgtacggtctcattctactg attctacctggttagccttactcggtatcgatga cgaggtggtgccatgaatattggcggaagat gttcaaaataggtattggtactgaagagctcgt taccctatctttatgcaagatagtttgattgcg ccacgcg (SEQ ID NO:153)	IAFSWLILLGMSYGIKTGIH LGVDIVLNAVPKRVSRALS LFGAFAAIMY(SEQ ID NO:154)	similar to gi 2224836 small integral membrane transport protein [Rhodobacter capsulatus]
78.	8504426/8504 426	ccatcctccaccatctctccctcactccctcat ccaacattgccagaaaaaacgctccac caccctcaccctgcaggaggtgcagggtcct cttattgatgccaagacctgcaatacctactay caggagaactcc (SEQ ID NO:155)	PPTISSLTPSSNIARKKTL PPFTLQELQVPLIDAKTCN TYYQ(SEQ ID NO:156)	similar to gi 4512604 mastin precursor [Canis sp.]
79.	4773473/4773 473	tgcaccgcgagcgagcgttttgcgggtcgggt gtgggtgcagggccaaagcggtcagtgggg gggggggtgggctcggggcgcggttggc ggccctgtcgggggggtc (SEQ ID NO:157)	HPQRAFCGAGVVVRAKA VSGGGVSGGGVCGGPV (SEQ ID NO:158)	similar to gi 4929928
80.	8483614/8483 614	gatccaggaggaggatcaggaccatgatg gacagccccaccaggatcacgctttgtgcc cgggggtcaggaaaggatcatctgcttcca gagcaatgctgcatgcacgcttctgggaga ggtaactgttctgttgcctgcacccgccata gatgaagctgtacagggaattg (SEQ ID NO:159)	NSCSSFIYGGCRGNKNSY LSQEACMQHCSGKQMY FLTPGTKAVILVGLSIMVLI LLLG(SEQ ID NO:160)	similar to gi 4539685 hepatocyte growth factor activator inhibitor type 2 splice variant 1 [Mus musculus]

81.	20695553/20695553	caattccagtttccatgattgacagcatgtcttggctgctttactttaatcgaggcatcatcacgtaagtgggctgaaactggacagccctagcttctcaggatggcctaaagacagtggttgtagtgccctttccatgtctcaagttggtgtgcgggctctgggtact (SEQ ID NO:161)	VPQSPTHQLEDMEKALNP TVFKAILKKLGLSKFQPTY VMMPRIKVKSSQDMLSIM EKLE(SEQ ID NO:162)	similar to gi 3236326 C1 inhibitor [Mus musculus]
82.	18598551/18598551	cgagggtccctctgaataaagacgacatagacggcatccagtatctgtatggctggggctctaaagcctgacccaaggcctccagccaccaccaactgaaccacagccgacagcacctcccactatgtgtccactatact (SEQ ID NO:163)	EGFPLNKDDIDGIQYLYGR GSKPDPRPPATTTTEPQP TAPPTMCPTIP(SEQ ID NO:164)	100% similar to gi 433435 gelatinase b [Mus musculus]
83.	29017225/29017225	gaattctccaggatagctgagggtggtgatacataggagaatccaagttacaatggatttcacgacaattttaaagcatttctccatactattatcaagttgaacctgctcagatct (SEQ ID NO:165)	DLSRFNFDNKYGRNALEIV VKSIVNLDSPMVSPPPDY PGEF(SEQ ID NO:166)	similar to gi 2078282 Sno [Drosophila melanogaster]
84.	29187133/29187133	cggaggccactggttgcaaggagccagtggtcgctggttctggcagggttggttagctggggcctgggttggtggcgaaccaatttcttggtgtctacactcgtgtcacacgtgtggtcaactggatcc (SEQ ID NO:167)	GGPLVCKEPSGRWFLAGL VSWGLGCGRPNFFGVYT RVTRVWNWI(SEQ ID NO:168)	similar to gi 4210355 dJ1170K4.2 (novel Trypsin family protein with class A LDL receptor domains) [Homo sapiens]
85.	2876041/2876041	ccgcgtcgacgacatgacggcaccgacggagtgggctgctcggaatctcccgatgggatgatcgtcccagcaggttcgaggccaacgtcaacgagacgacctggtgcgctcattaatgagcccctccgctcagcctctcgagggtcgaggcggccgtcatcagtgatgtgaaccacctcag (SEQ ID NO:169)	LRWFDITDDGRLDLREAE AEGLINERTKVSLTLASN VLGTINPIGKIAEQAHSVG AVMVVDA(SEQ ID NO:170)	similar to gi 5459388 putative aminotransferase [Streptomyces coelicolor]
86.	2960355/2960355	gtcgaccacgggtgacgactgacaagaatcccctccacggaggatagcgatcagtgagcgtgtcctcggttaagctccccacccanacccgtcaacaaggatgtacgaggcatcgacctggccaactcgcggtactccgtcaacaagggtcaataaccccgcgctccgacaagcaccacgtgttctcatcgacacgggtgcttggccagatcggcattagcgacaagangacgcacctcaccatgaatcgcatcacancgcnngggccnccnccgaagtntaccccgntgcatgggatntcacgcgggaanccnaattca (SEQ ID NO:171)	RVMPIHGEVRLVANADLA KATGVDENNVVLVEDGGV IDLVDGVPRVVGKVDASYI LVDGGVGELTEDTLTDRRI LGEEGFLSVTVVD(SEQ ID NO:172)	similar to gi 3413828 hypothetical protein SC9A10.09 [Streptomyces coelicolor]
87.	2963495/2963495	cgcgtcaggccacgtagtttcttggtgagcttagaaggcgtaccagccacggtcccgcatagccatcgagaaagtgttgctccagggtggagattccccgtgagccaggagcagggtctggaagatgagcagcatcatcccaggaaaggcatgacaggcgggttgaaacagtgcgcccactcccgttccggtgggtgcgaggacgatcccgtaacgtgg (SEQ ID NO:173)	SVTGSSSHPTGTGVGAAL FKPPVMAFLGMIVLIFQAL LLAHGGISTLGANTFSMAI AGPWAGYAFYKLTKK(SEQ ID NO:174)	similar to gi 2808789 putative cobalt transport protein [Streptomyces coelicolor]
88.	10076564/10076564	gatgtcgggtgttctcgtcgtccacgtctcgtcgtcaagctcgacgtcgtcagcgaaccagctccacccaccggcgtgtagtggtggcggagtggtcgtcgacaagtcccaggcgtgggggtcgggcggggcgcaagcgggcggaccactgccgtcagtcggcgtacgcgt (SEQ ID NO:175)	YADSTAVVGPLAPAPDPH AWDLGERHSAHITAPVGW ELVR(SEQ ID NO:176)	similar to gi 2894206 hypothetical protein Rv3258c [Mycobacterium tuberculosis]
89.	16399653/16399653	cgatcactccctgtgtaccggggccgtcaccatggcggcaaatccgctctggcagccgtctatcgccacatccagcgtagccagtcacataggcccggtggcgcgtacccagctgcctcgtgtggctcggcca (SEQ ID NO:177)	AATEAGQLDAANGRYVLA TLDVAIDGCQSGEFAAMV TAPVHKGVI(SEQ ID NO:178)	similar to gi 216477 pdxA protein [Escherichia coli]

90.	11076711/11076711	gatgtataccaagttggccagtcgagagtgatctcagctttgccagcgccggtccagtgctgcgagcccgaatgtcatcatggcgagcacacgcctcaccagggttggagccaggccagggcgaaccgtgggggtgccagcccagcgtataagagacgatgacaagcagatcacctgagcgagactgataacggaataagccatcgccctgccagctagcagacccgaccgacctaacggggttgcggacaatcgctcgagcaccggtacgacgttcaaacccggtcatgatcgctgggaag (SEQ ID NO:179)	QAIMTGFERRYGVLERLS ATPLGRSGLLAGKAMAYS VISLAQVILLVIVSLALGWH PHGSLALAPTIVSVVLA MMTFGLAALAMAGAGKA EVTLLGLANLVYI (SEQ ID NO:180)	similar to gi 5459396 putative integral membrane transport protein [Streptomyces coelicolor]
91.	11816129/11816129	ccagaggccgagggccctgcgctccagctcgtctacagccctgcaggcgaggagaaacgaggtcggtgccccgagggcttgagctggadccagggagcggtttgtgtgagtgaggacgaatgacctggaggggtggagcactgtactacaaccagctctgcgagaacacccaggcggtcaccgtcgagctgccccaggggttaccggatgcaaggccccagcctgcccgtcctagatgtcaatgagtgctgcagctgcccaggcctgcgcctaaccagtgccacaacctccagggcagctaccgctgcctgtgccccagggccagacctccttcgcgacggcaaggcctgcacctcactggagcggatggacaaaatgtaccacogtcagccaccgagacctctatgcccgtgctggccctggcctcgatccccgtacc (SEQ ID NO:181)	EENEVGCPEGFELDSQGA FCVDVDECLEGLDDCHYN QLCENTPGGHRCSPPRG YRMQGPSLPCLDVNECLQ LPKACAYQCHNLQGSYRC LCPPGQTLRLDGGKACTSL (SEQ ID NO:182)	similar to gi 3581785 FIBULIN 1 like protein [Homo sapiens]
92.	4035948/4035948	cctagcaataagccaagtagcagagctccggaaatcacccatgaacatcctgcgggatgccagttgtggggcaaaaaaccgagacaggcgcccgccgtcgagccgaatgagactggtagtcgtcgcaacaacaaagtctgtgtgagccagcaggtaggtgtatgagaagaaagccaaggacccgatggccaccacccggatgccaaggccgtcaagtccatcaatgaaattcaccgcatggcgccacaacacaatgaagaacacccgtcaccaagatcgaagtaggcgtc (SEQ ID NO:183)	TSILVTVFVILCANAVNFI DGLDGLASGVVAIGSLAFF SYTYLLAHEQDFVWATTTTS LITAATAGACLGFLPHNW HPARMFMGDSGALLGLL L (SEQ ID NO:184)	similar to gi 1710106 PUTATIVE UNDECAPRENYL-PHOSPHATE ALPHA-N-ACETYLGLUCOSAM INYLTRANSFERASE
93.	21645656/21645656	ccggtccctgcgggatgaggtacctgatggagcccgagacaggaacagaagctagaggcagcagctcaggaggacagccccgtcctccaaagccctcctgcagccagacccaaggccaattga (SEQ ID NO:185)	GPLRDEVPDGSRRHEQKL EAAQEDSPAPPSPSLQP DPRPL (SEQ ID NO:186)	similar to gi 2137458 interleukin-11 receptor alpha-chain precursor - mouse
94.	20396935/20396935	ccgcgtgagcgtcgacaatgtccaggaaacgggtgtgtatgaggccgtgattctaccggctggtttgcagggcatgctgagcgcgccggtatccatggcggcaccgcgctggtggcgactgcagttattatgaaggcggttcaacgtcacggtggagattccaacatgagcggccaaaggatgaacatggacacgacgcgcccaatcacggctcggggcttgcgacgatcagccggctg (SEQ ID NO:187)	RVSVDNAPGTGVYEGVD STGRGLQGMRRERARIHG GTARWGDSQYYEGGFNV TVEIP (SEQ ID NO:188)	similar to gi 5639946 histidine kinase CstS [Corynebacterium diphtheriae]
95.	4016127/4016127	atcgacatgacgatcgcgagatgccgggcgcgtcggtgtgcaccgctcgaccgggacgcgagacgcaatcctagccaggctgccagcagcatcgccggcgcaatcaccggcggtgactctacccgagcgcaactgacgggtcgctggtgtgatccaaagctgctgagctagggctctccagctgggtgtgcgagcccaacacaggtcggagtcaccctcggttaggtgagccgacggcgatgagggcttgcaggtatcttgcagctgccgagtcgggtgatcgcggtgctgcaagggctccgatggagtccgagggaggtcgtcagggccagagaaggccaccacgcaatgacgggggaatccgacagtagcagcggaaggataaccgaggaaggcgctcgccatggctccggaaaaccgc	KDKLDAEVHAGEGTPGDV IVLRFSGAMAKRPASVILP LLLSDSPVIAWWPFSGPD DLASDSIGALADRRITDSA ADKDPCKALIRRAAHLTEG DSDLCWARTTSWRALAA AALDQHPATVKFARVESA AGNAPAMLLAAWLGLR(S EQ ID NO:190)	similar to gi 3334791 hypothetical protein SC5A7.10c [Streptomyces coelicolor]

		agcacgatgacatccccgggggtgcctcac cggcacgacacctcggtcaagctgtccttac gagaacgcg (SEQ ID NO:189)		
96.	3941385/3941385	acgcgtgaggctgctgcgggagctcagcgag cgctggagctgtctctcgtggatgattcgtc cagcgtggcggaagtcaacttccgcagcgag ctcatgttcgtccgcaagctgctgcgacttcc ccgtgggtgcccacggccacgcgctggccat cgtgaccttctcgtccaagaactacgtgggtcc gcgcgtcgattacatctccaccgcccgcgcg gccagcacaagtgcgcgtgtctcc (SEQ ID NO:191)	LELVFLVDDSSSVGEVNF RSELMFVRKLLSDFPVVP TATRVAVTFSSKNYV(SEQ ID NO:192)	similar to gi 323091 immunodominant microneme protein Etp100 - Eimeria tenella
97.	10196003/10196003	ccgcgtgggtgatcgccatgctctgggcact gggggtgggtggcggaagtgtgattctcgtg ccatgagccggatcctcgccgctttcgtgctc gtcgggtgctgctggcagtttctcctggccg ccgtgcgctggtgctgctggcgcggtggcg atcacctggcggtgctgtgttcgcccaggtgct gcacgcggcgaccttgcagctttcacgcctc tgccattcatt (SEQ ID NO:193)	IGMLWALGVVAEVLMLFLA MSRILARFSVRRVLLASFL LAAVRWLLLGAVADHLAV LLFAQVLHAATFASFHASA (SEQ ID NO:194)	similar to gi 2072116 putative transporter of 3-phenylpropionic acid [Escherichia coli]
98.	13502044/13502044	acgacctggtgttccaagatgctctgcgcgagc acctgccgacgcgccgcaogtttcaagagaa ctgcttcaaaactcctcgcccagcggaacttc ggtgcatttctccgacctgttcgcttccgt tcgtggtgaacctgctcatccccgagcaggcg gcgcgcacgtgatcggaagctacagccc gggcgggtgcagaacccgaccacgagaag ttcccgccactaccgctggaccaccggccc gacgaggaaggccatcaggcggttacgaaag cgtgggttccaggtcgaatcctggtccggcgc ctacggccacggatactaccggtactgcgc ccgtcgcagcactcgagcgcccaagagc cgt (SEQ ID NO:195)	GVLQDALRAPARRPHVSR ELLQTPSPRRTFGAFLPD PVRVPVRGEPAPHRAGG AHRDRQATARAVAEPAPR EVPGLPLDHRPDEEGHQ ALRKRGFPGRILVRRLRP RILPRTAAARRTRAR(SEQ ID NO:196)	similar to gi 3327090 KIAA0638 protein [Homo sapiens]
99.	21425684/21425684	accggtgatgcaaagggtgctgtgacaaggg gattcatcggttcgggcaaggctgcacggca gctgcgtcatcatgattcgtgtctcttctc atccccgagggcagtgacgcatcaaggaa atcgccctggccctggcgtcggtatcctcac ggatgccttctgtgctggtgacccctgtccc ggccgtgatggcctgctagggtgacaaggca tggtggtgcccgggtggctggatcgagcct accccgctcgacatcgaggagaaggat caccacgaggaagaaagctggccgctggcc cacagcggatcacaccgaggccctgcacgc cgaggggatcggggtggagggtctctgaa ggcctcgatctgcacgtcgaaccgctcaggt gcaagccgtcgtcgatcgagaacagtgtct cggccgtcctgctggcatcggggacggct gcccttgatcacggccgatgaggtcgga ggattgctgctacccgagcgggttccagagt gcgtcgggtgacgtggtcctcgacgcgt (SEQ ID NO:197)	TGDAKGAVTRGFIGSGKV VTAAMVIMISVFVFIPEGM NAIKEIALALAVGILTDAFL VRMTLVPAVMALLGDKAW WLPGLDRRLPRLDIEGE GITHE(SEQ ID NO:198)	similar to gi 1881350 PROBABLE TRANSPORT PROTEIN, SIMILAR TO ANTIBIOTIC TRANSPORT- ASSOCIATED PROTEIN ACTII IN STREPTOMYCES COELICOLOR.
100.	8756491/8756491	tctagatcactctgtagcgcagtggttaaatgctg acacaatagaaaagtgcgaggacatcctcg aaitaatgagatggtggactggatgagtaag ttctcgtcgttcggcggtgctgcgtcagctgcc cctctccacttctgcttctcggcggttaccata ccgtattgcccgcgtgtcaccttgaatgcagc catgtcgtcgtcctcgtatcgaaatgatgtcca tcgaagatgccagctcagcatcggtatctgc agtgatgagtgctatcgccacacgaaac gccagcgcaaccgtgtctcgacgatacg aagtgtgggtatctcagctctgttacctatgg tcgtgtatataaagcaaagggaactt (SEQ	YRATRNAQRNRVLARYEV LGYLSSGTYGRVYKAK(SEQ ID NO:200)	similar to gi 1351369 MEIOTIC MRNA STABILITY PROTEIN KINASE UME5

		ID NO:199)		
101.	2930338/2930338	cgcccccggtggcgaaggagacagccgacgtggccaggaggagagaagacgtagctcggtttcgaatcagggcctcatatctcggagccatgaggtccgggcttgagctggtccccgagctggtcgacatgaccccttttagtggctgggaccagatgaggatgagtgctctgatcatgccaggacaggggacaccgcaatgccagtgccagtcctccggtgctgtctacgctg (SEQ ID NO:201)	SVKQAAGDWHWALRVSPVLGMITGTLILVLPATKRGHVDQLGDQLKARTSWLRDMKALIRNRSYVFSSLATSAVSFATG (SEQ ID NO:202)	similar to gi 3874275 predicted using Genefinder; Similarity to Yeast low-affinity glucose transporter HXT4 (PS:32467); cDNA EST EMBL:C12555
102.	20708193/20708193	gatcctcacgtcagggcgcttctcgcaccggaggcagcaccgagccagaactcaggatgacggaataggcggtccagccgcccagccgtcaacaccgagaccgaccaatagttcatgatccgggtgacatgtccgcactcggggtgtcggtggtgagtgcgaccaggtcactatgaccccgaaaacgtcgaggtgcccctcacaccagcgaaccatcagggcggtcgaatctggccagcactcgcgcactcgcacgatcggttgcgacgagagcgtggtgaccacccgctgagcagtactgacagaccgaaacgtggcggtcgaagcaggtgatcgaagtcacgtcgtcgcctagccgaggggtcgaatgaagtagtccaaagt (SEQ ID NO:203)	TLDYFTIDPRLGDDDDFDHLLQAAHVRGLSVLLDGVVNHVSRNRIVQDAQSAGPDSRAGRMVRWCEGHLDVFEGHSLVALNHDNPVREHVTRIMNYWCGRGVDGWRDAAYSVNP (SEQ ID NO:204)	similar to gi 3378523 cyclomaltodextrinase glucanotransferase [Thermotoga neapolitana]
103.	20610403/20610403	cgcgtagcggtaggtgtaggacaccatgccgaacccggcctcgcacatcgaggcaccatgggacacggcaagaccgagggccgcctcatgtgcgcacaggtgctcgcgaacggttcggctcggcgccatctctcgtctaccgacgatggccacgtccaatccatgttcggtcgagttcgggaatggctggacgctgtccagccaaggacccgtcaagcatttcctggctcactcgaaagctggactcaacgaggagtaccagcagctcatgccgtggaacgccaccatggcgtctacgacgaaggtgcccgcagcagcgtgaagct (SEQ ID NO:205)	PGLLAIEAPMGHGKTEAALMCAQVLAERFGLGGIFFGLPTMATSNPMFGRV (SEQ ID NO:206)	similar to gi 2506493 HYPOTHETICAL 100.5 KD PROTEIN IN IAP-CYSH INTERGENIC REGION
104.	10268661/10268661	actaggggattatcgacataaacgcgactgcgtaaggttggtgactcatccccagcgacatgaggcaaacgcatgacatccgagaatgcacgcgcgagggcaagatcatgatggcggtgatcgccggcggtggtgaccaaacttactgcacccagccggtgctgccgttgatcgccctcgacatggcgctgcagtgctgacgggtcaacctggggcagggcgccctgctggggttgccaccgggtggcggttttattgccatgggcgacggctt (SEQ ID NO:207)	IIMMAVIAGAVVTNIYCTQPVLP LIASDMGVAVSTVNLVAGAALLGFATGLAFLPMGD (SEQ ID NO:208)	similar to gi 1789035 orf, hypothetical protein [Escherichia coli]
105.	19536322/19536322	agtactgtcatgattacgcctagtgtgggtatctatttctcagcggttctcagatctccgaacccaagacgacgaggtcggacacgcgttctatctcgaccctcaagacgaggtcaagaggtggcagatcccagctacgtccgtgctcagggcggtcctccagctcggctgggtgatgcccggcgaaactgggtatcaggtcattggagaaaacggtaagggtcattggatcgacgactctttggacgaaaaagatccggcgagtgaaagccagcgtgacgctcgggtgggcaagaggcttgcggatcagtc (SEQ ID NO:209)	YFSQRSQISRTQDDEARTRASISTLQDEVKRWHPDYVRAQARSQLGWVMPGETGYQV (SEQ ID NO:210)	similar to gi 1870004 hypothetical protein Rv1024 [Mycobacterium tuberculosis]
106.	3150182/3150182	cccggctgcatgaccgggtggtggcaccacgcggtgttcgggtccggcctcgcgtcccgcatcgcccgatcgatctcgggtgctgttcagacctccggcgacagcaactt (SEQ ID NO:211)	GCMTGVATNAVFGSGLRAPASPGSIFAVLLQT (SEQ ID NO:212)	similar to gi 131498 PTS SYSTEM, MANNITOL-SPECIFIC IIABC COMPONENT

				(EIIABC-MTL) (MANNITOL- PERMEASE IABC COMPONENT) (PHOSPHOTRANSF ERASE ENZYME II, ABC
107.	13515411/135 15411	gtgcacatccggacgaaaattgctgcttcaat caagtccgacgtgtacagctacggggtgttg tgctggagatcatcaccggccacaagatct (SEQ ID NO:213)	LLSIKSDVYSYGVLEVLEIT GHK(SEQ ID NO:214)	similar to gi 836954 receptor protein kinase [Ipomoea trifida]
108.	4526774/4526 774	gattttggtttatcaaggcttattggtgaaggga atactagaatagtcacacacacactcctgga ccaatagggtacatggcacctgaataccgtta catgggggaagtttcacgcaaggtagacatat tcagctgggtattcttatactagagattgtaact ggtcaagacaatagtaccaaagttgactttatc gatcatgtatgtgaacactgcatggaaggcc acaaataaaatttatgtat (SEQ ID NO:215)	DFGLSRLIGEGNTRIVNTH TPGPIGYMAPEYRYMGEV SRKVDIFSLGILILEIVTGQ DNS(SEQ ID NO:216)	similar to gi 2911080 receptor kinase-like protein [Arabidopsis thaliana]
109.	3793822/3793 822	acgcgtactgagatcgggtatcgatgttcatct gataacgcataggacacgcgtcgccgcatc tctgggcagtcgacccgaccacccatgga agaccagatcgaacggcttctcctgcccgtact tctgcccacactcgtcctggatctcctgaggatt cccgggacgagctgacgttaacccggctgta cgaccatggacgttcccgaaggctcagagcg gtgggtagcgcaccccttcacccaggcccg cacctcgagggtacgcatgccgtcagcaacg gtgggtgaca (SEQ ID NO:217)	YTTVADGMRTLEVLGLGE KGRYTTALTFGNVHGAYK PGYVKLRPGILKEIQDECG KKYGKEKPFDLVFHGGSG STAQEIADAVSYGVKMN DTDTQYA(SEQ ID NO:218)	similar to gi 4049524 fructose 1,6- biphosphate aldolase [Streptomyces galbus]
110.	3670835/3670 835	agcttgcgcccgatgacctaacagatcatggc tagtcgcgtatgaaccagatcgcccgctgcg tttccgcgtgttctgtctgtttaccggctggctg tagcgggcccgcacacccggcgcgccgacc gctggacggcgttgcgttggcggtccgttcac actgaccgaccagatggccgggtgcgcac cgatcgcgatttcggcgccgctatcgcatcat gtatttcggctacaccttttcccgatgtgtgcc cgaccgacatgcagacgattggcggggctt acgcg (SEQ ID NO:219)	GVALGGPFTLTDQDGRVR TDRDFAGRYRIMYFGYTF CPDVCPTDM(SEQ ID NO:220)	similar to gi 2126490 regulatory protein prc - Rhodobacter sphaeroides
111.	2873001/2873 001.	ggatccacatgccaggggccccggtggcga aggagacagccgacgtggccaggaggag aagacgtagctcgggtttcgaatcagggcctt catatctcggagccatgagggccgggcttga gctggtccccgagctggtcggcatgacccctt tagtggctgggacaaaatgaggatgagtggt cctgtgatcatgccaggacaggggacaccc gcaatgccagtgccagtcctcggctgcctgc ttca (SEQ ID NO:221)	LPAVFICSFMVAAPIFGYL GDRFNKRVILSCGIFFWSA VTFSSSFIPQQYFWLLVLS RGLVGIGEASYSTIAPTIIG DLFTKNTRLMLSVFYFAI PLGSLGYITGSSVKQAA GDWHWALRVSPVLGMIT GTLILILVPATKR(SEQ ID NO:222)	similar to gi 3874275 predicted using Genefinder; Similarity to Yeast low-affinity glucose transporter HXT4 (PS:32467); cDNA EST EMBL:C12555
112.	3226165/3226 165	ctgcaaccgggtgggtatcgtccataccacgg ccatcgcttctctagctcggtagcatctggtc gggtatctccgcgaagaccgagtcgcccctg gcaaaaccacgcgctggatcgccggcgga gacaccactgacgccgagcgggtgtgcacc acgggtgacgactgacaagaatccctctcac cgaggatacggcgatcagtgagcgtgtcctc ggtaagctccccacccagatccgtcaaca aggatgtacgagcatcgaccttccaacaa ctcgcggtactcgtcaacaaggtcaataacc ccgcccgtcctcgacaagcaccacgtgttctca tcgacaccgggtgcttggccagatcggcaltta gcgacaagatgacgcacctcaccatgaatcg gcatcacagcggtggc (SEQ ID NO:223)	PRAVMPHGEVRHLVANA DLAKATGVDENNVVLVED GGVIDLVDGVPRVVGKVD ASYILVDGSGVGELTEDTL TDRRILGEEGFLSVTVVD TRSASVVSRAPIQARGFA EGDSVFAEITDQIVTELEK AMAGGMDDTHRLQ(SEQ ID NO:224)	similar to gi 3413828 hypothetical protein SC9A10.09 [Streptomyces coelicolor]

113.	3928075/3928075	ccgcactgtggcgaccatccttgccaccattaccattgccgacctagtctcacgggctgtaatacggcggtgcgcnaaacgggtaagacgaggttcccgcgaagctcatcaccgtgtgggtgctgagccacaaaaccactcctgccagccgacaccaatgaaacggcgcgacgaaagtcacccgcctgttcgcggcctggtgtattacgacgccgacggcaaaaaccataatgatgtggccaaatccattgacttcgatggcgaccgacactacacgtgacgtgcggaaaaccagat (SEQ ID NO:225)	ANGEDEVSRKLITVWGAE PQNPLLPADTNETGGTKVI TALFAGLVYYDADGKTHN DVAKSIDFDGDRITYTVTLR (SEQ ID NO:226)	similar to gi 2960090 dppA [Mycobacterium tuberculosis]
114.	20286807/20286807	cgccgattaccaaggctatggatgtgtggcc ttggcgtaacgctatactgtctgttcggtc gagtgccatttgatgcagagacggagtacttg ctgctgaaagtatcctgcatgacgattatgcc gtcccgacgcacatgggtagcgaccgctgtt ggtaggcccgcgaccagcagcttggccctcg tcgcaagagacgcccacgtgcgctgtccg gcgaggcgcatgcagtacgccatctgctcgat gcccttctcgacaaggatccagcgacgcgcc tcactctcgatcgtgtataacacacccatggct cgtggcagaatcatggttaatatgtagcagttgta tataccctcatcaccaagatggccaaagcgtg acaaggtagcgcg (SEQ ID NO:227)	ITKAMDVWALGVTLYCLLF GRVPFDAETEYLLLESILH DDYAVPT (SEQ ID NO:228)	similar to gi 1711543 SERINE/THREONIN E-PROTEIN KINASE SSP1
115.	20944739/20944739	tcggtctgaaccctccagatctctcttcat tctgccgattatggcgggtggcgttggtaggg cgctattccgctctatcggatagccacgttg ctgcatatggatcagggcgttgcgtcgcgtgc gtgctgccgatggtcatgctcgaggcttaacc gccatcattatctccgctgcctgaaccagctt ggtaaacgctatccgcatctgaccg (SEQ ID NO:229)	FIILPIMAGGVGEGAIPLSI GYATLLHMDQGValGRVL PMVMLGGLTAIIISGCLNQ LGKRYPHLT (SEQ ID NO:230)	similar to gi 1783249 homologous to citrate-sodium symport (citrate transporters); hypothetical [Bacillus subtilis]
116.	2974211/2974211	ccgcgtgaaggcgacgagcaacaccacgg agtgtgttcccggtgccacdcaggacgctg gccgagatcgtggcgaggcaaggctgcaag attaaggcctgagggccaagaccaacaccl acattcaa (SEQ ID NO:231)	GSSNTTECVPTSEHVA EIVGRQGCKIKALRAKTNT YIQ (SEQ ID NO:232)	similar to gi 2088718 weak similarity to human transformation upregulated nuclear protein (NID:g460789) [Caenorhabditis elegans]
117.	10286661/10286661	acgcgtgcaacgcctcgatgacggccgctgc catcgcaaacacgcggggtgcgggacga caccaccacactgagcgccctgctgcggcc agctcaaacgcatgccgcgcgcgtgcatctt ttcgggttatcgggtcaatgctgcacctgatca tcacggaacggcccgccatgcgcagctag gtttcatagccca (SEQ ID NO:233)	RDDQVQHCTDNREEMQR ARHAFELAAQGRSVVVVS SGDPGVFAMAAVIEALH A (SEQ ID NO:234)	similar to gi 3128335 precorrin-3 methylase [Rhodobacter capsulatus]
118.	20945165/20945165	gcatggcctcggaaccgagttcgtcctcgctt cctggttagacgagcttggcgtccgagaggat ctgtccgtgaggaagtccgggtcaaccgcg ggcgtccgcggcctcgtcaatgatctcgtct gggtcaacgtgatgggtacagctcacgcaa tgcccccacagacgtccagatcccagctct cggaatgaccacgcgagtgccgtcttcgatg gcgggtggtgatgacctctccacgaactgctga atcgttcggcaatgtcatgccatgaggattc gacggcggtcacggttagaccacttcgcgtg gcgggtgagcacgtcgtcgtacttgagcacatt cttgcgtctcgcggctaacg (SEQ ID NO:235)	RNAEQRKNVLKYDDVLNR QREVYRDRRRILMGDDI AEQIQFVEEVITTAIEDRT RVGHSEDWDLGLWEAL RELYPITLTQQEIDEAGGR PRLTADFLTEQILSDAKLV YQEREDELGSEAM (SEQ ID NO:236)	similar to gi 2251198 SecA [Streptomyces lividans]
119.	3927847/3927847	tccgaccgcgtggtaaaactggcgaccttaatt gctgaagatgagcaagctgaaatgaattgt tttcccgacgcgtggttcgatgattgcgtcagt taccctaaaaaccatgtaitaagagcaca	RVVKLATLIAEDEQAEMNI VLPAAWLHDCVSYPKNHV LRAQSALHAADKAIVFLRS INYPKQYLLAIHHAISAHSV	similar to gi 2506682 HYPOTHETICAL 25.9 KD PROTEIN IN

		gtgcattacatgcagcagataaagcgattgtat ttttgcgcagtaattaccccaacaatactt attagcaattcatcatgcaattcagcgacag tgtcagtggtataaatacaggcaatgatttag aagctcaaatagtgcaagatgcagatagattg gatgcgctaggggcaattggcgtggctcgttg cattcaagtaagtagccagttacagcgccac tatattctgaagttgacccctcagcgagacac gatctctag (SEQ ID NO:237)	SGKIQAMSLEAQIVQDAD RLDALGAIGVARCIQVSSQ LQRPLYSEVDPFSETRSL(SEQ ID NO:238)	DCM-SERU INTERGENIC REGION
120.	4033506/4033 506	ictagattgaactcgaccgcaggtgctgctg aggcagaccagccttcgacactactgtgggt gcaactcaccagcatggccaatgacctccc atcgacgatgagagccgcacaacgaccggg atgccatggagcctgacggcagccttgcgca cc (SEQ ID NO:239)	PWHPGRCAALIVDGKVG HAGELHPTVVSAGLPQR TCAVEFNL(SEQ ID NO:240)	similar to gil3122893] PHENYLALANYL- TRNA SYNTHETASE BETA CHAIN (PHENYLALANINE- TRNA LIGASE BETA CHAIN) (PHERS)
121.	21643932/216 43932	gccggcggtgtcaacctcatggtgtggccttc attaccgacgtcatcgatgccaggaggtcat gtccggggagcgtgaagacgggtgtcatctatg gcgtgaactccttcgcccgaacttgcccag gccattgccgtgggaatcgggcgagccatgct gacgatgatcggtaccagtcctctcccaag gtgggtccgttcagtcggagtcgctcgtcaatc acctgtacacgctcgccaccgcatcccgac gatctgctgctcgtggcgtgcccgtcgtatgct gggctaccgctcaccgcgacaagggtggtc gccaacgcccagcaggttggtcgtcgccacg cagtacaggccgagcaaaactcctgacccat aacggaggcacatcatggacacgctcatgcg gatcaccgaccacttgacaacctcgccgggt atccaattgaaaattgacaagcgtgggggtgc ctccgtcacattgtgacgcgt (SEQ ID NO:241)	NLMVWAFITDVIDAQEVM SGEREDGVIYGVNSFARK LAQAIAGGIGGAMLTMIY (SEQ ID NO:242)	similar to gil3915488] HYPOTHETICAL SYMPORTER IN COTT-RAPA INTERGENIC REGION
122.	2797911/2797 9114	cgatcctgcacaaagggtgctgttctcgtctgc ctcgagcatgttcctgatgcgctcatcgtgg tgtccactcaccaggttgacgacctactgac agctatgacagggtgattgtactgtcatgtgc cgggtcgtcttcgacggaaccttaaggagtt cgtggatctggcgccagagtggttcgacgctc gtgctgaaatggcctacctcgtgtggtggccg acgaatgaggctcacaacgcggtcgtgaact gcgcccgtgtctggttgccgcccctgatggtc gtggcctcatcatggtgtcaatgacaccgccc ggtgagccgtattggttagctcagtgccggg gacgcggggagaacctggtcgtcaacgcg c (SEQ ID NO:243)	DPAQRVRFLAVLEHVPDD RVIVVSTHQVDDLTDSDYD RVIVLSCGRVFDGTPKEF VDL(SEQ ID NO:244)	similar to gil4587878 ABC transporter subunit PenJ [Pediococcus pentosaceus]
123.	20941626/209 41626	caatggctggcggtgatctcggggtttgctggt gtgctgatcatcatcccccgggtggcgagttg ttcacgctcggtgtgtcgcgtgtgttcgg cgatgttctctgttttaccattgtctacgcgc atcctcagccaalacgacacaccgaccacca gcaactcttcgcccggctgtgcaatacttgg gatgagcgcggtgtgcccgtctctgtgaggt cccgcgtgtgcatgctgtttgatgctggcg ctgggcacttgcggcatgaccgcgcact (SEQ ID NO:245)	QWLAVICGFVGVLIHHPGG ELFTPALLPLCSAMFFCF YQLLTRILSQYDTPPTS FAGLCNTLVMSALVPFFW QVPTLWHACLMLALGTG (SEQ ID NO:246)	similar to gil3860646 unknown [Rickettsia prowazekii], also to OCTAPEPTIDE- REPEAT PROTEIN T2 (mouse)
124.	37004299/370 04299	cgcgcccagaggccgctgagcccaggaag aagaagtggacactgagcctgaagaacctg cgccggaggacagcgccaaatacacctgc cgcggtgcgaaccgcggggcccatcaac gccacctacaagggtgatgtatccagcgga	RKKKWTLNLRPEDSG KYTCRVSNRAGAINATYK VDVIQRTRSKPVLGTGHPV NTTVDFGGTTSFQCKVRS DVKPVIQWLKRVE(SEQ ID	similar to gil1168177 fibroblast growth factor receptor type 1, FGFR1

		cccggtccaagcccggtgctcacaggcacgca ccccgtgaacacgacggtggactcgggggg accacgtcctccagtgcaagggtgcgacg acgtgaagccggtgatccagtggtgaagcg cgtggagtacggcgccgagggccgccaac ctccaccatcgaigtggcgccagaagttgt gggtctgcccacgggtgacgtgtgtcgggc ccgacgggtcctacctaataagctgtctatc acccgtgcccggcaggacgaltcgggcatgt acatctgccttggcgccaacacatgggtac agcttccgacgagccttctcaccgtgtct (SEQ ID NO:247)	NO:248)	{Val423,Thr424 deletion} [Xenopus laevis=African clawed frogs, embryos, Peptide Mu
125.	326847/326847	ggttccgtcagatttctgaacaagggtggc gtcctgtctgtggcgggggagggcactcg cctggggtgacctaaccgaagggtatgtacc gtgtggggtgcccagccggaagacctgt ccagctgcaggcggagcggattcggtgggt ggagcagctggccggtgagcgccagggac ccgtgcaccgtcc (SEQ ID NO:249)	GFRQISLNKVAVLLAGGQ GTRLGVTPKGMRYRVLG SRKTLYQLQAERIRRV AGERHGTCTV(SEQ ID NO:250)	similar to gi 4507759 sperm associated antigen 2
126.	29914845/29914845	cgatccattcattataagctgcaagagacaa atataatcttaagaggagcataaaagcagc atgtattataaccattagtagtcatcagattgc ctgaaaattaataaaaacgtaaccaatta (SEQ ID NO:251)	LFNFQANRDELNTGII:4AA FMLLFKDYICLFAAYNEWI (SEQ ID NO:252)	similar to gi 2792502 clathrin assembly protein long form [Rattus norvegicus]
127.	27365065/27365065	tgcactctgttctgtctattctcacagccat gttagaaagcgaacgtttgacctcttggacc tgctgtctccaggctaagagctgtaggcgag aggacagagcattcacggacacttccagct gcacatccaccttctggagctctggaagatgg cggtatgagggtctgttagctccacacctcc gaatcggtaaagctgaagctgaagagccca gacatcagcccagcagccagctcctccaga gcattcc (SEQ ID NO:253)	NALEEAGCWADVWALQL QLYRFGGVEATQALIRHLP ELQKGGCADWKVSVNAL SSALQLLAWAQAGPKRVK RSLSNMGCENEQEQRV(S EQ ID NO:254)	similar to gi 2492916 APOLIPOPROTEIN F PRECURSOR (APO-F)
128.	30575179/30575179	ccggacagaggttctgcaagcagctgtcctg ctcaggcgctgtgtggcgagctagtggtct gcttgatgcacacctacatgcctgcactata ctggggcgacagcttctgcgaggcagcttca tcgacctgtgtgtgtgctgacctgtctact gcttcgagaaaggccagcgcccgagaagac tgacagtgttactgtgtcaagatgccataac cagagctgcgagaggtgccagactgtggtg tgca (SEQ ID NO:255)	GQRFRKRLSSLRRVVGGL VALPGSHPYIAALYWGDS FCAGSLIDPCWVLTAAHC LQKRPAPEELTVVLGQDR HNQSCERCQT LAV(SEQ ID NO:256)	similar to gi 4165317 FXII [Sus scrofa]
129.	17676856/17676856	agccttgtagtgggtccgggggaatgggagc cacactctgtctacgcccagggaatggcggt ggicagcaactgtcctctctcgaatccag ccgtctctctattggcacatggcgattattcc acagcccagagtgaacatcatgacacaatc ctcatgccctctgg (SEQ ID NO:257)	EDCVMLHSGLWNNAPC ANERDGWICEKRSSC(SEQ ID NO:258)	similar to gi 560484 Fc-E receptor II (Fc-ERII/CD23) [Mus musculus]
130.	7511820/7511820	caccgactcctgtctccggggccaaggga cggaagttccaggagacagtcacagaggag agggacacagggtgttggaactaaaagtga cttcagtctcactctgtcccggtcactgcctcca cctcattgga (SEQ ID NO:259)	SNEVEAVNGTEVRLKCTF KSKHPVSPSSVTVSWNFR PLAPGDEESV(SEQ ID NO:260)	similar to gi 5032247 epithelial V-like antigen
131.	38406286/38406286	gtgcactggggtcaggggtttctcacactcca caaagagggtatacctatggtctcctcatg atgaagaagatgaatggtcggttcaaaaaga aggaggaaggagacattcgagtcaggtgtg gctggtagctgcccgtgcctccacaccagcct cactgagctccatggttagactggtgtgcaca ctagacaccaccagactctggtcagagatct (SEQ ID NO:261)	ISDQSLVSSVQHSTME LSEAGVEAAAATSTAMTR MSLSSFFLNRPFIFFIMEET IGIPLFVGSVRNPDP SA(SEQ ID NO:262)	similar to gi 2500773 ALPHA-2- ANTIPLASMIN PRECURSOR (ALPHA-2-PLASMIN INHIBITOR) (ALPHA- 2-PI) (ALPHA-2-AP)
132.	25236336/25236336	atatcaagaatgtataattcaagaaaactacc attaccctgcacagataatgacattgtgtgt gcatctatctcaccagtggtatatacaagaac atccaaaagcatgtcttccaaatgttaattata	IKNVIIQENYHYPAHDNDIA VHLSSPVLVYSNIQKACL PNVNYIFLYNSEAVVTAW (SEQ ID NO:264)	similar to gi 4758508 airway trypsin-like protease

		tattcctatacaattcagaagcagtgggtactgc atgggg (SEQ ID NO:263)		
--	--	--	--	--

EQUIVALENTS

From the foregoing detailed description of the specific embodiments of the invention, it should be apparent that particular novel compositions and methods involving nucleic acids, polypeptides, antibodies, detection and treatment have been described. Although these

- 5 particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims that follow. In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made as a matter of routine for a person of ordinary skill in the art to the invention without departing from the spirit and scope
- 10 of the invention as defined by the claims. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

What is claimed is:

1. An isolated nucleic acid molecule encoding a polypeptide comprising an amino acid sequence that is at least 85% identical to a polypeptide including an amino acid sequence selected from the group consisting of SEQ ID NO:2*n*, wherein *n* is any integer 1-30, or the complement thereof.

2. The isolated nucleic acid molecule of claim 1, said molecule hybridizing under stringent conditions to a nucleic acid sequence complementary to a nucleic acid molecule comprising the sequence of nucleotides selected from the group consisting of SEQ ID NO:2*n*-1.

3. The isolated nucleic acid molecule of claim 1, said molecule encoding a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2*n*, or an amino acid sequence comprising one or more conservative substitutions in the amino acid sequence selected from the group consisting of SEQ ID NO: 2*n*.

4. The isolated nucleic acid molecule of claim 1, wherein said molecule encodes a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2*n*.

5. The isolated nucleic acid molecule of claim 1, wherein said molecule comprises the sequence of nucleotides selected from the group consisting of SEQ ID NO:2*n*-1 or the complement thereof.

6. An oligonucleotide less than 100 nucleotides in length and comprising at least 6 contiguous nucleotides selected from the group consisting of SEQ ID NO:2*n*-1 or the complement thereof.

7. A vector comprising the nucleic acid molecule of claim 1.

8. The vector of claim 7, wherein said vector is an expression vector.

9. A host cell comprising the isolated nucleic acid molecule of claim 1.
10. A substantially purified polypeptide comprising an amino acid sequence at least 80% identical to a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2*n*, wherein *n* is any integer 1-30.
11. The polypeptide of claim 10, wherein said polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 2*n*.
12. An antibody that selectively binds to the polypeptide of claim 10.
13. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of a therapeutic selected from the group consisting of the nucleic acid of claim 1.
14. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of a therapeutic selected from the group consisting of the polypeptide of claim 10.
15. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of a therapeutic selected from the group consisting of the antibody of claim 12.
16. A kit comprising in one or more containers, a therapeutically or prophylactically effective amount of the pharmaceutical composition of claim 13.
17. A method of detecting the presence of the polypeptide of claim 10 in a sample, comprising contacting the sample with a compound that selectively binds to said polypeptide under conditions allowing the formation of a complex between said polypeptide and said compound, and detecting said complex, if present, thereby identifying said polypeptide in said sample.

18. A method of detecting the presence of a nucleic acid molecule of claim 1 in a sample, the method comprising contacting the sample with a nucleic acid probe or primer that selectively binds to the nucleic acid molecule and determining whether the nucleic acid probe or primer bound to the nucleic acid molecule of claim 1 is present in the sample.

19. A method for modulating the activity of the polypeptide of claim 10, the method comprising contacting a cell sample comprising the polypeptide of claim 10 with a compound that binds to said polypeptide in an amount sufficient to modulate the activity of the polypeptide.

20. A method for screening for a modulator of activity or of latency or predisposition to an ORFX-associated disorder, said method comprising:

- a) contacting a test compound with the polypeptide of claim 10; and
- b) determining if said test compound binds to said polypeptide,

wherein binding of said test compound to said polypeptide indicates the test compound is a modulator of activity or of latency or predisposition to an ORFX-associated disorder.

21. A method for screening for a modulator of activity or of latency or predisposition to an ORFX-associated disorder, said method comprising:

- a) administering a test compound to a test subject at an increased risk ORFX-associated disorder, wherein said test subject recombinantly expresses a polypeptide encoded by the nucleotide of claim 1;
- b) measuring expression the activity of said protein in said test subject;
- c) measuring the activity of said protein in a control subject that recombinantly expresses said protein and is not at increased risk for an ORFX-associated disorder; and
- d) comparing expression of said protein in said test subject and said control subject, wherein a change in the activity of said protein in said test subject relative to said control subject indicates the test compound is a modulator or of latency of predisposition to an ORFX-associated disorder.

22. The method of claim 20, wherein said test animal is a recombinant test animal that expresses a test protein transgene or expresses said transgene under the control of a

promoter at an increased level relative to a wild-type test animal, and wherein said promoter is not the native gene promoter of said transgene.

23. A method for determining the presence of or predisposition to a disease associated with altered levels of a polypeptide of claim 11 in a subject, the method comprising:

- a) measuring the amount of the polypeptide in a sample from said subject; and
- b) comparing the amount of said polypeptide in step (a) to the amount of the polypeptide present in a control sample,

wherein an alteration in the level of the polypeptide in step (a) as compared to the control sample indicates the presence of or predisposition to a disease in said subject.

24. *The method of claim 23, wherein said subject is a human.*

25. A method for determining the presence of or predisposition to a disease associated with altered levels the nucleic acid molecule of claim 1 in a subject, the method comprising:

- a) measuring the amount of the nucleic acid in a sample from the mammalian subject; and
- b) comparing the amount of said nucleic acid in step (a) to the amount of the nucleic acid present in a control sample,

wherein an alteration in the level of the nucleic acid in step (a) as compared to the control sample indicates the presence of or predisposition to said disease in said subject.

26. *The method of claim 25, wherein said subject is a human.*

27. A method of treating or preventing a pathological condition associated with an ORFX-associated disorder in a subject, the method comprising administering to said subject the polypeptide of claim 10 in an amount sufficient to alleviate or prevent said pathological condition.

28. *The method of claim 27, wherein said subject is a human.*

29. A method of treating or preventing a pathological condition associated with an ORFX-associated disorder in a subject, the method comprising administering to said subject the nucleic acid molecule of claim 1 in an amount sufficient to alleviate or prevent said pathological condition.

30. The method of claim 29, wherein said subject is a human.

31. A method of treating or preventing a pathological condition associated with an ORFX-associated disorder in a subject, the method comprising administering to said subject the antibody of claim 12 in an amount sufficient to alleviate or prevent said pathological condition.

32. The method of claim 31, wherein said subject is a human.

This Page Blank (uspto)